id,input,output
,"The integrity of the intestinal barrier is fundamental to maintain healthy gut homeostasis, as well as physiological intestinal permeability. It is widely known that, under chronic inflammation, intestinal homeostasis is altered, resulting in an impairment of the barrier functions and thus, an increase in intestinal permeability.","[{'entity1': 'intestinal barrier integrity', 'relationship': 'fundamental', 'entity2': 'healthy gut homeostasis'}, {'entity1': 'intestinal barrier integrity', 'relationship': 'fundamental', 'entity2': 'physiological intestinal permeability'}, {'entity1': 'chronic inflammation', 'relationship': 'result', 'entity2': 'impairment of barrier functions'}, {'entity1': 'impairment of barrier functions', 'relationship': 'increase', 'entity2': 'intestinal permeability'}]"
,"In order to induce an intestinal inflammation status in vitro, human HCoEpiC cells were exposed to supernatants (SN) derived from phytohemagglutinin (PHA)-treated PBMCs, which have been reported to be concentrated in pro-inflammatory cytokines such as TNF-α, IL-8 and IL-17.","[{'entity1': 'phytohemagglutinin-treated PBMCs supernatants', 'relationship': 'induce', 'entity2': 'intestinal inflammation'}, {'entity1': 'phytohemagglutinin-treated PBMCs supernatants', 'relationship': 'concentrated', 'entity2': 'TNF-alpha'}, {'entity1': 'phytohemagglutinin-treated PBMCs supernatants', 'relationship': 'concentrated', 'entity2': 'IL-8'}, {'entity1': 'phytohemagglutinin-treated PBMCs supernatants', 'relationship': 'concentrated', 'entity2': 'IL-17'}]"
,"Transepithelial electrical resistance (TEER) measurements, expressed in Ω/cm,2 were performed with a -Millicell® ERS-2 device, after either a 24-hours or a 72-hours incubation period, with/without PHA-treated-PBMCs SN, with/without either the Veh. or c-MIM-1, added 30 minutes before the SN.","[{'entity1': 'Transepithelial electrical resistance', 'relationship': 'performed', 'entity2': 'Millicell ERS-2 device'}, {'entity1': 'Transepithelial electrical resistance', 'relationship': 'incubation period', 'entity2': '24 hours'}, {'entity1': 'Transepithelial electrical resistance', 'relationship': 'incubation period', 'entity2': '72 hours'}, {'entity1': 'c-MIM-1', 'relationship': 'added', 'entity2': 'PHA-treated PBMCs supernatants'}]"
,"Interestingly, c-MIM-1 protected the epithelial cells against the PHA-stimulated PBMCs SN-induced disruption, after 24 hours.","[{'entity1': 'c-MIM-1', 'relationship': 'protected', 'entity2': 'epithelial cells'}, {'entity1': 'PHA-stimulated PBMCs supernatants', 'relationship': 'disruption', 'entity2': 'epithelial cells'}]"
,"In light of the previous encouraging results, we wanted to investigate if the tested medicine could modulate the expression of one of the proteins present within the tight junctions, involved in the regulation of the epithelial barrier permeability.","[{'entity1': 'tested medicine', 'relationship': 'modulate', 'entity2': 'expression of tight junction protein'}, {'entity1': 'tight junction protein', 'relationship': 'involved', 'entity2': 'regulation of epithelial barrier permeability'}]"
,"Overall, in inflammatory conditions, the Veh. did not modulate the claudin-1 expression at the mRNA level, compared with the SN from the PHA-treated PBMCs condition. However, when the cells were treated with c-MIM-1, a slight increase (of about 20%) in the claudin-1 expression was observed.","[{'entity1': 'c-MIM-1', 'relationship': 'increase', 'entity2': 'claudin-1 expression'}]"
,"In addition, ROC Curve Analysis demonstrated that NLR, SII, and NLPR might be acceptable in the differentiation of M-ACC and MS-ACC patients. The areas under the curve (AUC) for NLR, SII, and NLPR were 0.760, 0.723, and 0.778, respectively.","[{'entity1': 'NLR', 'relationship': 'acceptable', 'entity2': 'differentiation of M-ACC and MS-ACC patients'}, {'entity1': 'SII', 'relationship': 'acceptable', 'entity2': 'differentiation of M-ACC and MS-ACC patients'}, {'entity1': 'NLPR', 'relationship': 'acceptable', 'entity2': 'differentiation of M-ACC and MS-ACC patients'}]"
,"The optimal cut-off values were identified as 6.399, 1261, and 0.044 for NLR, SII, and NLPR. Sensitivities for NLR, SII, and NLPR were found to be 71.15%, 72.22%, and 61.54%, while specificities were 80.56%, 73.08%, and 91.67%.","[{'entity1': 'NLR cut-off value', 'relationship': 'identified', 'entity2': '6.399'}, {'entity1': 'SII cut-off value', 'relationship': 'identified', 'entity2': '1261'}, {'entity1': 'NLPR cut-off value', 'relationship': 'identified', 'entity2': '0.044'}, {'entity1': 'NLR sensitivity', 'relationship': 'found', 'entity2': '71.15%'}, {'entity1': 'SII sensitivity', 'relationship': 'found', 'entity2': '72.22%'}, {'entity1': 'NLPR sensitivity', 'relationship': 'found', 'entity2': '61.54%'}, {'entity1': 'NLR specificity', 'relationship': 'found', 'entity2': '80.56%'}, {'entity1': 'SII specificity', 'relationship': 'found', 'entity2': '73.08%'}, {'entity1': 'NLPR specificity', 'relationship': 'found', 'entity2': '91.67%'}]"
,Univariate and multivariable binary logistic analyses were conducted to evaluate the clinical significance of Inflammation  Indices  as  biomarkers  in  distinguishing  between  ACC  and  CCC  patients.,"[{'entity1': 'Univariate and multivariable binary logistic analyses', 'relationship': 'conducted', 'entity2': 'evaluate clinical significance of Inflammation Indices as biomarkers in distinguishing between ACC and CCC patients'}]"
,"It was shown that when the NLR was more than the cutoff value, there was an increased risk of (10.308 times higher) moderate to severe degree inflammation compared to the lower NLR","[{'entity1': 'NLR more than cutoff value', 'relationship': 'increased risk', 'entity2': 'moderate to severe degree inflammation'}]"
,"Chronic pain as a symptom or a disease, the IASP classification of chronic pain for the international classification of diseases (ICD-11).","[{'entity1': 'Chronic pain', 'relationship': 'classification', 'entity2': 'IASP classification of chronic pain'}, {'entity1': 'IASP classification of chronic pain', 'relationship': 'for', 'entity2': 'international classification of diseases (ICD-11)'}]"
,Mechanisms and therapeutic relevance of neuro-immune communication.,"[{'entity1': 'Mechanisms', 'relationship': 'relevance', 'entity2': 'neuro-immune communication'}, {'entity1': 'therapeutic', 'relationship': 'relevance', 'entity2': 'neuro-immune communication'}]"
,"The neuropathic pain triad, neurons, immune cells and glia.","[{'entity1': 'The neuropathic pain triad', 'relationship': 'consists of', 'entity2': 'neurons, immune cells and glia'}]"
,Functional brain imaging reveals rapid blockade of abdominal pain response upon anti-TNF therapy in crohn’s disease.,"[{'entity1': 'Functional brain imaging', 'relationship': 'reveals', 'entity2': 'rapid blockade of abdominal pain response upon anti-TNF therapy in crohn’s disease'}]"
,Neuron-glial communication mediated by TNF-α and glial activation in dorsal root ganglia in visceral inflammatory hypersensitivity.,"[{'entity1': 'Neuron-glial communication', 'relationship': 'mediated by', 'entity2': 'TNF-α and glial activation'}, {'entity1': 'TNF-α and glial activation', 'relationship': 'in', 'entity2': 'dorsal root ganglia'}, {'entity1': 'TNF-α and glial activation', 'relationship': 'in', 'entity2': 'visceral inflammatory hypersensitivity'}]"
,"Ulcerative colitis exacerbates lipopolysaccharide-induced damage to the nigral dopaminergic system, potential risk factor in Parkinson`s disease.","[{'entity1': 'Ulcerative colitis', 'relationship': 'exacerbates', 'entity2': 'lipopolysaccharide-induced damage to the nigral dopaminergic system'}, {'entity1': 'lipopolysaccharide-induced damage to the nigral dopaminergic system', 'relationship': 'potential risk factor', 'entity2': ""Parkinson's disease""}]"
,Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis.,"[{'entity1': 'Vagus nerve stimulation', 'relationship': 'inhibits', 'entity2': 'cytokine production'}, {'entity1': 'Vagus nerve stimulation', 'relationship': 'attenuates', 'entity2': 'disease severity in rheumatoid arthritis'}]"
,Neuroinflammation and Comorbidity of Pain and Depression.,"[{'entity1': 'Neuroinflammation', 'relationship': 'Comorbidity', 'entity2': 'Pain and Depression'}]"
,"An assessment of the effects of central interleukin-1β, −2, −6, and tumor necrosis factor-α administration on some behavioural, neurochemical, endocrine and immune parameters in the rat.","[{'entity1': 'interleukin-1β, −2, −6, and tumor necrosis factor-α ', 'relationship': 'effects', 'entity2': 'behavioural, neurochemical, endocrine and immune parameters'}]"
,Reduced glutathione as a physiological co-activator in the activation of peptidylarginine deiminase.,"[{'entity1': 'Reduced glutathione', 'relationship': 'co-activator', 'entity2': 'activation of peptidylarginine deiminase'}]"
,Characterization of the hypercitrullination reaction in human neutrophils and other leukocytes.,"[{'entity1': 'hypercitrullination reaction', 'relationship': 'characterization', 'entity2': 'human neutrophils'}, {'entity1': 'hypercitrullination reaction', 'relationship': 'characterization', 'entity2': 'other leukocytes'}]"
,Release of active peptidyl arginine deiminases by neutrophils can explain production of extracellular citrullinated autoantigens in rheumatoid arthritis synovial fluid.,"[{'entity1': 'Release of active peptidyl arginine deiminases', 'relationship': 'explain', 'entity2': 'production of extracellular citrullinated autoantigens'}, {'entity1': 'production of extracellular citrullinated autoantigens', 'relationship': 'in', 'entity2': 'rheumatoid arthritis synovial fluid'}]"
,Demonstration of extracellular peptidylarginine deiminase (PAD) activity in synovial fluid of patients with rheumatoid arthritis using a novel assay for citrullination of fibrinogen.,"[{'entity1': 'extracellular peptidylarginine deiminase activity', 'relationship': 'demonstration', 'entity2': 'synovial fluid'}, {'entity1': 'synovial fluid', 'relationship': 'of', 'entity2': 'patients with rheumatoid arthritis'}]"
,Reactive oxygen species inhibit catalytic activity of peptidylarginine deiminase.,"[{'entity1': 'Reactive oxygen species', 'relationship': 'inhibit', 'entity2': 'catalytic activity of peptidylarginine deiminase'}]"
,Smoking as a trigger for inflammatory rheumatic diseases.,"[{'entity1': 'Smoking', 'relationship': 'trigger', 'entity2': 'inflammatory rheumatic diseases'}]"
,Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells.,"[{'entity1': 'Smoking', 'relationship': 'increases', 'entity2': 'peptidylarginine deiminase 2 enzyme expression'}, {'entity1': 'Smoking', 'relationship': 'increases', 'entity2': 'citrullination in BAL cells'}]"
,Smoking is associated with increased levels of extracellular peptidylarginine deiminase 2 (PAD2) in the lungs.,"[{'entity1': 'Smoking', 'relationship': 'associated', 'entity2': 'increased levels of extracellular peptidylarginine deiminase 2'}, {'entity1': 'extracellular peptidylarginine deiminase 2', 'relationship': 'in', 'entity2': 'the lungs'}]"
,Expression of citrulline and homocitrulline residues in the lungs of non-smokers and smokers: implications for autoimmunity in rheumatoid arthritis.,"[{'entity1': 'Expression of citrulline and homocitrulline residues', 'relationship': 'implications', 'entity2': 'autoimmunity in rheumatoid arthritis'}, {'entity1': 'citrulline and homocitrulline residues', 'relationship': 'in', 'entity2': 'the lungs of non-smokers and smokers'}]"
,Off-pump CABG surgery reduces systemic inflammation compared with on-pump surgery but does not change systemic endothelial responses.,"[{'entity1': 'Off-pump CABG surgery', 'relationship': 'reduces', 'entity2': 'systemic inflammation'}, {'entity1': 'Off-pump CABG surgery', 'relationship': 'compared', 'entity2': 'on-pump surgery'}]"
,Soluble VCAM-1 is a very early marker of endothelial cell activation in cardiopulmonary bypass.,"[{'entity1': 'Soluble VCAM-1', 'relationship': 'marker', 'entity2': 'endothelial cell activation'}, {'entity1': 'endothelial cell activation', 'relationship': 'in', 'entity2': 'cardiopulmonary bypass'}]"
,Changes in adhesion molecule expression and oxidative burst activity of granulocytes and monocytes during open-heart surgery with cardiopulmonary bypass compared with abdominal surgery.,"[{'entity1': 'Changes in adhesion molecule expression and oxidative burst activity', 'relationship': 'of', 'entity2': 'granulocytes and monocytes'}, {'entity1': 'adhesion molecule expression and oxidative burst activity of granulocytes and monocytes', 'relationship': 'during', 'entity2': 'open-heart surgery with cardiopulmonary bypass'}, {'entity1': 'open-heart surgery with cardiopulmonary bypass', 'relationship': 'compared', 'entity2': 'abdominal surgery'}]"
,Release of soluble vascular endothelial growth factor receptor-1 (sFlt-1) during coronary artery bypass surgery.,"[{'entity1': 'Release of soluble vascular endothelial growth factor receptor-1', 'relationship': 'during', 'entity2': 'coronary artery bypass surgery'}]"
,Generation of monoclonal antibodies against peptidylarginine deiminase 2 (PAD2) and development of a PAD2-specific enzyme-linked immunosorbent assay.,"[{'entity1': 'Generation of monoclonal antibodies', 'relationship': 'against', 'entity2': 'peptidylarginine deiminase 2'}, {'entity1': 'development', 'relationship': 'of', 'entity2': 'a PAD2-specific enzyme-linked immunosorbent assay'}]"
,Oxidation of glutathione and cysteine in human plasma associated with smoking.,"[{'entity1': 'Oxidation of glutathione and cysteine', 'relationship': 'associated', 'entity2': 'smoking'}, {'entity1': 'glutathione and cysteine', 'relationship': 'in', 'entity2': 'human plasma'}]"
,Regulation of chemokine activity by posttranslational modification.,"[{'entity1': 'Regulation of chemokine activity', 'relationship': 'by', 'entity2': 'posttranslational modification'}]"
,Proteome analysis of rheumatoid arthritis gut mucosa.,"[{'entity1': 'Proteome analysis', 'relationship': 'of', 'entity2': 'rheumatoid arthritis gut mucosa'}]"
,Spontaneous secretion of the citrullination enzyme PAD2 and cell surface exposure of PAD4 by neutrophils.,"[{'entity1': 'Spontaneous secretion', 'relationship': 'of', 'entity2': 'the citrullination enzyme PAD2'}, {'entity1': 'cell surface exposure', 'relationship': 'of', 'entity2': 'PAD4'}, {'entity1': 'PAD4', 'relationship': 'by', 'entity2': 'neutrophils'}]"
,Inflammatory but not apoptotic death of granulocytes citrullinates fibrinogen.,"[{'entity1': 'Inflammatory death of granulocytes', 'relationship': 'citrullinates', 'entity2': 'fibrinogen'}]"
,"These are mitofusins(Mfn1 & Mfn2) transmembrane GTPases embedded in the mitochondrial outer membrane, Optic atro- phy1 (OPA) is a dynamin-related GTPases associated with the mitochondrial inner membrane or intermembrane space.","[{'entity1': 'mitofusins', 'relationship': 'embedded', 'entity2': 'mitochondrial outer membrane'}, {'entity1': 'Optic atrophy1', 'relationship': 'associated', 'entity2': 'mitochondrial inner membrane'}, {'entity1': 'Optic atrophy1', 'relationship': 'associated', 'entity2': 'intermembrane space'}]"
,"Proper balance of the antagonist activities of fusion and fission is crucial for fundamental mitochondrial integrity and func- tioning including energy metabolism, ROS generation, and apoptosis regulation.","[{'entity1': 'balance of fusion and fission', 'relationship': 'crucial', 'entity2': 'mitochondrial integrity'}, {'entity1': 'balance of fusion and fission', 'relationship': 'crucial', 'entity2': 'mitochondrial functioning'}, {'entity1': 'balance of fusion and fission', 'relationship': 'crucial', 'entity2': 'energy metabolism'}, {'entity1': 'balance of fusion and fission', 'relationship': 'crucial', 'entity2': 'ROS generation'}, {'entity1': 'balance of fusion and fission', 'relationship': 'crucial', 'entity2': 'apoptosis regulation'}]"
,Fission promotes the removal of damaged mitochondria by mitophagy to maintain proper assembly of electron transport chain complexes.,"[{'entity1': 'Fission', 'relationship': 'promotes', 'entity2': 'removal of damaged mitochondria'}, {'entity1': 'removal of damaged mitochondria', 'relationship': 'maintain', 'entity2': 'proper assembly of electron transport chain complexes'}]"
,"Fusion allows for mitochondrial interconnection, favoring mtDNA mixing, signal transmission and exchange of metabolites with in- network.","[{'entity1': 'Fusion', 'relationship': 'allows', 'entity2': 'mitochondrial interconnection'}, {'entity1': 'Fusion', 'relationship': 'favoring', 'entity2': 'mtDNA mixing'}, {'entity1': 'Fusion', 'relationship': 'allows', 'entity2': 'signal transmission'}, {'entity1': 'Fusion', 'relationship': 'allows', 'entity2': 'exchange of metabolites'}]"
,"On the other hand, fission ensures equal organelle segregation between daughter cells and target defective mitochondria for their subsequent removal through mitophagy.","[{'entity1': 'fission', 'relationship': 'ensures', 'entity2': 'equal organelle segregation between daughter cells'}, {'entity1': 'fission', 'relationship': 'target', 'entity2': 'defective mitochondria'}, {'entity1': 'defective mitochondria', 'relationship': 'removal through', 'entity2': 'mitophagy'}]"
,"The dynamic process controls mitochondrial morphology, biogenesis, transportation and localization, quality control and degradation, and apoptotic cell deaths.","[{'entity1': 'The dynamic process', 'relationship': 'controls', 'entity2': 'mitochondrial morphology'}, {'entity1': 'The dynamic process', 'relationship': 'controls', 'entity2': 'biogenesis'}, {'entity1': 'The dynamic process', 'relationship': 'controls', 'entity2': 'transportation'}, {'entity1': 'The dynamic process', 'relationship': 'controls', 'entity2': 'localization'}, {'entity1': 'The dynamic process', 'relationship': 'controls', 'entity2': 'quality control'}, {'entity1': 'The dynamic process', 'relationship': 'controls', 'entity2': 'degradation'}, {'entity1': 'The dynamic process', 'relationship': 'controls', 'entity2': 'apoptotic cell deaths'}]"
,"Inflammation is a biological response of the immune system that can be triggered by a variety of factors, including pathogens, damaged cells and toxic compounds. These  factors  may induce  acute  and/or  chronic  inflammatory  responses  in  the heart, pancreas, liver, kidney, lung, brain, intestinal tract and reproductive system, potentially leading to tissue damage or disease.","[{'entity1': 'Inflammation', 'relationship': 'triggered by', 'entity2': 'pathogens'}, {'entity1': 'Inflammation', 'relationship': 'triggered by', 'entity2': 'damaged cells'}, {'entity1': 'Inflammation', 'relationship': 'triggered by', 'entity2': 'toxic compounds'}, {'entity1': 'factors', 'relationship': 'induce', 'entity2': 'acute inflammatory responses'}, {'entity1': 'factors', 'relationship': 'induce', 'entity2': 'chronic inflammatory responses'}, {'entity1': 'Inflammatory responses', 'relationship': 'potentially leading to', 'entity2': 'tissue damage'}, {'entity1': 'Inflammatory responses', 'relationship': 'potentially leading to', 'entity2': 'disease'}]"
,"Various pathogenic factors, such as infection, tissue injury, or cardiac infarction, can induce inflammation by causing  tissue  damage.","[{'entity1': 'pathogenic factors', 'relationship': 'induce', 'entity2': 'inflammation'}, {'entity1': 'infection', 'relationship': 'induce', 'entity2': 'inflammation'}, {'entity1': 'tissue injury', 'relationship': 'induce', 'entity2': 'inflammation'}, {'entity1': 'cardiac infarction', 'relationship': 'induce', 'entity2': 'inflammation'}, {'entity1': 'pathogenic factors', 'relationship': 'cause', 'entity2': 'tissue damage'}]"
,DAMPs are host biomolecules that can initiate and perpetuate a non-infectious inflammatory response.,"[{'entity1': 'DAMPs', 'relationship': 'initiate', 'entity2': 'non-infectious inflammatory response'}, {'entity1': 'DAMPs', 'relationship': 'perpetuate', 'entity2': 'non-infectious inflammatory response'}]"
,Disrupted cells can also recruit innate inflammatory cells in the absence of pathogens by releasing DAMPs,"[{'entity1': 'Disrupted cells', 'relationship': 'recruit', 'entity2': 'innate inflammatory cells'}, {'entity1': 'DAMPs', 'relationship': 'released by', 'entity2': 'Disrupted cells'}]"
,"More than ten members of the TLR family have been identified, and TLRs are the most well-studied of the known PRRs","[{'entity1': 'TLRs', 'relationship': 'well-studied', 'entity2': 'PRRs'}]"
,Transmission of PAMPs and DAMPs is mediated by myeloid differentiation factor-88 (MyD88) along with TLRs.,"[{'entity1': 'Transmission of PAMPs', 'relationship': 'mediated by', 'entity2': 'myeloid differentiation factor-88'}, {'entity1': 'Transmission of DAMPs', 'relationship': 'mediated by', 'entity2': 'myeloid differentiation factor-88'}, {'entity1': 'Transmission of PAMPs', 'relationship': 'mediated by', 'entity2': 'TLRs'}, {'entity1': 'Transmission of DAMPs', 'relationship': 'mediated by', 'entity2': 'TLRs'}]"
,"DAMPs and PAMPs share receptors, such as TLR4, suggesting similarities between infectious and noninfectious inflammatory responses","[{'entity1': 'DAMPs', 'relationship': 'share', 'entity2': 'TLR4'}, {'entity1': 'PAMPs', 'relationship': 'share', 'entity2': 'TLR4'}, {'entity1': 'TLR4', 'relationship': 'suggest', 'entity2': 'similarities between infectious and noninfectious inflammatory responses'}]"
,Coagulation in sepsis.,"[{'entity1': 'Coagulation', 'relationship': 'in', 'entity2': 'sepsis'}]"
,Thrombin: coagulation’s master regulator of innate immunity.,"[{'entity1': 'Thrombin', 'relationship': 'master regulator', 'entity2': 'coagulation'}, {'entity1': 'Thrombin', 'relationship': 'regulator', 'entity2': 'innate immunity'}]"
,The roles of fibrinogen and fibrin in hemostasis and thrombosis.,"[{'entity1': 'fibrinogen', 'relationship': 'roles', 'entity2': 'hemostasis and thrombosis'}, {'entity1': 'fibrin', 'relationship': 'roles', 'entity2': 'hemostasis and thrombosis'}]"
,Blood coagulation and the risk of atherothrombosis: a complex relationship.,"[{'entity1': 'Blood coagulation', 'relationship': 'risk', 'entity2': 'atherothrombosis'}, {'entity1': 'Blood coagulation', 'relationship': 'complex relationship', 'entity2': 'atherothrombosis'}]"
,Disseminated intravascular coagulation in sepsis.,"[{'entity1': 'Disseminated intravascular coagulation', 'relationship': 'in', 'entity2': 'sepsis'}]"
,"The inflammatory response is an adaptive mechanism that evolved to fight against infections and tissue damage. This complex mechanism is vital for the proper function of the organism, and because of that, is under tight regulation involving a complex network of factors, cells, and systems.","[{'entity1': 'inflammatory response', 'relationship': 'evolved', 'entity2': 'fight against infections and tissue damage'}, {'entity1': 'inflammatory response', 'relationship': 'vital', 'entity2': 'proper function of the organism'}]"
,"Physiological inflammation is perfectly orchestrated to allow the mobilization of leukocytes from the circulation to the injured tissues for the removal of pathogens, tissue repair, and return to homeostasis.","[{'entity1': 'Physiological inflammation', 'relationship': 'orchestrated', 'entity2': 'mobilization of leukocytes'}, {'entity1': 'mobilization of leukocytes', 'relationship': 'removal', 'entity2': 'pathogens'}, {'entity1': 'mobilization of leukocytes', 'relationship': 'repair', 'entity2': 'tissue'}, {'entity1': 'mobilization of leukocytes', 'relationship': 'return', 'entity2': 'homeostasis'}]"
,"However, when the self-limited nature of the inflammatory response and the mechanisms of resolution fail, inflammation might become chronic, leading to the development of many disabling serious diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), or psoriasis.","[{'entity1': 'inflammatory response', 'relationship': 'fail', 'entity2': 'mechanisms of resolution'}, {'entity1': 'inflammatory response', 'relationship': 'become', 'entity2': 'chronic'}, {'entity1': 'chronic inflammatory response', 'relationship': 'leading', 'entity2': 'development of disabling serious diseases'}]"
,"This resulted in enormous improvements in the treatments for immune-mediated inflammatory diseases, but also revealed the com-plexity of the cytokine networks and immune cell subtypes involved in non-resolvinginflammatory responses.","[{'entity1': 'enormous improvements', 'relationship': 'resulted', 'entity2': 'treatments for immune-mediated inflammatory diseases'}, {'entity1': 'enormous improvements', 'relationship': 'revealed', 'entity2': 'complexity of cytokine networks and immune cell subtypes'}, {'entity1': 'complexity of cytokine networks and immune cell subtypes', 'relationship': 'involved', 'entity2': 'non-resolving inflammatory responses'}]"
,"While an acute inflammatory response is protective, chronic neuroinflammation leads to inflamma-tory conditions such as multiple sclerosis, and it also contributes to other neurological [1] and psychiatric disorders such as Alzheimer’s or Parkinson’s disease [2].","[{'entity1': 'acute inflammatory response', 'relationship': 'protective', 'entity2': ''}, {'entity1': 'chronic neuroinflammation', 'relationship': 'leads to', 'entity2': 'inflammatory conditions'}, {'entity1': 'chronic neuroinflammation', 'relationship': 'contributes to', 'entity2': 'neurological and psychiatric disorders'}]"
,Experimental Encephalitozoon cuniculi infection acquired from fermented meat products.,"[{'entity1': 'Encephalitozoon cuniculi infection', 'relationship': 'acquired from', 'entity2': 'fermented meat products'}]"
,Acute disseminated encephalomyelitis and reactivation of cerebral toxoplasmosis in a child: case report.,"[{'entity1': 'Acute disseminated encephalomyelitis', 'relationship': 'reactivation', 'entity2': 'cerebral toxoplasmosis'}]"
,The course of infection caused by Encephalitozoon cuniculi genotype III in immunocompetent and immunodeficient mice.,"[{'entity1': 'infection', 'relationship': 'caused by', 'entity2': 'Encephalitozoon cuniculi genotype III'}, {'entity1': 'infection', 'relationship': 'course', 'entity2': 'immunocompetent and immunodeficient mice'}]"
,Microsporidiosis is not just in AIDS patients.,"[{'entity1': 'Microsporidiosis', 'relationship': 'in', 'entity2': 'AIDS patients'}]"
,"Insulin resistance (IR) is known to be characteristic of type 2 diabetes mellitus,             and is regarded as an important mechanism in disease pathogenesis.","[{'entity1': 'Insulin resistance', 'relationship': 'characteristic', 'entity2': 'Type 2 diabetes mellitus'}, {'entity1': 'Insulin resistance', 'relationship': 'mechanism', 'entity2': 'disease pathogenesis'}]"
,One of the key pathogenetic             mechanisms  of  IR  progression  is  impaired  free  fatty  acid  (FFA)  metabolism.,"[{'entity1': 'pathogenesis', 'relationship': 'progression', 'entity2': 'impaired free fatty acid metabolism'}]"
,"Plasminogen-            activator inhibitor 1 (PAI-1) and key inflammation markers, ie, interleukin 6 (IL-6) and C-reactive             protein (CRP), also play a role.","[{'entity1': 'Plasminogen-activator inhibitor 1', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'Interleukin 6', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'C-reactive protein', 'relationship': 'role', 'entity2': 'Insulin resistance'}]"
,"Among  proinflammatory  cytokines  contributing  to         IR  development,  the  role  of  interleukin  (IL)-6,  which  has         autocrine and paracrine properties and is involved in insulin         reception and free fatty acid (FFA) metabolism regulation,         has been extensively studied.","[{'entity1': 'Interleukin 6', 'relationship': 'contributing', 'entity2': 'Insulin resistance development'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'insulin reception'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'free fatty acid metabolism regulation'}]"
69.0,"Recent literature delineated the importance of IL-8 and IL-10 in the molecular mechanisms driving GI inflammatory diseases.14,15 The fact that c-MIM-1 includes ULD of IL-8 and LD of IL-10 in its formulation thus motivated the choice of assessing the cellular effects of this medicine in an in vitro model of intestinal inflammation","[{'entity1': 'IL-8', 'relationship': 'importance', 'entity2': 'molecular mechanisms driving GI inflammatory diseases'}, {'entity1': 'IL-10', 'relationship': 'importance', 'entity2': 'molecular mechanisms driving GI inflammatory diseases'}, {'entity1': 'c-MIM-1', 'relationship': 'includes', 'entity2': 'ULD of IL-8'}, {'entity1': 'c-MIM-1', 'relationship': 'includes', 'entity2': 'LD of IL-10'}, {'entity1': 'c-MIM-1', 'relationship': 'assessed', 'entity2': 'cellular effects in an in vitro model of intestinal inflammation'}]"
70.0,"Numerous treatment strategies have been employed in order to reduce inflammation and immunotherapies are one of them.  For  instance,  the  use  of  cytokine-based  therapies  has  been  reported  in  the  management  of  sepsis,  diabetes,  or cardiovascular  diseases  with  quite  promising  results.","[{'entity1': 'treatment strategies', 'relationship': 'employed', 'entity2': 'reduce inflammation'}, {'entity1': 'immunotherapies', 'relationship': 'instance', 'entity2': 'cytokine-based therapies'}, {'entity1': 'cytokine-based therapies', 'relationship': 'reported', 'entity2': 'management of sepsis, diabetes, cardiovascular diseases'}]"
72.0,"Cortical Neurons were cultured from cortexes removed from rat fetuses. The cortexes were dissociated by trypsin-EDTA for 20 min at 37°C. The cells were cultured in Neurobasal medium supplemented with B27, L-glutamine, antibiotics, FCS and BDNF.","[{'entity1': 'Cortical Neurons', 'relationship': 'cultured from', 'entity2': 'cortexes from rat fetuses'}, {'entity1': 'cortexes', 'relationship': 'removed from', 'entity2': 'rat fetuses'}, {'entity1': 'cortexes', 'relationship': 'dissociated by', 'entity2': 'trypsin-EDTA'}, {'entity1': 'Cortical Neurons', 'relationship': 'cultured in', 'entity2': 'Neurobasal medium with supplements'}]"
73.0,"Astrocytes and microglia were cultured from rat glial cells. The cells were seeded in flasks and after 5 days, dissociated and added to neuron cultures.","[{'entity1': 'Astrocytes and microglia', 'relationship': 'cultured from', 'entity2': 'rat glial cells'}, {'entity1': 'rat glial cells', 'relationship': 'seeded in', 'entity2': 'flasks'}, {'entity1': 'rat glial cells', 'relationship': 'dissociated after', 'entity2': '5 days'}, {'entity1': 'Astrocytes and microglia', 'relationship': 'added to', 'entity2': 'neuron cultures'}]"
74.0,"After 8 days coculture, cells were treated with c-MIM-2, MK801 or vehicle. After 9 days coculture, cells were treated with or without LPS/IFN-gamma combination.","[{'entity1': 'cells', 'relationship': 'treated after', 'entity2': '8 days coculture'}, {'entity1': 'cells', 'relationship': 'treated with', 'entity2': 'c-MIM-2, MK801 or vehicle'}, {'entity1': 'cells ', 'relationship': 'treated after', 'entity2': '9 days coculture'}, {'entity1': 'cells', 'relationship': 'treated with', 'entity2': 'LPS/IFN-gamma'}]"
75.0,"After LPS/IFN-gamma treatment, supernatants were collected to quantify TNF-alpha release. Cortical neuron survival was analyzed after 48 hours incubation.","[{'entity1': 'supernatants', 'relationship': 'collected after', 'entity2': 'LPS/IFN-gamma treatment'}, {'entity1': 'TNF-alpha', 'relationship': 'release quantified from', 'entity2': 'supernatants'}, {'entity1': 'Cortical neuron survival', 'relationship': 'analyzed after', 'entity2': '48 hours incubation'}]"
76.0,Neuronal cell survival was quantified by MAP2 immunostaining. Released TNF-alpha was measured by ELISA.,"[{'entity1': 'Neuronal cell survival', 'relationship': 'quantified by', 'entity2': 'MAP2 immunostaining'}, {'entity1': 'Released TNF-alpha', 'relationship': 'measured by', 'entity2': 'ELISA'}]"
,"Recent literature delineated the importance of IL-8 and IL-10 in the molecular mechanisms driving GI inflammatory diseases.14,15 The fact that c-MIM-1 includes ULD of IL-8 and LD of IL-10 in its formulation thus motivated the choice of assessing the cellular effects of this medicine in an in vitro model of intestinal inflammation (Figure 2B, red box).","[{'entity1': 'IL-8', 'relationship': 'importance', 'entity2': 'molecular mechanisms driving GI inflammatory diseases'}, {'entity1': 'IL-10', 'relationship': 'importance', 'entity2': 'molecular mechanisms driving GI inflammatory diseases'}, {'entity1': 'c-MIM-1', 'relationship': 'includes', 'entity2': 'ULD of IL-8'}, {'entity1': 'c-MIM-1', 'relationship': 'includes', 'entity2': 'LD of IL-10'}, {'entity1': 'cellular effects of c-MIM-1', 'relationship': 'assessing', 'entity2': 'in vitro model of intestinal inflammation'}]"
,"In a more general approach, c-MIM-2 and c-MIM-3 have been investigated in vitro, on the immune axis in different cell types and inflamed experimental contexts (Figure 2B, blue box).","[{'entity1': 'c-MIM-2', 'relationship': 'investigated', 'entity2': 'in vitro'}, {'entity1': 'c-MIM-3', 'relationship': 'investigated', 'entity2': 'in vitro'}, {'entity1': 'c-MIM-2', 'relationship': 'investigated', 'entity2': 'immune axis'}, {'entity1': 'c-MIM-3', 'relationship': 'investigated', 'entity2': 'immune axis'}, {'entity1': 'c-MIM-2', 'relationship': 'investigated', 'entity2': 'different cell types'}, {'entity1': 'c-MIM-3', 'relationship': 'investigated', 'entity2': 'different cell types'}, {'entity1': 'c-MIM-2', 'relationship': 'investigated', 'entity2': 'inflamed experimental contexts'}, {'entity1': 'c-MIM-3', 'relationship': 'investigated', 'entity2': 'inflamed experimental contexts'}]"
,"These two formulations employ ULD of IL-1β and TNF-α in association with ULD of PGE2, or ULD of IL-6, IL-13, and OSM, and LD of IL-10, or LD of TGF-β and IL- 1Ra.","[{'entity1': 'Two formulations', 'relationship': 'employ', 'entity2': 'ULD of IL-1β'}, {'entity1': 'Two formulations', 'relationship': 'employ', 'entity2': 'TNF-α'}, {'entity1': 'Two formulations', 'relationship': 'employ', 'entity2': 'ULD of PGE2'}, {'entity1': 'Two formulations', 'relationship': 'employ', 'entity2': 'ULD of IL-6'}, {'entity1': 'Two formulations', 'relationship': 'employ', 'entity2': 'ULD of IL-13'}, {'entity1': 'Two formulations', 'relationship': 'employ', 'entity2': 'ULD of OSM'}, {'entity1': 'Two formulations', 'relationship': 'employ', 'entity2': 'LD of IL-10'}, {'entity1': 'Two formulations', 'relationship': 'employ', 'entity2': 'LD of TGF-β'}, {'entity1': 'Two formulations', 'relationship': 'employ', 'entity2': 'LD of IL-1Ra'}]"
,"Finally, in the case of c-MIM-4, which employs ULD of both IL-6 and IL-12 in its formulation, as well as IL-4 at LD, one of the goals of this study was to assess its effects using an in vitro preclinical model of neuronal inflammation (Figure 2B, yellow box).","[{'entity1': 'c-MIM-4', 'relationship': 'employs', 'entity2': 'ULD of IL-6'}, {'entity1': 'c-MIM-4', 'relationship': 'employs', 'entity2': 'ULD of IL-12'}, {'entity1': 'c-MIM-4', 'relationship': 'employs', 'entity2': 'LD of IL-4'}, {'entity1': 'effects of c-MIM-4', 'relationship': 'assess', 'entity2': 'in vitro preclinical model of neuronal inflammation'}]"
80.0,"Standard anesthetic techniques were used, and intra-operative monitoring was in accordance with guidelines. Standard guidelines for anti-coagulation therapy were followed.",[]
81.0,"Blood samples were drawn 2 hrs before surgery and 2 hrs after surgery (from the closure of the skin) in 6 mL dry tubes (VACUETTE, Greiner Bio-One, Frickenhausen, Germany), from which serum was isolated.","[{'entity1': 'Blood samples', 'relationship': 'drawn from', 'entity2': 'patients'}, {'entity1': 'Blood samples', 'relationship': 'drawn', 'entity2': 'before surgery'}, {'entity1': 'Blood samples', 'relationship': 'drawn', 'entity2': 'after surgery'}, {'entity1': 'Serum', 'relationship': 'isolated from', 'entity2': 'blood samples'}]"
82.0,"Serum IL-6, IL-10 and CXCL-8 were measured using the Cytometric Bead Array Human Inflammatory Cytokine Kit II (Cat. no. 551811) from BD Biosciences (Franklin Lakes, NJ, USA) after dilution of 5 μL serum in 20 μL PBS according to the manufacturer’s instructions.","[{'entity1': 'IL-6', 'relationship': 'measured in', 'entity2': 'Serum'}, {'entity1': 'IL-10', 'relationship': 'measured in', 'entity2': 'Serum'}, {'entity1': 'CXCL-8', 'relationship': 'measured in', 'entity2': 'Serum'}]"
83.0,"Neutrophil activation markers were measured in serum diluted 1:50 in sample diluent following the manufacturer’s instructions using the Luminex Bio-Plex® 200 system (Bio-Rad Laboratories, Hercules, CA, USA) by means of the one- plex myeloperodidase (MPO) assay (R&D, Abingdon, UK), and the two-plex MMP-9 and lipocalin-2/NGAL (R&D) assay.","[{'entity1': 'Neutrophil activation markers', 'relationship': 'measured in', 'entity2': 'serum'}, {'entity1': 'Myeloperoxidase', 'relationship': 'measured by', 'entity2': 'Luminex assay'}, {'entity1': 'MMP-9', 'relationship': 'measured by', 'entity2': 'Luminex assay'}, {'entity1': 'Lipocalin-2', 'relationship': 'measured by', 'entity2': 'Luminex assay'}]"
84.0,"PAD2 was measured using an in-house PAD2-specific assay on a Luminex platform.25 In brief, the murine monoclonal anti-PAD2 antibody DN2 was coupled to beads, and patient serum diluted 1:3 in sample buffer was added.","[{'entity1': 'PAD2', 'relationship': 'measured in', 'entity2': 'patient serum'}, {'entity1': 'anti-PAD2 antibody', 'relationship': 'used to measure', 'entity2': 'PAD2'}]"
85.0,"PAD activity in serum was determined using a previously described assay for matrix-bound fibrinogen citrullination.13 In brief, Nunc ELISA plates (Roskilde, Denmark) were coated with fibrinogen (1.0 μg/mL).","[{'entity1': 'PAD activity', 'relationship': 'determined in', 'entity2': 'serum'}, {'entity1': 'citrullination', 'relationship': 'target', 'entity2': 'fibrinogen'}, {'entity1': 'fibrinogen', 'relationship': 'used for', 'entity2': 'assay of PAD activity'}]"
86.0,"Peptidylarginine deiminase (PAD) catalyzes citrullination, a post-translational modification that can alter structure, function and antigenicity of proteins. Citrullination in the lungs due to smoking is believed to initiate an anti-citrulline immune response in rheumatoid arthritis.","[{'entity1': 'Peptidylarginine deiminase', 'relationship': 'catalyzes', 'entity2': 'citrullination'}, {'entity1': 'citrullination', 'relationship': 'alter', 'entity2': 'structure, function and antigenicity of proteins'}, {'entity1': 'Citrullination', 'relationship': 'initiate', 'entity2': 'anti-citrulline immune response'}, {'entity1': 'anti-citrulline immune response', 'relationship': 'in', 'entity2': 'rheumatoid arthritis'}]"
87.0,"Citrullination in other inflamed organs has also been demonstrated, but it is not known whether smoking or inflammatory processes in general result in release of relevant amounts of PAD into the circulation with potential to cause citrullination of proteins at various anatomical sites.","[{'entity1': 'Citrullination', 'relationship': 'demonstrated', 'entity2': 'other inflamed organs'}, {'entity1': 'smoking', 'relationship': 'result', 'entity2': 'release of PAD into the circulation'}, {'entity1': 'inflammatory processes', 'relationship': 'result', 'entity2': 'release of PAD into the circulation'}, {'entity1': 'release of PAD into the circulation', 'relationship': 'potential', 'entity2': 'citrullination of proteins at various anatomical sites'}]"
88.0,Coronary artery bypass grafting (CABG) using cardiopulmonary bypass (CPB) induces an acute systemic inflammation response.,"[{'entity1': 'Coronary artery bypass grafting using cardiopulmonary bypass', 'relationship': 'induces', 'entity2': 'acute systemic inflammation response'}]"
89.0,"Neutrophils are considered a major source of PAD2 and PAD4, and PAD released from neutrophils is capable of citrullinating extracellular proteins.","[{'entity1': 'Neutrophils', 'relationship': 'source', 'entity2': 'PAD2 and PAD4'}, {'entity1': 'PAD released from neutrophils', 'relationship': 'capable', 'entity2': 'citrullinating extracellular proteins'}]"
90.0,"Standard anesthetic techniques were used, and intra-operative monitoring was in accordance with guidelines. Standard guidelines for anti-coagulation therapy were followed.","[{'entity1': 'Standard anesthetic techniques', 'relationship': 'used'}, {'entity1': 'intra-operative monitoring', 'relationship': 'accordance', 'entity2': 'guidelines'}, {'entity1': 'Standard guidelines', 'relationship': 'followed', 'entity2': 'anti-coagulation therapy'}]"
91.0,"Blood samples were drawn 2 hrs before surgery and 2 hrs after surgery (from the closure of the skin) in 6 mL dry tubes (VACUETTE, Greiner Bio-One, Frickenhausen, Germany), from which serum was isolated.","[{'entity1': 'Blood samples', 'relationship': 'drawn', 'entity2': '2 hrs before surgery'}, {'entity1': 'Blood samples', 'relationship': 'drawn', 'entity2': '2 hrs after surgery'}]"
92.0,"Serum IL-6, IL-10 and CXCL-8 were measured using the Cytometric Bead Array Human Inflammatory Cytokine Kit II (Cat. no. 551811) from BD Biosciences (Franklin Lakes, NJ, USA) after dilution of 5 μL serum in 20 μL PBS according to the manufacturer’s instructions.","[{'entity1': 'Serum IL-6', 'relationship': 'measured'}, {'entity1': 'Serum IL-10', 'relationship': 'measured'}, {'entity1': 'Serum CXCL-8', 'relationship': 'measured'}]"
93.0,"Neutrophil activation markers were measured in serum diluted 1:50 in sample diluent following the manufacturer’s instructions using the Luminex Bio-Plex® 200 system (Bio-Rad Laboratories, Hercules, CA, USA) by means of the one- plex myeloperodidase (MPO) assay (R&D, Abingdon, UK), and the two-plex MMP-9 and lipocalin-2/NGAL (R&D) assay.","[{'entity1': 'Neutrophil activation markers', 'relationship': 'measured', 'entity2': 'serum'}, {'entity1': 'myeloperoxidase', 'relationship': 'measured', 'entity2': 'serum'}, {'entity1': 'MMP-9', 'relationship': 'measured', 'entity2': 'serum'}, {'entity1': 'lipocalin-2', 'relationship': 'measured', 'entity2': 'serum'}]"
94.0,"The levels of all three molecules increased after surgery (Figure 3A–C). To address the degree of neutrophil activation, we quantified MPO, MMP-9 and lipocalin-2, as markers of degranulation of the primary, secondary and tertiary granules, respectively.","[{'entity1': 'The levels', 'relationship': 'increased', 'entity2': 'after surgery'}, {'entity1': 'MPO', 'relationship': 'quantified'}, {'entity1': 'MMP-9', 'relationship': 'quantified'}, {'entity1': 'lipocalin-2', 'relationship': 'quantified'}]"
95.0,"Citrullination alters the function and antigenicity of
many proteins2,4,27 and is thought
to play a critical
role in the pathogenesis of certain autoimmune diseases,
especially RA.7","[{'entity1': 'Citrullination', 'relationship': 'alters', 'entity2': 'function and antigenicity of many proteins'}, {'entity1': 'Citrullination', 'relationship': 'role', 'entity2': 'pathogenesis of certain autoimmune diseases'}]"
96.0,"Citrullination in this respect is thought
to occur at the very sites of PAD release, eg, in the
lungs, periodontal tissue or gut.15,19,28","[{'entity1': 'Citrullination', 'relationship': 'occur', 'entity2': 'sites of PAD release'}]"
97.0,"In this study, we
put forward the hypothesis that PAD is released into the
circulation following smoking or acute inflammation.","[{'entity1': 'PAD', 'relationship': 'released', 'entity2': 'circulation'}, {'entity1': 'PAD release', 'relationship': 'following', 'entity2': 'smoking'}, {'entity1': 'PAD release', 'relationship': 'following', 'entity2': 'acute inflammation'}]"
98.0,"PAD2 was present in detectable concentrations in the
blood from most patients before surgery, and was found to
be markedly increased after surgery.","[{'entity1': 'PAD2', 'relationship': 'present', 'entity2': 'blood'}, {'entity1': 'PAD2', 'relationship': 'increased', 'entity2': 'after surgery'}]"
99.0,"This was not the case
for PAD4 levels.","[{'entity1': 'PAD4 levels', 'relationship': 'not the case', 'entity2': ''}]"
100.0,"Although smokers tended to have slightly
higher blood levels of PAD2 than non-smokers, there was
a great overlap between our groups.","[{'entity1': 'smokers', 'relationship': 'have', 'entity2': 'higher blood levels of PAD2'}]"
101.0,"Increased amounts of
PAD2 along with increased numbers of macrophages have
previously been shown in the lungs of smokers.","[{'entity1': 'Increased amounts of PAD2', 'relationship': 'along with', 'entity2': 'increased numbers of macrophages'}, {'entity1': 'Increased amounts of PAD2', 'relationship': 'shown', 'entity2': 'lungs of smokers'}]"
102.0,"Neutrophils
are a predominant source of PAD2 and PAD4,9,10,12 and our
finding that the increase in PAD2 levels during surgery
correlated with the increase in neutrophil activation markers –
but not with changes in proinflammatory cytokines – is in
keeping with this.","[{'entity1': 'Neutrophils', 'relationship': 'source', 'entity2': 'PAD2 and PAD4'}, {'entity1': 'increase in PAD2 levels', 'relationship': 'correlated', 'entity2': 'increase in neutrophil activation markers'}]"
103.0,"Insulin resistance (IR) is known to be characteristic of type 2 diabetes mellitus, and is regarded as an important mechanism in disease pathogenesis. One of the key pathogenetic mechanisms of IR progression is impaired free fatty acid (FFA) metabolism. Plasminogen-activator inhibitor 1 (PAI-1) and key inflammation markers, ie, interleukin 6 (IL-6) and C-reactive protein (CRP), also play a role.","[{'entity1': 'Insulin resistance', 'relationship': 'characteristic', 'entity2': 'Type 2 diabetes mellitus'}, {'entity1': 'Insulin resistance', 'relationship': 'mechanism', 'entity2': 'disease pathogenesis'}, {'entity1': 'pathogenesis', 'relationship': 'progression', 'entity2': 'impaired free fatty acid metabolism'}, {'entity1': 'Plasminogen-activator inhibitor 1', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'Interleukin 6', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'C-reactive protein', 'relationship': 'role', 'entity2': 'Insulin resistance'}]"
104.0,"Among proinflammatory cytokines contributing to IR development, the role of interleukin (IL)-6, which has autocrine and paracrine properties and is involved in insulin reception and free fatty acid (FFA) metabolism regulation, has been extensively studied.","[{'entity1': 'Interleukin 6', 'relationship': 'contributing', 'entity2': 'Insulin resistance development'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'insulin reception'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'free fatty acid metabolism regulation'}]"
105.0,Reduced glutathione as a physiological co-activator in the activation of peptidylarginine deiminase.,"[{'entity1': 'Reduced glutathione', 'relationship': 'co-activator', 'entity2': 'activation of peptidylarginine deiminase'}]"
106.0,Characterization of the hypercitrullination reaction in human neutrophils and other leukocytes.,"[{'entity1': 'hypercitrullination reaction', 'relationship': 'characterization', 'entity2': 'human neutrophils'}, {'entity1': 'hypercitrullination reaction', 'relationship': 'characterization', 'entity2': 'other leukocytes'}]"
107.0,Release of active peptidyl arginine deiminases by neutrophils can explain production of extracellular citrullinated autoantigens in rheumatoid arthritis synovial fluid.,"[{'entity1': 'Release of active peptidyl arginine deiminases', 'relationship': 'explain', 'entity2': 'production of extracellular citrullinated autoantigens in rheumatoid arthritis synovial fluid'}]"
108.0,Demonstration of extracellular peptidylarginine deiminase (PAD) activity in synovial fluid of patients with rheumatoid arthritis using a novel assay for citrullination of fibrinogen.,"[{'entity1': 'extracellular peptidylarginine deiminase activity', 'relationship': 'demonstration', 'entity2': 'synovial fluid of patients with rheumatoid arthritis'}]"
109.0,Reactive oxygen species inhibit catalytic activity of peptidylarginine deiminase.,"[{'entity1': 'Reactive oxygen species', 'relationship': 'inhibit', 'entity2': 'catalytic activity of peptidylarginine deiminase'}]"
110.0,Smoking as a trigger for inflammatory rheumatic diseases.,"[{'entity1': 'Smoking', 'relationship': 'trigger', 'entity2': 'inflammatory rheumatic diseases'}]"
111.0,Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells.,"[{'entity1': 'Smoking', 'relationship': 'increases', 'entity2': 'peptidylarginine deiminase 2 enzyme expression in human lungs'}, {'entity1': 'Smoking', 'relationship': 'increases', 'entity2': 'citrullination in BAL cells'}]"
112.0,Smoking is associated with increased levels of extracellular peptidylarginine deiminase 2 (PAD2) in the lungs.,"[{'entity1': 'Smoking', 'relationship': 'associated', 'entity2': 'increased levels of extracellular peptidylarginine deiminase 2 in the lungs'}]"
113.0,Expression of citrulline and homocitrulline residues in the lungs of non-smokers and smokers: implications for autoimmunity in rheumatoid arthritis.,"[{'entity1': 'Expression of citrulline and homocitrulline residues', 'relationship': 'implications', 'entity2': 'autoimmunity in rheumatoid arthritis'}]"
114.0,Off-pump CABG surgery reduces systemic inflammation compared with on-pump surgery but does not change systemic endothelial responses.,"[{'entity1': 'Off-pump CABG surgery', 'relationship': 'reduces', 'entity2': 'systemic inflammation'}]"
115.0,Soluble VCAM-1 is a very early marker of endothelial cell activation in cardiopulmonary bypass.,"[{'entity1': 'Soluble VCAM-1', 'relationship': 'marker', 'entity2': 'endothelial cell activation in cardiopulmonary bypass'}]"
116.0,Changes in adhesion molecule expression and oxidative burst activity of granulocytes and monocytes during open-heart surgery with cardiopulmonary bypass compared with abdominal surgery.,"[{'entity1': 'open-heart surgery with cardiopulmonary bypass', 'relationship': 'Changes', 'entity2': 'adhesion molecule expression of granulocytes and monocytes'}, {'entity1': 'open-heart surgery with cardiopulmonary bypass', 'relationship': 'Changes', 'entity2': 'oxidative burst activity of granulocytes and monocytes'}]"
117.0,Release of soluble vascular endothelial growth factor receptor-1 (sFlt-1) during coronary artery bypass surgery.,"[{'entity1': 'Release', 'relationship': '', 'entity2': 'soluble vascular endothelial growth factor receptor-1 during coronary artery bypass surgery'}]"
118.0,Generation of monoclonal antibodies against peptidylarginine deiminase 2 (PAD2) and development of a PAD2-specific enzyme-linked immunosorbent assay.,"[{'entity1': 'Generation', 'relationship': '', 'entity2': 'monoclonal antibodies against peptidylarginine deiminase 2'}, {'entity1': 'development', 'relationship': '', 'entity2': 'a PAD2-specific enzyme-linked immunosorbent assay'}]"
119.0,Oxidation of glutathione and cysteine in human plasma associated with smoking.,"[{'entity1': 'Oxidation of glutathione and cysteine', 'relationship': 'associated', 'entity2': 'smoking'}]"
120.0,Regulation of chemokine activity by posttranslational modification.,"[{'entity1': 'Regulation', 'relationship': '', 'entity2': 'chemokine activity by posttranslational modification'}]"
121.0,Mitochondria are organelles with highly dynamic ultrastructure maintained by flexible fusion and fission rates governed by Guanosine Triphosphatases (GTPases) dependent proteins. Balanced control of mitochondrial quality control is crucial for maintaining cellular energy and metabolic homeostasis;,"[{'entity1': 'Mitochondria', 'relationship': 'maintained by', 'entity2': 'flexible fusion and fission rates'}, {'entity1': 'fusion and fission rates', 'relationship': 'governed by', 'entity2': 'Guanosine Triphosphatases (GTPases) dependent proteins'}, {'entity1': 'Balanced control', 'relationship': 'crucial for', 'entity2': 'maintaining cellular energy and metabolic homeostasis'}]"
122.0,"However, dysfunction of the dynamics of fusion and fission causes loss of integrity and functions with the accumulation of damaged mitochondria and mitochondrial deoxyribose nucleic acid (mtDNA) that can halt energy production and induce oxidative stress.","[{'entity1': 'dysfunction of the dynamics of fusion and fission', 'relationship': 'causes', 'entity2': 'loss of integrity and functions'}, {'entity1': 'dysfunction of the dynamics of fusion and fission', 'relationship': 'causes', 'entity2': 'accumulation of damaged mitochondria and mitochondrial deoxyribose nucleic acid (mtDNA)'}, {'entity1': 'accumulation of damaged mitochondria and mitochondrial deoxyribose nucleic acid (mtDNA)', 'relationship': 'can', 'entity2': 'halt energy production'}, {'entity1': 'accumulation of damaged mitochondria and mitochondrial deoxyribose nucleic acid (mtDNA)', 'relationship': 'induce', 'entity2': 'oxidative stress'}]"
123.0,"Mitochondrial derived reactive oxygen species (ROS) can mediate redox signaling or, in excess, causing activation of inflammatory proteins and further exacerbate mitochondrial deterioration and oxidative stress.","[{'entity1': 'Mitochondrial derived reactive oxygen species (ROS)', 'relationship': 'can mediate', 'entity2': 'redox signaling'}, {'entity1': 'Mitochondrial derived reactive oxygen species (ROS)', 'relationship': 'causing', 'entity2': 'activation of inflammatory proteins'}, {'entity1': 'Mitochondrial derived reactive oxygen species (ROS)', 'relationship': 'exacerbate', 'entity2': 'mitochondrial deterioration and oxidative stress'}]"
124.0,"These are mitofusins(Mfn1 & Mfn2) transmembrane GTPasesembedded in the mitochondrial outer membrane, Optic atro-pathy1 (OPA) is a dynamin-related GTPases associated with themitochondrial inner membrane or intermembrane space.","[{'entity1': 'mitofusins', 'relationship': 'embedded', 'entity2': 'mitochondrial outer membrane'}, {'entity1': 'Optic atro-pathy1', 'relationship': 'associated', 'entity2': 'mitochondrial inner membrane'}]"
125.0,"Proper balance of the antagonist activities of fusion and fissionis crucial for fundamental mitochondrial integrity and func-tioning including energy metabolism, ROS generation, andapoptosis regulation.","[{'entity1': 'balance', 'relationship': 'crucial', 'entity2': 'mitochondrial integrity'}, {'entity1': 'balance', 'relationship': 'crucial', 'entity2': 'mitochondrial functioning'}]"
126.0,Fission promotes the removal ofdamaged mitochondria by mitophagy to maintain properassembly of electron transport chain complexes.,"[{'entity1': 'Fission', 'relationship': 'promotes', 'entity2': 'removal of damaged mitochondria'}]"
127.0,"This canallow mitochondria to exchange lipid membranes, and intra-mitochondrial contents while fusion escapes autophagy-mediated destruction to maintain proper mitochondrialultrastructure and elongation","[{'entity1': 'mitochondria', 'relationship': 'allow', 'entity2': 'exchange lipid membranes'}, {'entity1': 'fusion', 'relationship': 'escapes', 'entity2': 'autophagy-mediated destruction'}, {'entity1': 'fusion', 'relationship': 'maintain', 'entity2': 'mitochondrial ultrastructure'}, {'entity1': 'fusion', 'relationship': 'maintain', 'entity2': 'elongation'}]"
128.0,"Fusion allowsfor mitochondrial interconnection, favoring mtDNA mixing,signal transmission and exchange of metabolites with in-network.","[{'entity1': 'Fusion', 'relationship': 'allows', 'entity2': 'mitochondrial interconnection'}, {'entity1': 'Fusion', 'relationship': 'favoring', 'entity2': 'mtDNA mixing'}, {'entity1': 'Fusion', 'relationship': 'allow', 'entity2': 'signal transmission'}, {'entity1': 'Fusion', 'relationship': 'allow', 'entity2': 'exchange of metabolites'}]"
129.0,"On the other hand, fission ensures equal organellesegregation between daughter cells and target defective mito-chondria for their subsequent removal through mitophagy.","[{'entity1': 'fission', 'relationship': 'ensures', 'entity2': 'organelle segregation between daughter cells'}, {'entity1': 'fission', 'relationship': 'target', 'entity2': 'removal of defective mitochondria'}]"
130.0,"The dynamic process controls mitochondrial morphology,biogenesis, transportation and localization, quality controland degradation, and apoptotic cell deaths.","[{'entity1': 'dynamic process', 'relationship': 'controls', 'entity2': 'mitochondrial morphology'}, {'entity1': 'dynamic process', 'relationship': 'controls', 'entity2': 'mitochondrial biogenesis'}, {'entity1': 'dynamic process', 'relationship': 'controls', 'entity2': 'mitochondrial transportation and localization'}, {'entity1': 'dynamic process', 'relationship': 'controls', 'entity2': 'mitochondrial quality control and degradation'}, {'entity1': 'dynamic process', 'relationship': 'controls', 'entity2': 'apoptotic cell deaths'}]"
131.0,"Mitochondria are integral to normal cellular function asthey are responsible for energy production through oxidativephosphorylation; they synthesize key molecules including thephospholipids and Heme, calcium homeostasis, apoptotic acti-vation, and cell death.","[{'entity1': 'Mitochondria', 'relationship': 'responsible', 'entity2': 'energy production'}, {'entity1': 'Mitochondria', 'relationship': 'synthesize', 'entity2': 'key molecules'}, {'entity1': 'Mitochondria', 'relationship': 'responsible', 'entity2': 'calcium homeostasis'}, {'entity1': 'Mitochondria', 'relationship': 'responsible', 'entity2': 'apoptotic activation'}, {'entity1': 'Mitochondria', 'relationship': 'responsible', 'entity2': 'cell death'}]"
132.0,"As the principal functions of mitochondria are tosynthesize ATP from the oxidation of sugar, fat, and proteinsthrough the process of OXPHOS via endosymbiotic principle.","[{'entity1': 'mitochondria', 'relationship': 'synthesize', 'entity2': 'ATP'}]"
133.0,"Under normalconditions, 1–2% of electrons can leak from electron transportchain and reduced to superoxide radical there by producingreactive oxygen species (ROS), which will be detoxified bythe action of antioxidant enzymes such as superoxide dismu-tase, catalase, and glutathione peroxidase.","[{'entity1': 'electrons', 'relationship': 'leak', 'entity2': 'electron transport chain'}, {'entity1': 'electrons', 'relationship': 'reduced', 'entity2': 'superoxide radical'}, {'entity1': 'superoxide radical', 'relationship': 'producing', 'entity2': 'reactive oxygen species'}, {'entity1': 'reactive oxygen species', 'relationship': 'detoxified', 'entity2': 'antioxidant enzymes'}]"
134.0,"However, whenthe production of ROS overrides the capability of antioxidants,oxidative stress will damage cellular macromolecules (i.e.DNA, lipids and proteins).","[{'entity1': 'production of ROS', 'relationship': 'overrides', 'entity2': 'capability of antioxidants'}, {'entity1': 'oxidative stress', 'relationship': 'damage', 'entity2': 'cellular macromolecules'}]"
135.0,This is linked to multiple patholo-gical conditions such as: neurodegenerative diseases; diabetes;cancer; and premature aging.,"[{'entity1': 'oxidative stress', 'relationship': 'linked', 'entity2': 'neurodegenerative diseases'}, {'entity1': 'oxidative stress', 'relationship': 'linked', 'entity2': 'diabetes'}, {'entity1': 'oxidative stress', 'relationship': 'linked', 'entity2': 'cancer'}, {'entity1': 'oxidative stress', 'relationship': 'linked', 'entity2': 'premature aging'}]"
136.0,The damaged mitochondriawith cellular stress are removed by selective mitochondrialautophagy called mitophagy otherwise damaged mitochondriaaccumulated and induce mitochondrion mediated cell death.,"[{'entity1': 'damaged mitochondria', 'relationship': 'removed', 'entity2': 'mitophagy'}, {'entity1': 'damaged mitochondria', 'relationship': 'induce', 'entity2': 'mitochondrion mediated cell death'}]"
137.0,"Fusion and fission regulate mitochondrial damage and repairantagonistically; fusion enriches damaged mitochondria withnormal genome and proteins to escape mitochondria fromdamage while fission, in contrast, destined damaged mito-chondria for destruction by mitophagy.","[{'entity1': 'Fusion', 'relationship': 'regulate', 'entity2': 'mitochondrial damage and repair'}, {'entity1': 'fusion', 'relationship': 'enriches', 'entity2': 'damaged mitochondria'}, {'entity1': 'fusion', 'relationship': 'allow to escape', 'entity2': 'mitochondria from damage'}, {'entity1': 'fission', 'relationship': 'destined', 'entity2': 'removal of damaged mitochondria'}]"
138.0,"Alteration ofnormal mitochondrial function results in signaling distur-bance, energy-dependent disturbance, and genetic defects ofthe mitochondrial genome","[{'entity1': 'Alteration of normal mitochondrial function', 'relationship': 'results', 'entity2': 'signaling disturbance'}, {'entity1': 'Alteration of normal mitochondrial function', 'relationship': 'results', 'entity2': 'energy-dependent disturbance'}, {'entity1': 'Alteration of normal mitochondrial function', 'relationship': 'results', 'entity2': 'genetic defects ofthe mitochondrial genome'}]"
139.0,"Imbalanced activities of fusion and opposite fission lead to mitochondrial dysfunction. These further results in; mitochondrial fragmentation, loss of oxidative phosphorylation (OXPHOS), mtDNA depletion and ROS production.","[{'entity1': 'Imbalanced activities', 'relationship': 'lead to', 'entity2': 'mitochondrial dysfunction'}, {'entity1': 'mitochondrial dysfunction', 'relationship': 'results in', 'entity2': 'mitochondrial fragmentation'}, {'entity1': 'mitochondrial dysfunction', 'relationship': 'results in', 'entity2': 'loss of oxidative phosphorylation'}, {'entity1': 'mitochondrial dysfunction', 'relationship': 'results in', 'entity2': 'mtDNA depletion'}, {'entity1': 'mitochondrial dysfunction', 'relationship': 'results in', 'entity2': 'ROS production'}]"
140.0,"Mitochondrial respiratory chain, NADPH oxidases, and 5-lipoxygenase are the major cellular sources of ROS production.","[{'entity1': 'Mitochondrial respiratory chain', 'relationship': 'source of', 'entity2': 'ROS production'}, {'entity1': 'NADPH oxidases', 'relationship': 'source of', 'entity2': 'ROS production'}, {'entity1': '5-lipoxygenase', 'relationship': 'source of', 'entity2': 'ROS production'}]"
141.0,"Surprisingly, oxidative stress activates several transcription factors (NF-kB and activated protein 1) leading to the production and activation of pro-inflammatory cytokines, chemokines, and lymphocytes which in turn leads to the production of more ROS and RNS, principally in the form of superoxide, nitric oxide (NO), and peroxynitrite.","[{'entity1': 'oxidative stress', 'relationship': 'activates', 'entity2': 'transcription factors'}, {'entity1': 'transcription factors', 'relationship': 'leading to', 'entity2': 'production of pro-inflammatory cytokines'}, {'entity1': 'transcription factors', 'relationship': 'leading to', 'entity2': 'activation of pro-inflammatory cytokines'}, {'entity1': 'transcription factors', 'relationship': 'leading to', 'entity2': 'production of chemokines'}, {'entity1': 'transcription factors', 'relationship': 'leading to', 'entity2': 'production of lymphocytes'}, {'entity1': 'lymphocytes', 'relationship': 'leads to', 'entity2': 'production of ROS'}, {'entity1': 'lymphocytes', 'relationship': 'leads to', 'entity2': 'production of RNS'}]"
142.0,Mitochondrial Dysfunctions induce caspase-1 activation and the release of pro-inflammatory cytokines like IL1B and IL18 which finally leads to sterile inflammation.,"[{'entity1': 'Mitochondrial Dysfunctions', 'relationship': 'induce', 'entity2': 'caspase-1 activation'}, {'entity1': 'Mitochondrial Dysfunctions', 'relationship': 'induce', 'entity2': 'release of pro-inflammatory cytokines'}, {'entity1': 'release of pro-inflammatory cytokines', 'relationship': 'leads to', 'entity2': 'sterile inflammation'}]"
143.0,Uncontrolled and excessive release of mitochondrial DAMPs associated with severity and contributes to the dysregulated process observed in numerous inflammatory and autoimmune conditions.,"[{'entity1': 'release of mitochondrial DAMPs', 'relationship': 'associated with', 'entity2': 'severity'}, {'entity1': 'release of mitochondrial DAMPs', 'relationship': 'contributes to', 'entity2': 'dysregulated process in inflammatory and autoimmune conditions'}]"
144.0,Non-communicable diseases (NCDs) are increasingly becoming the leading public causes of morbidity and mortality globally.,"[{'entity1': 'Non-communicable diseases', 'relationship': 'becoming', 'entity2': 'leading public causes of morbidity and mortality'}]"
145.0,"Cardiovascular diseases accounted for most NCD deaths (17.5 million NCD deaths), followed by cancers (8.2million NCD deaths), respiratory diseases (4.0 million NCD deaths) and diabetes mellitus (1.5million NCD deaths).","[{'entity1': 'Cardiovascular diseases', 'relationship': 'accounted for', 'entity2': 'most NCD deaths'}, {'entity1': 'cancers', 'relationship': 'accounted for', 'entity2': 'NCD deaths'}, {'entity1': 'respiratory diseases', 'relationship': 'accounted for', 'entity2': 'NCD deaths'}, {'entity1': 'diabetes mellitus', 'relationship': 'accounted for', 'entity2': 'NCD deaths'}]"
146.0,A common feature of all NCDs is excessive fatigue which results from mitochondrial function impairment; the crucial organelle responsible for cellular energy production.,"[{'entity1': 'mitochondrial function impairment', 'relationship': 'results in', 'entity2': 'excessive fatigue in NCDs'}, {'entity1': 'mitochondria', 'relationship': 'responsible for', 'entity2': 'cellular energy production'}]"
147.0,"Thus, lack of repair mechanism of damaged mtDNA means cells cannot copy mtDNA accurately resulting in errors of transcription, deletions and mutations and also oxidation from ROS results in a series of cellular abuse.","[{'entity1': 'lack of repair mechanism of damaged mtDNA', 'relationship': 'results in', 'entity2': 'errors of transcription, deletions and mutations'}, {'entity1': 'oxidation from ROS', 'relationship': 'results in', 'entity2': 'cellular abuse'}]"
148.0,"Cardiovascular disease/atherosclerosis, obesity and type 2 diabetes are closely associated with chronic inflammation characterized by abnormal cytokine production, increased levels of acute-phase reactants and activation of a network of inflammatory signaling pathways.","[{'entity1': 'Cardiovascular disease/atherosclerosis, obesity and type 2 diabetes', 'relationship': 'associated with', 'entity2': 'chronic inflammation'}, {'entity1': 'chronic inflammation', 'relationship': 'characterized by', 'entity2': 'abnormal cytokine production'}, {'entity1': 'chronic inflammation', 'relationship': 'characterized by', 'entity2': 'increased levels of acute-phase reactants'}, {'entity1': 'chronic inflammation', 'relationship': 'characterized by', 'entity2': 'activation of inflammatory signaling pathways'}]"
149.0,"Mitochondrial dysfunction because of unbalanced fusion and fission, genetic defects of mtDNA or oxidative damage with ROS and RNS can impair energy metabolism, the central alteration in obesity.","[{'entity1': 'Mitochondrial dysfunction', 'relationship': 'impair', 'entity2': 'energy metabolism'}, {'entity1': 'energy metabolism', 'relationship': 'alteration in', 'entity2': 'obesity'}]"
150.0,"Therefore, preventing chronic sterile inflammation derived with mitochondrial dysfunction resulting in oxidative stress and DAMPs activated inflammasome can significantly diminish non-communicable diseases.","[{'entity1': 'preventing chronic sterile inflammation', 'relationship': 'diminish', 'entity2': 'non-communicable diseases'}, {'entity1': 'mitochondrial dysfunction', 'relationship': 'result in', 'entity2': 'oxidative stress'}, {'entity1': 'mitochondrial dysfunction', 'relationship': 'result in', 'entity2': 'DAMPs activated inflammasome'}]"
151.0,"Insulin resistance (IR) is known to be characteristic of type 2 diabetes mellitus,             and is regarded as an important mechanism in disease pathogenesis.","[{'entity1': 'Insulin resistance', 'relationship': 'characteristic', 'entity2': 'Type 2 diabetes mellitus'}, {'entity1': 'Insulin resistance', 'relationship': 'mechanism', 'entity2': 'disease pathogenesis'}]"
152.0,"Among  proinflammatory  cytokines  contributing  to         IR  development,  the  role  of  interleukin  (IL)-6,  which  has         autocrine and paracrine properties and is involved in insulin         reception and free fatty acid (FFA) metabolism regulation,         has been extensively studied.","[{'entity1': 'Interleukin 6', 'relationship': 'contributing', 'entity2': 'Insulin resistance development'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'insulin reception'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'free fatty acid metabolism regulation'}]"
153.0,One of the key pathogenetic             mechanisms  of  IR  progression  is  impaired  free  fatty  acid  (FFA)  metabolism.,"[{'entity1': 'pathogenesis', 'relationship': 'progression', 'entity2': 'impaired free fatty acid metabolism'}]"
154.0,"Plasminogen-            activator inhibitor 1 (PAI-1) and key inflammation markers, ie, interleukin 6 (IL-6) and C-reactive             protein (CRP), also play a role.","[{'entity1': 'Plasminogen-activator inhibitor 1', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'Interleukin 6', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'C-reactive protein', 'relationship': 'role', 'entity2': 'Insulin resistance'}]"
155.0,The mitochondrial proteome and human disease.,"[{'entity1': 'mitochondrial proteome', 'relationship': 'human disease'}]"
156.0,"Mitochondrial dynamics and inheritance during cell division, development and disease.","[{'entity1': 'Mitochondrial dynamics', 'relationship': 'inheritance', 'entity2': 'cell division, development and disease'}]"
157.0,Putting an equal sign between mitochondria and bacteria.,"[{'entity1': 'mitochondria', 'relationship': 'equal', 'entity2': 'bacteria'}]"
158.0,"Insulin resistance (IR) is known to be characteristic of type 2 diabetes mellitus,             and is regarded as an important mechanism in disease pathogenesis.","[{'entity1': 'Insulin resistance', 'relationship': 'characteristic', 'entity2': 'Type 2 diabetes mellitus'}, {'entity1': 'Insulin resistance', 'relationship': 'mechanism', 'entity2': 'disease pathogenesis'}]"
159.0,One of the key pathogenetic             mechanisms  of  IR  progression  is  impaired  free  fatty  acid  (FFA)  metabolism.,"[{'entity1': 'pathogenesis', 'relationship': 'progression', 'entity2': 'impaired free fatty acid metabolism'}]"
160.0,"Plasminogen-            activator inhibitor 1 (PAI-1) and key inflammation markers, ie, interleukin 6 (IL-6) and C-reactive             protein (CRP), also play a role.","[{'entity1': 'Plasminogen-activator inhibitor 1', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'Interleukin 6', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'C-reactive protein', 'relationship': 'role', 'entity2': 'Insulin resistance'}]"
161.0,"Among  proinflammatory  cytokines  contributing  to         IR  development,  the  role  of  interleukin  (IL)-6,  which  has         autocrine and paracrine properties and is involved in insulin         reception and free fatty acid (FFA) metabolism regulation,         has been extensively studied.","[{'entity1': 'Interleukin 6', 'relationship': 'contributing', 'entity2': 'Insulin resistance development'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'insulin reception'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'free fatty acid metabolism regulation'}]"
162.0,DAMPs cause inflammatory responses.,"[{'entity1': 'DAMPs', 'relationship': 'cause', 'entity2': 'inflammatory responses'}]"
163.0,Oxidatively damaged mitochondrial DNA induces inflammatory responses.,"[{'entity1': 'Oxidatively damaged mitochondrial DNA', 'relationship': 'induces', 'entity2': 'inflammatory responses'}]"
164.0,Mitochondrial dysfunction and oxidative stress activate inflammasomes.,"[{'entity1': 'Mitochondrial dysfunction', 'relationship': 'activate', 'entity2': 'inflammasomes'}, {'entity1': 'oxidative stress', 'relationship': 'activate', 'entity2': 'inflammasomes'}]"
165.0,NADPH oxidase expression contributes to oxidative tissue injury.,"[{'entity1': 'NADPH oxidase expression', 'relationship': 'contributes', 'entity2': 'oxidative tissue injury'}]"
166.0,The glutathione system is a new drug target in neuroimmune disorders.,"[{'entity1': 'The glutathione system', 'relationship': 'target', 'entity2': 'neuroimmune disorders'}]"
167.0,Mitochondrial dysfunction increases inflammatory responsiveness to cytokines in chondrocytes.,"[{'entity1': 'Mitochondrial dysfunction', 'relationship': 'increases', 'entity2': 'inflammatory responsiveness to cytokines in chondrocytes'}]"
168.0,Targeting antioxidants to mitochondria is critical in sepsis.,"[{'entity1': 'Targeting antioxidants to mitochondria', 'relationship': 'critical', 'entity2': 'sepsis'}]"
169.0,Immunology and oxidative stress are clinically and basically related to multiple sclerosis.,"[{'entity1': 'Immunology', 'relationship': 'related', 'entity2': 'multiple sclerosis'}, {'entity1': 'oxidative stress', 'relationship': 'related', 'entity2': 'multiple sclerosis'}]"
170.0,The toll like receptor (TLR) pathway contributes to chronic inflammation.,"[{'entity1': 'The toll like receptor (TLR) pathway', 'relationship': 'contributes', 'entity2': 'chronic inflammation'}]"
171.0,Regulation of mitochondrial biogenesis in muscle by endurance exercise.,"[{'entity1': 'mitochondrial biogenesis', 'relationship': 'Regulation', 'entity2': 'endurance exercise'}]"
172.0,Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy.,"[{'entity1': 'Aerobic training', 'relationship': 'safe', 'entity2': ''}, {'entity1': 'Aerobic training', 'relationship': 'improves', 'entity2': 'exercise capacity'}, {'entity1': 'exercise capacity', 'relationship': 'in', 'entity2': 'patients with mitochondrial myopathy'}]"
173.0,Short- and long-term effects of endurance training in patients with mitochondrial myopathy.,"[{'entity1': 'endurance training', 'relationship': 'effects', 'entity2': 'patients with mitochondrial myopathy'}]"
174.0,"Aerobic conditioning in patients with mitochondrial myopathies: physiological, biochemical, and genetic effects.","[{'entity1': 'Aerobic conditioning', 'relationship': 'in', 'entity2': 'patients with mitochondrial myopathies'}, {'entity1': 'Aerobic conditioning', 'relationship': 'effects', 'entity2': 'physiological, biochemical, and genetic effects'}]"
175.0,"Insulin resistance (IR) is known to be characteristic of type 2 diabetes mellitus,             and is regarded as an important mechanism in disease pathogenesis. One of the key pathogenetic             mechanisms  of  IR  progression  is  impaired  free  fatty  acid  (FFA)  metabolism.  Plasminogen-            activator inhibitor 1 (PAI-1) and key inflammation markers, ie, interleukin 6 (IL-6) and C-reactive             protein (CRP), also play a role.","[{'entity1': 'Insulin resistance', 'relationship': 'characteristic', 'entity2': 'Type 2 diabetes mellitus'}, {'entity1': 'Insulin resistance', 'relationship': 'mechanism', 'entity2': 'disease pathogenesis'}, {'entity1': 'pathogenesis', 'relationship': 'progression', 'entity2': 'impaired free fatty acid metabolism'}, {'entity1': 'Plasminogen-activator inhibitor 1', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'Interleukin 6', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'C-reactive protein', 'relationship': 'role', 'entity2': 'Insulin resistance'}]"
176.0,"Among  proinflammatory  cytokines  contributing  to         IR  development,  the  role  of  interleukin  (IL)-6,  which  has         autocrine and paracrine properties and is involved in insulin         reception and free fatty acid (FFA) metabolism regulation,         has been extensively studied.","[{'entity1': 'Interleukin 6', 'relationship': 'contributing', 'entity2': 'Insulin resistance development'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'insulin reception'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'free fatty acid metabolism regulation'}]"
177.0,"This study was aimed at assessing the changing levels of            the metabolic proinflammation IR markers IL-6, CRP and            PAI-1,  and  their  association  with  presence  or  absence  of            T2DM in MI patients during their hospital stay.","[{'entity1': 'metabolic proinflammation IR markers', 'relationship': 'including', 'entity2': 'IL-6'}, {'entity1': 'metabolic proinflammation IR markers', 'relationship': 'including', 'entity2': 'CRP'}, {'entity1': 'metabolic proinflammation IR markers', 'relationship': 'including', 'entity2': 'PAI-1'}, {'entity1': 'metabolic proinflammation IR markers', 'relationship': 'association', 'entity2': 'presence or absence of T2DM'}, {'entity1': 'metabolic proinflammation IR markers', 'relationship': 'assessment', 'entity2': 'MI patients'}]"
178.0,MI is accompanied both by activated inflammatory            response and IR. Strong correlations between IL-6 and FFA concentrations            demonstrate that nonspecific inflammation factors are involved in IR development            in MI patients.,"[{'entity1': 'MI', 'relationship': 'accompanied', 'entity2': 'activated inflammatory response'}, {'entity1': 'MI', 'relationship': 'accompanied', 'entity2': 'Insulin resistance'}, {'entity1': 'Inflammation factors', 'relationship': 'involved', 'entity2': 'Insulin resistance development'}, {'entity1': 'Inflammation factors', 'relationship': 'demonstrated', 'entity2': 'Strong correlations between IL-6 and FFA'}]"
179.0,"Insulin resistance (IR) is known to be characteristic of type 2 diabetes mellitus,             and is regarded as an important mechanism in disease pathogenesis.","[{'entity1': 'Insulin resistance', 'relationship': 'characteristic', 'entity2': 'Type 2 diabetes mellitus'}, {'entity1': 'Insulin resistance', 'relationship': 'mechanism', 'entity2': 'disease pathogenesis'}]"
180.0,One of the key pathogenetic             mechanisms  of  IR  progression  is  impaired  free  fatty  acid  (FFA)  metabolism.,"[{'entity1': 'pathogenesis', 'relationship': 'progression', 'entity2': 'impaired free fatty acid metabolism'}]"
181.0,"Plasminogen-            activator inhibitor 1 (PAI-1) and key inflammation markers, ie, interleukin 6 (IL-6) and C-reactive             protein (CRP), also play a role.","[{'entity1': 'Plasminogen-activator inhibitor 1', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'Interleukin 6', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'C-reactive protein', 'relationship': 'role', 'entity2': 'Insulin resistance'}]"
182.0,"Among  proinflammatory  cytokines  contributing  to         IR  development,  the  role  of  interleukin  (IL)-6,  which  has         autocrine and paracrine properties and is involved in insulin         reception and free fatty acid (FFA) metabolism regulation,         has been extensively studied.","[{'entity1': 'Interleukin 6', 'relationship': 'contributing', 'entity2': 'Insulin resistance development'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'insulin reception'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'free fatty acid metabolism regulation'}]"
183.0,"CRP,  serum  FFA,  and  glucose  concentrations  were measured at the same study time points using standard Thermo Fisher Scientific (Vantaa, Finland) test systems on a Konelab 30i  biochemistry  analyzer  (Thermo  Fisher  Scientific  Oy, Vantaa, Finland).","[{'entity1': 'CRP', 'relationship': 'measured', 'entity2': 'study time points'}, {'entity1': 'serum FFA', 'relationship': 'measured', 'entity2': 'study time points'}, {'entity1': 'glucose concentrations', 'relationship': 'measured', 'entity2': 'study time points'}]"
184.0,"C-peptide and insulin concentrations were measured  by  enzyme-linked  immunosorbent  assay  with BioMedica (Waterloo, NSW, Australia) and Diagnostic Sys-tems Laboratories (Webster, TX, USA) lab kits, respectively.","[{'entity1': 'C-peptide concentrations', 'relationship': 'measured by', 'entity2': 'enzyme-linked immunosorbent assay'}, {'entity1': 'insulin concentrations', 'relationship': 'measured by', 'entity2': 'enzyme-linked immunosorbent assay'}]"
185.0,"PAI-1 concentrations were found to be increased in both groups, but at the same time at day 1 the diabetic MI patients had  a  4.6-fold  increase  in  PAI-1  levels  compared  to  the  controls","[{'entity1': 'PAI-1 concentrations', 'relationship': 'increased', 'entity2': 'both groups'}, {'entity1': 'diabetic MI patients', 'relationship': 'increase', 'entity2': 'PAI-1 levels'}, {'entity1': 'Increase in diabetic MI patients', 'relationship': 'compared to', 'entity2': 'controls'}]"
186.0,"Measurement of the key inflammation markers showed that  at  day  1,  the  whole  study  population  had  3.6-  and 19-fold increased IL-6 and CRP concentrations, respectively","[{'entity1': 'inflammation markers', 'relationship': 'increased', 'entity2': 'whole study population'}, {'entity1': 'IL-6 concentrations', 'relationship': 'increased', 'entity2': 'whole study population'}, {'entity1': 'CRP concentrations', 'relationship': 'increased', 'entity2': 'whole study population'}]"
187.0,"The diabetic MI patients had more pronounced changes in the levels of inflammation markers: IL-6  and  CRP  concentrations  were  5.3-fold  and  26-fold higher,  respectively","[{'entity1': 'diabetic MI patients', 'relationship': 'changes', 'entity2': 'inflammation markers levels'}, {'entity1': 'IL-6 concentrations', 'relationship': 'higher', 'entity2': 'diabetic MI patients'}, {'entity1': 'CRP concentrations', 'relationship': 'higher', 'entity2': 'diabetic MI patients'}]"
188.0,Correlation  analysis demonstrated  the  correlations between CRP and FFA concentrations,"[{'entity1': 'CRP', 'relationship': 'correlated', 'entity2': 'FFA concentrations'}]"
189.0,The diabetic MI patients had a positive correlation between CRP and PAI-1 concentrations,"[{'entity1': 'diabetic MI patients', 'relationship': 'correlation', 'entity2': 'CRP and PAI-1 concentrations'}]"
190.0,"Insulin resistance (IR) is known to be characteristic of type 2 diabetes mellitus, and is regarded as an important mechanism in disease pathogenesis.","[{'entity1': 'Insulin resistance', 'relationship': 'characteristic', 'entity2': 'Type 2 diabetes mellitus'}, {'entity1': 'Insulin resistance', 'relationship': 'mechanism', 'entity2': 'disease pathogenesis'}]"
191.0,One of the key pathogenetic mechanisms of IR progression is impaired free fatty acid (FFA) metabolism.,"[{'entity1': 'pathogenesis', 'relationship': 'progression', 'entity2': 'impaired free fatty acid metabolism'}]"
192.0,"Plasminogen-activator inhibitor 1 (PAI-1) and key inflammation markers, ie, interleukin 6 (IL-6) and C-reactive protein (CRP), also play a role.","[{'entity1': 'Plasminogen-activator inhibitor 1', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'Interleukin 6', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'C-reactive protein', 'relationship': 'role', 'entity2': 'Insulin resistance'}]"
193.0,"Among proinflammatory cytokines contributing to IR development, the role of interleukin (IL)-6, which has autocrine and paracrine properties and is involved in insulin reception and free fatty acid (FFA) metabolism regulation, has been extensively studied.","[{'entity1': 'Interleukin 6', 'relationship': 'contributing', 'entity2': 'Insulin resistance development'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'insulin reception'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'free fatty acid metabolism regulation'}]"
194.0,IL-6 has recently been established to be capable of stimulating PAI-1 in vitro generation in different cells; PAI-1 is not only the key component of the fibrinolytic system but also an IR marker.,"[{'entity1': 'Interleukin 6', 'relationship': 'stimulating', 'entity2': 'Plasminogen-activator inhibitor 1'}, {'entity1': 'Plasminogen-activator inhibitor 1', 'relationship': 'marker', 'entity2': 'Insulin resistance'}]"
195.0,"Inflammation  is  a  biological  response  of  the  immune  system  that  can  be  triggered  by  a  variety  of  factors,  including  pathogens,  damaged  cells  and  toxic  compounds.","[{'entity1': 'Inflammation', 'relationship': 'response of', 'entity2': 'immune system'}, {'entity1': 'Inflammation', 'relationship': 'triggered by', 'entity2': 'pathogens'}, {'entity1': 'Inflammation', 'relationship': 'triggered by', 'entity2': 'damaged cells'}, {'entity1': 'Inflammation', 'relationship': 'triggered by', 'entity2': 'toxic compounds'}]"
196.0,"These  factors  may  induce  acute  and/or  chronic  inflammatory  responses  in  the  heart, pancreas, liver, kidney, lung, brain, intestinal tract and reproductive system,  potentially leading to tissue damage or disease.","[{'entity1': 'factors', 'relationship': 'induce', 'entity2': 'inflammatory responses'}, {'entity1': 'inflammatory responses', 'relationship': 'in', 'entity2': 'heart'}, {'entity1': 'inflammatory responses', 'relationship': 'in', 'entity2': 'pancreas'}, {'entity1': 'inflammatory responses', 'relationship': 'in', 'entity2': 'liver'}, {'entity1': 'inflammatory responses', 'relationship': 'in', 'entity2': 'kidney'}, {'entity1': 'inflammatory responses', 'relationship': 'in', 'entity2': 'lung'}, {'entity1': 'inflammatory responses', 'relationship': 'in', 'entity2': 'brain'}, {'entity1': 'inflammatory responses', 'relationship': 'in', 'entity2': 'intestinal tract'}, {'entity1': 'inflammatory responses', 'relationship': 'in', 'entity2': 'reproductive system'}, {'entity1': 'inflammatory responses', 'relationship': 'leading to', 'entity2': 'tissue damage'}, {'entity1': 'inflammatory responses', 'relationship': 'leading to', 'entity2': 'disease'}]"
197.0,"Various pathogenic factors, such as infection, tissue injury, or cardiac infarction, can induce inflammation by causing  tissue damage.","[{'entity1': 'pathogenic factors', 'relationship': 'induce', 'entity2': 'inflammation'}, {'entity1': 'infection', 'relationship': 'induce', 'entity2': 'inflammation'}, {'entity1': 'tissue injury', 'relationship': 'induce', 'entity2': 'inflammation'}, {'entity1': 'cardiac infarction', 'relationship': 'induce', 'entity2': 'inflammation'}, {'entity1': 'pathogenic factors', 'relationship': 'cause', 'entity2': 'tissue damage'}]"
198.0,The inflammatory response is the coordinate activation  of signaling  pathways that regulate inflammatory  mediator  levels  in  resident  tissue  cells and  inflammatory  cells  recruited  from  the  blood.,"[{'entity1': 'inflammatory response', 'relationship': 'activation of', 'entity2': 'signaling pathways'}, {'entity1': 'signaling pathways', 'relationship': 'regulate', 'entity2': 'inflammatory mediator levels'}, {'entity1': 'inflammatory mediator levels', 'relationship': 'in', 'entity2': 'resident tissue cells'}, {'entity1': 'inflammatory mediator levels', 'relationship': 'in', 'entity2': 'inflammatory cells'}, {'entity1': 'inflammatory cells', 'relationship': 'recruited from', 'entity2': 'blood'}]"
199.0,"Inflammation is a common pathogenesis of many chronic diseases,  including  cardiovascular  and  bowel  diseases, diabetes, arthritis, and cancer.","[{'entity1': 'Inflammation', 'relationship': 'pathogenesis of', 'entity2': 'chronic diseases'}, {'entity1': 'chronic diseases', 'relationship': 'including', 'entity2': 'cardiovascular diseases'}, {'entity1': 'chronic diseases', 'relationship': 'including', 'entity2': 'bowel diseases'}, {'entity1': 'chronic diseases', 'relationship': 'including', 'entity2': 'diabetes'}, {'entity1': 'chronic diseases', 'relationship': 'including', 'entity2': 'arthritis'}, {'entity1': 'chronic diseases', 'relationship': 'including', 'entity2': 'cancer'}]"
200.0,"MAPKs  are  a  family  of  serine/threonine  protein kinases  that  direct  cellular  responses  to  a  variety  of stimuli,  including  osmotic  stress,  mitogens,  heat  shock, and inflammatory cytokines (such as IL-1, TNF-α, and IL-6),  which  regulate  cell  proliferation,  differentiation,  cell survival and apoptosis","[{'entity1': 'MAPKs', 'relationship': 'direct', 'entity2': 'cellular responses'}, {'entity1': 'cellular responses', 'relationship': 'to', 'entity2': 'variety of stimuli'}, {'entity1': 'variety of stimuli', 'relationship': 'including', 'entity2': 'osmotic stress'}, {'entity1': 'variety of stimuli', 'relationship': 'including', 'entity2': 'mitogens'}, {'entity1': 'variety of stimuli', 'relationship': 'including', 'entity2': 'heat shock'}, {'entity1': 'variety of stimuli', 'relationship': 'including', 'entity2': 'inflammatory cytokines'}, {'entity1': 'inflammatory cytokines', 'relationship': 'such as', 'entity2': 'IL-1'}, {'entity1': 'inflammatory cytokines', 'relationship': 'such as', 'entity2': 'TNF-alpha'}, {'entity1': 'inflammatory cytokines', 'relationship': 'such as', 'entity2': 'IL-6'}, {'entity1': 'MAPKs', 'relationship': 'regulate', 'entity2': 'cell proliferation'}, {'entity1': 'MAPKs', 'relationship': 'regulate', 'entity2': 'cell differentiation'}, {'entity1': 'MAPKs', 'relationship': 'regulate', 'entity2': 'cell survival'}, {'entity1': 'MAPKs', 'relationship': 'regulate', 'entity2': 'apoptosis'}]"
201.0,"Activation of the MAPKs, including Erk1/2, JNK, leads to phosphorylation and activation of p38 transcription factors","[{'entity1': 'Activation', 'relationship': 'of', 'entity2': 'MAPKs'}, {'entity1': 'MAPKs', 'relationship': 'including', 'entity2': 'Erk1/2'}, {'entity1': 'MAPKs', 'relationship': 'including', 'entity2': 'JNK'}, {'entity1': 'Activation of MAPKs', 'relationship': 'leads to', 'entity2': 'phosphorylation and activation of p38 transcription factors'}]"
202.0,"NF-κB pathway. This pathway is triggered by TLRs and inflammatory cytokines, such as TNF and IL-1, leading to activation of  RelA/p50  complexes  that  regulate  expression  of  inflammatory cytokines.","[{'entity1': 'NF-kappaB pathway', 'relationship': 'triggered by', 'entity2': 'TLRs'}, {'entity1': 'NF-kappaB pathway', 'relationship': 'triggered by', 'entity2': 'inflammatory cytokines'}, {'entity1': 'inflammatory cytokines', 'relationship': 'such as', 'entity2': 'TNF'}, {'entity1': 'inflammatory cytokines', 'relationship': 'such as', 'entity2': 'IL-1'}, {'entity1': 'TLRs and inflammatory cytokines', 'relationship': 'leading to', 'entity2': 'activation of RelA/p50 complexes'}, {'entity1': 'RelA/p50 complexes', 'relationship': 'regulate', 'entity2': 'expression of inflammatory cytokines'}]"
203.0,"Markers are used in clinical applications to indicate normal versus pathogenic biological processes, and assess responses  to  therapeutic  interventions.","[{'entity1': 'Markers', 'relationship': 'used', 'entity2': 'clinical applications'}, {'entity1': 'Markers', 'relationship': 'indicate', 'entity2': 'normal versus pathogenic biological processes'}, {'entity1': 'Markers', 'relationship': 'assess', 'entity2': 'responses to therapeutic interventions'}]"
204.0,"Inflammatory cytokines are classified as ILs, colony stimulating  factors  (CSF),  IFNs,  TNFs,  TGFs,  and chemokines,  and  are  produced  by  cells  primarily  to inflammation, inhibit recruit leukocytes to the site of infection or injury","[{'entity1': 'Inflammatory cytokines', 'relationship': 'classified as', 'entity2': 'ILs'}, {'entity1': 'Inflammatory cytokines', 'relationship': 'classified as', 'entity2': 'colony stimulating factors'}, {'entity1': 'Inflammatory cytokines', 'relationship': 'classified as', 'entity2': 'IFNs'}, {'entity1': 'Inflammatory cytokines', 'relationship': 'classified as', 'entity2': 'TNFs'}, {'entity1': 'Inflammatory cytokines', 'relationship': 'classified as', 'entity2': 'TGFs'}, {'entity1': 'Inflammatory cytokines', 'relationship': 'classified as', 'entity2': 'chemokines'}, {'entity1': 'Inflammatory cytokines', 'relationship': 'produced by cells', 'entity2': 'inflammation'}, {'entity1': 'Inflammatory cytokines', 'relationship': 'produced by cells', 'entity2': 'inhibit inflammation'}, {'entity1': 'Inflammatory cytokines', 'relationship': 'produced by cells', 'entity2': 'recruit leukocytes'}, {'entity1': 'leukocytes', 'relationship': 'to', 'entity2': 'site of infection or injury'}]"
205.0,"Markers are used in clinical applications to indicate normal versus pathogenic biological processes, and assess responses  to  therapeutic  interventions.","[{'entity1': 'Markers', 'relationship': 'used', 'entity2': 'clinical applications'}, {'entity1': 'Markers', 'relationship': 'indicate', 'entity2': 'normal versus pathogenic biological processes'}, {'entity1': 'Markers', 'relationship': 'assess', 'entity2': 'responses to therapeutic interventions'}]"
206.0,"Neutrophils target microorganisms in the body, can also damage host cells and tissues [74]. Neutrophils are key mediators of the inflammatory response, and program antigen presenting cells to activate T cells and release localized factors to attract monocytes and dendritic cells [7].","[{'entity1': 'Neutrophils', 'relationship': 'target', 'entity2': 'microorganisms'}, {'entity1': 'Neutrophils', 'relationship': 'damage', 'entity2': 'host cells and tissues'}, {'entity1': 'Neutrophils', 'relationship': 'mediators', 'entity2': 'inflammatory response'}, {'entity1': 'Neutrophils', 'relationship': 'program', 'entity2': 'antigen presenting cells'}]"
207.0,"Macrophages are important components of the mononuclear phagocyte system, and are critical in inflammation initiation, maintenance, and resolution [75]. During inflammation, macrophages present antigens, undergo phagocytosis, and modulate the immune response by producing cytokines and growth factors.","[{'entity1': 'Macrophages', 'relationship': 'components', 'entity2': 'mononuclear phagocyte system'}, {'entity1': 'Macrophages', 'relationship': 'critical', 'entity2': 'inflammation initiation'}, {'entity1': 'Macrophages', 'relationship': 'critical', 'entity2': 'inflammation maintenance'}, {'entity1': 'Macrophages', 'relationship': 'critical', 'entity2': 'inflammation resolution'}, {'entity1': 'macrophages', 'relationship': 'present', 'entity2': 'antigens'}, {'entity1': 'macrophages', 'relationship': 'undergo', 'entity2': 'phagocytosis'}, {'entity1': 'macrophages', 'relationship': 'modulate', 'entity2': 'immune response'}]"
208.0,"Mast cells, which reside in connective tissue matrices and on epithelial surfaces, are effector cells that initiate inflammatory responses. Activated mast cell release a variety of inflammatory mediators, including cytokines, chemokines, histamine, proteases, prostaglandins, leukotrienes, and serglycin proteoglycans [76].","[{'entity1': 'Mast cells', 'relationship': 'initiate', 'entity2': 'inflammatory responses'}, {'entity1': 'Activated mast cell', 'relationship': 'release', 'entity2': 'inflammatory mediators'}]"
209.0,"Multiple groups have demonstrated that platelets impact inflammatory processes, from atherosclerosis to infection. Platelet interactions with inflammatory cells may mediate pro-inflammatory outcomes. The acute phase response (APR) is the earliest response to infection or injury, and some studies have indicated that platelets induce the APR [77].","[{'entity1': 'platelets', 'relationship': 'impact', 'entity2': 'inflammatory processes'}, {'entity1': 'Platelet interactions', 'relationship': 'mediate', 'entity2': 'pro-inflammatory outcomes'}, {'entity1': 'platelets', 'relationship': 'induce', 'entity2': 'acute phase response'}]"
210.0,"To prevent progression from acute inflammation to persistent, chronic inflammation, the inflammatory response must be suppressed to prevent additional tissue damage. Inflammation resolution is a well-managed process involving the spatially- and temporally-controlled production of mediators, during which chemokine gradients are diluted over time.","[{'entity1': 'inflammatory response', 'relationship': 'prevent progression', 'entity2': 'chronic inflammation'}, {'entity1': 'inflammatory response', 'relationship': 'suppressed', 'entity2': 'additional tissue damage'}, {'entity1': 'Inflammation resolution', 'relationship': 'process', 'entity2': 'production of mediators'}]"
211.0,"Chronic inflammation occurs when acute inflammatory mechanisms fail to eliminate tissue injury [81], and may lead to a host of diseases, such as cardiovascular diseases, atherosclerosis, type 2 diabetes, rheumatoid arthritis, and cancers [82]. ","[{'entity1': 'Chronic inflammation', 'relationship': 'occurs', 'entity2': 'acute inflammatory mechanisms fail'}, {'entity1': 'Chronic inflammation', 'relationship': 'lead to', 'entity2': 'diseases'}]"
212.0,"It is estimated that some 15% of human cancers are associated with chronic infection and inflammation [83]. Acute and chronic inflammation-mediated tissue injury is observed in many organ systems, including the heart, pancreas, liver, kidney, lung, brain, intestinal tract, and reproductive system.","[{'entity1': 'human cancers', 'relationship': 'associated', 'entity2': 'chronic infection and inflammation'}, {'entity1': 'Acute and chronic inflammation', 'relationship': 'mediated', 'entity2': 'tissue injury'}]"
213.0,"Pancreatitis, caused by pancreatic duct obstruction,  trypsinogen  gene  mutation,  or  alcoholism, is an inflammatory disease of the pancreas [117].","[{'entity1': 'Pancreatitis', 'relationship': 'caused by', 'entity2': 'pancreatic duct obstruction'}, {'entity1': 'Pancreatitis', 'relationship': 'caused by', 'entity2': 'trypsinogen gene mutation'}, {'entity1': 'Pancreatitis', 'relationship': 'caused by', 'entity2': 'alcoholism'}, {'entity1': 'Pancreatitis', 'relationship': 'is', 'entity2': 'an inflammatory disease of the pancreas'}]"
214.0,There is a strong link between antecedent CP and PC,"[{'entity1': 'antecedent CP', 'relationship': 'link', 'entity2': 'PC'}]"
215.0,"Inflammation in the liver protects this organ from infection and injury, but excessive inflammation may lead to extensive loss of hepatocytes, ischemia-reperfusion injury, metabolic alterations, and eventually permanent hepatic damage","[{'entity1': 'Inflammation in the liver', 'relationship': 'protects', 'entity2': 'this organ'}, {'entity1': 'excessive inflammation', 'relationship': 'may lead to', 'entity2': 'extensive loss of hepatocytes'}, {'entity1': 'excessive inflammation', 'relationship': 'may lead to', 'entity2': 'ischemia-reperfusion injury'}, {'entity1': 'excessive inflammation', 'relationship': 'may lead to', 'entity2': 'metabolic alterations'}, {'entity1': 'excessive inflammation', 'relationship': 'may lead to', 'entity2': 'eventually permanent hepatic damage'}]"
216.0,Approximately 90% of COPD cases are associated with cigarette smoking-induced inflammation in small airways and lung parenchyma,"[{'entity1': '90% of COPD cases', 'relationship': 'are associated with', 'entity2': 'cigarette smoking-induced inflammation in small airways and lung parenchyma'}]"
217.0,"Kidney inflammation contributes to progressive renal injury, which may lead to glomerulonephritis, end-stage renal disease, or acute or chronic kidney disease","[{'entity1': 'Kidney inflammation', 'relationship': 'contributes to', 'entity2': 'progressive renal injury'}, {'entity1': 'progressive renal injury', 'relationship': 'may lead to', 'entity2': 'glomerulonephritis'}, {'entity1': 'progressive renal injury', 'relationship': 'may lead to', 'entity2': 'end-stage renal disease'}, {'entity1': 'progressive renal injury', 'relationship': 'may lead to', 'entity2': 'acute or chronic kidney disease'}]"
218.0,"The complex, polygenetic inflammatory bowel diseases (IBDs) are characterized by an excessive inflammatory response to gut lumen microbial flora","[{'entity1': 'The complex, polygenetic inflammatory bowel diseases', 'relationship': 'are characterized by', 'entity2': 'an excessive inflammatory response to gut lumen microbial flora'}]"
219.0,"Inflammatory  responses  occur  in  the  brain  in many  central  nervous  system  (CNS)  diseases,  including  autoimmune  diseases,  neurodegenerative  diseases  like  Alzheimer’s  (AD)  and  Parkinson’s  disease  (PD),  and  epilepsy.","[{'entity1': 'Inflammatory responses', 'relationship': 'occur', 'entity2': 'brain'}, {'entity1': 'Inflammatory responses', 'relationship': 'occur', 'entity2': 'central nervous system diseases'}, {'entity1': 'central nervous system diseases', 'relationship': 'including', 'entity2': 'autoimmune diseases'}, {'entity1': 'central nervous system diseases', 'relationship': 'including', 'entity2': 'Alzheimer’s disease'}, {'entity1': 'central nervous system diseases', 'relationship': 'including', 'entity2': ""Parkinson's disease""}, {'entity1': 'central nervous system diseases', 'relationship': 'including', 'entity2': 'epilepsy'}]"
220.0,"Inflammation-associated  CNS  diseases  result  from  activation  of  the  brain’s  resident  immune  cells  and  microglia,  which  produce  pro-inflammatory  markers  [162].","[{'entity1': 'Inflammation-associated CNS diseases', 'relationship': 'result from', 'entity2': 'activation of brain resident immune cells and microglia'}, {'entity1': 'brain resident immune cells and microglia', 'relationship': 'produce', 'entity2': 'pro-inflammatory markers'}]"
221.0,These  inflammation  processes  also  involve  both  the  innate  and  adaptive immune systems and resemble immune responses  to  systemic  infection.,"[{'entity1': 'These inflammation processes', 'relationship': 'involve', 'entity2': 'innate immune system'}, {'entity1': 'These inflammation processes', 'relationship': 'involve', 'entity2': 'adaptive immune system'}, {'entity1': 'These inflammation processes', 'relationship': 'resemble', 'entity2': 'immune responses to systemic infection'}]"
222.0,Cytokines  and  TLRs  are  major  inflammatory  mediators  in  the  transition  between  innate  and adaptive.,"[{'entity1': 'Cytokines and TLRs', 'relationship': 'are', 'entity2': 'major inflammatory mediators'}, {'entity1': 'Cytokines and TLRs', 'relationship': 'in', 'entity2': 'transition between innate and adaptive immune system'}]"
223.0,Inflammatory responses in the CNS may also  be triggered by endogenous ligands recognized by TLRs.,"[{'entity1': 'Inflammatory responses in CNS', 'relationship': 'triggered by', 'entity2': 'endogenous ligands recognized by TLRs'}]"
224.0,"DAMPs,  such  as  heat-shock  proteins  and  extracellular  matrix degradation molecules, entering the brain through  a damaged blood-brain barrier may initiate inflammatory  responses.","[{'entity1': 'DAMPs like heat-shock proteins and extracellular matrix degradation molecules', 'relationship': 'entering', 'entity2': 'brain through damaged blood-brain barrier'}, {'entity1': 'DAMPs like heat-shock proteins and extracellular matrix degradation molecules', 'relationship': 'initiate', 'entity2': 'inflammatory responses'}]"
225.0,"The CNS  inflammatory  response  is  strong  in  reaction to both infectious agents and brain injury, such  as  tissue damage observed following ischemic, traumatic, or  excitotoxic brain injury, or seizure [160, 163, 164].","[{'entity1': 'CNS inflammatory response', 'relationship': 'strong reaction to', 'entity2': 'infectious agents'}, {'entity1': 'CNS inflammatory response', 'relationship': 'strong reaction to', 'entity2': 'brain injury'}, {'entity1': 'brain injury', 'relationship': 'such as', 'entity2': 'ischemic brain injury'}, {'entity1': 'brain injury', 'relationship': 'such as', 'entity2': 'traumatic brain injury'}, {'entity1': 'brain injury', 'relationship': 'such as', 'entity2': 'excitotoxic brain injury'}, {'entity1': 'brain injury', 'relationship': 'such as', 'entity2': 'seizure'}]"
226.0,Inflammation  is  frequently  a  key  element  in  the  pathological  progression  of  organ  disease.,"[{'entity1': 'Inflammation', 'relationship': 'key element in', 'entity2': 'pathological progression of organ disease'}]"
227.0,"Three  main  pathways,  NF-κB,  MAPK,  and  JAK-STAT,  play  major  roles in inflammation, and dysregulation of one or more  of these pathways may lead to inflammation-associated  disease.","[{'entity1': 'NF-kB, MAPK and JAK-STAT pathways', 'relationship': 'major roles', 'entity2': 'inflammation'}, {'entity1': 'dysregulation of NF-kB, MAPK and JAK-STAT pathways', 'relationship': 'lead to', 'entity2': 'inflammation-associated disease'}]"
228.0,"The  hallmarks  of  inflammation  are  observed  during  many  normal  reproductive  processes,  including  menstruation,  ovulation,  implantation,  and  parturition.","[{'entity1': 'hallmarks of inflammation', 'relationship': 'observed during', 'entity2': 'menstruation'}, {'entity1': 'hallmarks of inflammation', 'relationship': 'observed during', 'entity2': 'ovulation'}, {'entity1': 'hallmarks of inflammation', 'relationship': 'observed during', 'entity2': 'implantation'}, {'entity1': 'hallmarks of inflammation', 'relationship': 'observed during', 'entity2': 'parturition'}]"
229.0,Oxidative stress and redox regulation of lung inflammation in COPD.,"[{'entity1': 'Oxidative stress', 'relationship': 'regulation', 'entity2': 'lung inflammation'}, {'entity1': 'redox regulation', 'relationship': 'of', 'entity2': 'lung inflammation'}]"
230.0,Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease.,"[{'entity1': 'Markers', 'relationship': 'relation', 'entity2': 'long-term mortality'}, {'entity1': 'Markers', 'relationship': 'of', 'entity2': 'myocardial damage and inflammation'}, {'entity1': 'unstable coronary artery disease', 'relationship': '', 'entity2': ''}]"
231.0,"Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder.","[{'entity1': 'Inflammation', 'relationship': 'and', 'entity2': 'phenomenology, pathophysiology, comorbidity, treatment'}, {'entity1': 'Inflammation', 'relationship': '', 'entity2': 'bipolar disorder'}]"
232.0,Inflammatory markers and onset of cardiovascular events.,"[{'entity1': 'Inflammatory markers', 'relationship': 'onset', 'entity2': 'cardiovascular events'}]"
233.0,Key mechanisms governing resolution of lung inflammation.,"[{'entity1': 'Key mechanisms', 'relationship': 'governing', 'entity2': 'resolution of lung inflammation'}]"
234.0,T cells in vascular inflammatory diseases.,"[{'entity1': 'T cells', 'relationship': 'in', 'entity2': 'vascular inflammatory diseases'}]"
235.0,"NF-κB, STAT3 - key players in liver inflammation and cancer.","[{'entity1': 'NF-κB', 'relationship': '', 'entity2': 'key players'}, {'entity1': 'STAT3', 'relationship': '', 'entity2': 'key players'}, {'entity1': 'key players', 'relationship': 'in', 'entity2': 'liver inflammation and cancer'}]"
236.0,Inflammation and Cardiovascular Disease and Protection by the Mediterranean Diet.,"[{'entity1': 'Inflammation', 'relationship': 'and', 'entity2': 'Cardiovascular Disease'}, {'entity1': 'Mediterranean Diet', 'relationship': 'Protection', 'entity2': 'Cardiovascular Disease'}]"
237.0,Controversies  in  ventricular  remodelling.,"[{'entity1': 'Controversies', 'relationship': 'in', 'entity2': 'ventricular remodelling'}]"
238.0,The immune system and cardiac repair.,"[{'entity1': 'The immune system', 'relationship': 'and', 'entity2': 'cardiac repair'}]"
239.0,Endogenous  ligands  of  Toll-like  receptors: implications  for  regulating  inflammatory  and  immune responses.,"[{'entity1': 'Endogenous ligands', 'relationship': 'of', 'entity2': 'Toll-like receptors'}, {'entity1': 'Endogenous ligands', 'relationship': 'implications for regulating', 'entity2': 'inflammatory and immune responses'}]"
240.0,Mechanisms  of  Disease: Toll-like receptors in cardiovascular disease.,"[{'entity1': 'Toll-like receptors', 'relationship': 'in', 'entity2': 'cardiovascular disease'}]"
241.0,"CRP,  a  major  culprit  in  complement-mediated tissue damage in acute myocardial infarction?","[{'entity1': 'CRP', 'relationship': 'culprit in', 'entity2': 'complement-mediated tissue damage in acute myocardial infarction'}]"
242.0,"Oxygen, oxidative stress, hypoxia, and heart failure.","[{'entity1': 'Oxygen'}, {'entity1': 'oxidative stress'}, {'entity1': 'hypoxia'}, {'relationship': 'and', 'entity2': 'heart failure'}]"
243.0,Oxidative  Stress  and Cardiovascular  Injury:  Part  I:  Basic  Mechanisms  and  In Vivo  Monitoring  of  ROS.,"[{'entity1': 'Oxidative Stress', 'relationship': 'and', 'entity2': 'Cardiovascular Injury'}, {'entity1': 'Basic Mechanisms', 'relationship': 'and', 'entity2': 'In Vivo Monitoring of ROS'}]"
244.0,Regulating the regulator: NF-κB  signaling  in  heart.,"[{'entity1': 'NF-κB signaling', 'relationship': 'in', 'entity2': 'heart'}]"
245.0,Chemokines  and  disease.,"[{'entity1': 'Chemokines', 'relationship': 'and', 'entity2': 'disease'}]"
246.0,lymphocyte  traffic control by chemokines.,"[{'entity1': 'lymphocyte traffic', 'relationship': 'control by', 'entity2': 'chemokines'}]"
247.0,"Biology of TNFα and IL-10, and their imbalance in heart failure.","[{'entity1': 'Biology', 'relationship': 'of', 'entity2': 'TNFα'}, {'entity1': 'Biology', 'relationship': 'of', 'entity2': 'IL-10'}, {'entity1': 'TNFα', 'relationship': 'and', 'entity2': 'IL-10'}, {'entity1': 'TNFα and IL-10', 'relationship': 'imbalance', 'entity2': 'heart failure'}]"
248.0,Targeting  the  transforming  growth  factor (TGF)-β cascade in the remodeling heart: Benefits  and perils.,"[{'entity1': 'transforming growth factor (TGF)-β cascade', 'relationship': 'Targeting', 'entity2': 'the remodeling heart'}, {'entity1': 'transforming growth factor (TGF)-β cascade', 'relationship': 'in', 'entity2': 'the remodeling heart'}, {'entity1': 'Targeting transforming growth factor (TGF)-β cascade in the remodeling heart', 'relationship': 'Benefits and perils'}]"
249.0,Relation between age  and  cardiovascular  disease  in  men  and  women  with diabetes compared with non-diabetic people: a population-based retrospective cohort study.,"[{'entity1': 'age', 'relationship': 'Relation between', 'entity2': 'cardiovascular disease in men and women with diabetes'}, {'entity1': 'cardiovascular disease', 'relationship': 'compared with', 'entity2': 'non-diabetic people'}]"
250.0,"Clinical Update:  Cardiovascular  Disease  in  Diabetes  Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations.","[{'entity1': 'Clinical Update', 'relationship': 'Cardiovascular Disease in', 'entity2': 'Diabetes Mellitus'}, {'entity1': 'Atherosclerotic Cardiovascular Disease', 'relationship': 'and', 'entity2': 'Heart Failure'}, {'entity1': 'Atherosclerotic Cardiovascular Disease and Heart Failure', 'relationship': 'in', 'entity2': 'Type 2 Diabetes Mellitus'}, {'entity1': 'Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus', 'relationship': 'Mechanisms, Management, and Clinical Considerations'}]"
251.0,The identification of TNFR5 as a therapeutic target in diabetes.,"[{'entity1': 'TNFR5', 'relationship': 'identification', 'entity2': 'therapeutic target'}, {'entity1': 'TNFR5', 'relationship': 'as', 'entity2': 'therapeutic target in diabetes'}]"
252.0,A Review on Diabetes Mellitus Type II.,"[{'entity1': 'Review', 'relationship': 'on', 'entity2': 'Diabetes Mellitus Type II'}]"
253.0,Interleukin-1–receptor antagonist in type 2 diabetes mellitus.,"[{'entity1': 'Interleukin-1–receptor antagonist', 'relationship': 'in', 'entity2': 'type 2 diabetes mellitus'}]"
254.0,Islet inflammation  in  type  2  diabetes.,"[{'entity1': 'Islet inflammation', 'relationship': 'in', 'entity2': 'type 2 diabetes'}]"
255.0,"Inflammation  as  a  link  between  obesity,  metabolic syndrome and type 2 diabetes.","[{'entity1': 'Inflammation', 'relationship': 'as a link between', 'entity2': 'obesity, metabolic syndrome and type 2 diabetes'}]"
256.0,Role of IL-1β in type 2 diabetes.,"[{'entity1': 'IL-1β', 'relationship': 'Role', 'entity2': 'type 2 diabetes'}]"
257.0,Type  2  diabetes  as  an inflammatory disease.,"[{'entity1': 'Type 2 diabetes', 'relationship': 'as an', 'entity2': 'inflammatory disease'}]"
258.0,Pathogenic mechanisms of pancreatitis.,"[{'entity1': 'Pathogenic mechanisms', 'relationship': 'of', 'entity2': 'pancreatitis'}]"
259.0,The epidemiology of pancreatitis and pancreatic cancer.,"[{'entity1': 'The epidemiology', 'relationship': 'of', 'entity2': 'pancreatitis and pancreatic cancer'}]"
260.0,Role of immune cells  and  immune-based  therapies  in  pancreatitis  and pancreatic ductal adenocarcinoma.,"[{'entity1': 'immune cells and immune-based therapies', 'relationship': 'Role', 'entity2': 'pancreatitis and pancreatic ductal adenocarcinoma'}]"
261.0,IL-6 trans-signaling promotes pancreatitis-associated  lung  injury  and  lethality.,"[{'entity1': 'IL-6 trans-signaling', 'relationship': 'promotes', 'entity2': 'pancreatitis-associated lung injury and lethality'}]"
262.0,Whole genomes redefine the mutational landscape of pancreatic cancer.,"[{'entity1': 'Whole genomes', 'relationship': 'redefine', 'entity2': 'mutational landscape of pancreatic cancer'}]"
263.0,Inflammation to cancer: The molecular biology in the pancreas (Review).,"[{'entity1': 'Inflammation to cancer', 'relationship': 'The molecular biology', 'entity2': 'pancreas'}]"
264.0,Inflammation  and  Cancer  V.  Chronic pancreatitis and pancreatic cancer.,"[{'entity1': 'Inflammation', 'relationship': 'and', 'entity2': 'Cancer V'}, {'entity1': 'Chronic pancreatitis', 'relationship': 'and', 'entity2': 'pancreatic cancer'}]"
265.0,Pancreatic cancer.,[{'entity1': 'Pancreatic cancer'}]
266.0,BRCA2 is inactivated late  in  the  development  of  pancreatic  intraepithelial neoplasia: evidence and implications.,"[{'entity1': 'BRCA2', 'relationship': 'is inactivated', 'entity2': 'development of pancreatic intraepithelial neoplasia'}, {'entity1': 'inactivation of BRCA2 late in development of pancreatic intraepithelial neoplasia', 'relationship': 'evidence and implications'}]"
267.0,Regulation  of  vascular  endothelial  growth  factor expression by acidosis in human cancer cells.,"[{'entity1': 'acidosis', 'relationship': 'Regulation of', 'entity2': 'vascular endothelial growth factor expression in human cancer cells'}]"
268.0,Interleukin-8 and human cancer biology.,"[{'entity1': 'Interleukin-8', 'relationship': 'and', 'entity2': 'human cancer biology'}]"
269.0,Decoding cell death signals in liver inflammation.,"[{'entity1': 'Decoding cell death signals', 'relationship': 'in', 'entity2': 'liver inflammation'}]"
270.0,"Hepatic Fibrosis,  Inflammation,  and  Steatosis:  Influence  on  the MR Viscoelastic and Diffusion Parameters in Patients with Chronic Liver Disease.","[{'entity1': 'Hepatic Fibrosis, Inflammation, and Steatosis', 'relationship': 'Influence on', 'entity2': 'MR Viscoelastic and Diffusion Parameters'}, {'entity1': 'MR Viscoelastic and Diffusion Parameters', 'relationship': 'in', 'entity2': 'Patients with Chronic Liver Disease'}]"
271.0,"Physiology and pathophysiology of liver inflammation, damage and repair.","[{'entity1': 'Physiology and pathophysiology', 'relationship': 'of', 'entity2': 'liver inflammation, damage and repair'}]"
272.0,Pathophysiology of  hepatitis  C  virus infection  and  related  liver  disease.,"[{'entity1': 'Pathophysiology', 'relationship': 'of', 'entity2': 'hepatitis C virus infection and related liver disease'}]"
273.0,Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage.,"[{'entity1': 'Cytokines', 'relationship': 'induced during', 'entity2': 'chronic hepatitis B virus infection'}, {'entity1': 'Cytokines induced during chronic hepatitis B virus infection', 'relationship': 'promote', 'entity2': 'pathway for NK cell–mediated liver damage'}]"
274.0,Innate immunity in alcoholic liver disease.,"[{'entity1': 'Innate immunity', 'relationship': 'in', 'entity2': 'alcoholic liver disease'}]"
275.0,"Non-alcoholic steatohepatitis-induced  fibrosis:  Toll-like receptors, reactive oxygen species and Jun N-terminal kinase.","[{'entity1': 'Non-alcoholic steatohepatitis-induced fibrosis', 'relationship': 'Toll-like receptors, reactive oxygen species and Jun N-terminal kinase'}]"
276.0,DAMPs  ramp  up  drug  toxicity.,"[{'entity1': 'DAMPs', 'relationship': 'ramp up', 'entity2': 'drug toxicity'}]"
277.0,Sterile  Inflammation  in  the  Liver.,"[{'entity1': 'Sterile Inflammation', 'relationship': 'in', 'entity2': 'Liver'}]"
278.0,Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene.,"[{'entity1': 'Defective LPS Signaling', 'relationship': 'in', 'entity2': 'C3H/HeJ and C57BL/10ScCr Mice'}, {'entity1': 'Mutations', 'relationship': 'in', 'entity2': 'Tlr4 Gene'}]"
279.0,Innate  immune response  and  hepatic  inflammation.,"[{'entity1': 'Innate immune response', 'relationship': 'and', 'entity2': 'hepatic inflammation'}]"
280.0,STAT6 and lung inflammation.,"[{'entity1': 'STAT6', 'relationship': 'and', 'entity2': 'lung inflammation'}]"
281.0,Relevance of granulocyte apoptosis to resolution of inflammation at the respiratory mucosa.,"[{'entity1': 'granulocyte apoptosis', 'relationship': 'Relevance to', 'entity2': 'resolution of inflammation at the respiratory mucosa'}]"
282.0,Targeting  immune  pathways  for therapy in asthma and chronic obstructive pulmonary disease.,"[{'entity1': 'immune pathways', 'relationship': 'Targeting for therapy', 'entity2': 'asthma and chronic obstructive pulmonary disease'}]"
283.0,Lung inflammation caused by  inhaled  toxicants:  a  review.,"[{'entity1': 'Lung inflammation', 'relationship': 'caused by', 'entity2': 'inhaled toxicants'}]"
284.0,Inflammation in  lung  diseases:  new  therapeutic  approach.,"[{'entity1': 'Inflammation', 'relationship': 'in', 'entity2': 'lung diseases'}, {'entity1': 'new therapeutic approach', 'relationship': 'for', 'entity2': 'Inflammation in lung diseases'}]"
285.0,"Responsiveness of blood and sputum inflammatory cells in Japanese COPD patients,  non-COPD  smoking  controls,  and  non-COPD nonsmoking controls.","[{'entity1': 'Responsiveness', 'relationship': 'of', 'entity2': 'blood and sputum inflammatory cells in Japanese COPD patients, non-COPD smoking controls, and non-COPD nonsmoking controls'}]"
286.0,"Strober  W,  Fuss  I,  Mannon  P.  The  fundamental  basis  of inflammatory bowel disease. J Clin Invest. 2007; 117:514–521.","[{'entity1': 'inflammatory bowel disease', 'relationship': 'basis', 'entity2': 'fundamental'}]"
287.0,"Fukata  M,  Arditi  M.  The  role  of  pattern  recognition receptors  in  intestinal  inflammation.  Mucosal  Immunol. 2013; 6:451–463.","[{'entity1': 'pattern recognition receptors', 'relationship': 'role', 'entity2': 'intestinal inflammation'}]"
288.0,"Thompson  MR,  Kaminski  JJ,  Kurt-Jones  EA,  Fitzgerald KA. Pattern Recognition Receptors and the Innate Immune Response to Viral Infection. Viruses. 2011; 3:920–940.","[{'entity1': 'Pattern Recognition Receptors', 'relationship': 'Immune Response', 'entity2': 'Viral Infection'}]"
289.0,"Goswami  B,  Rajappa  M,  Sharma  M,  Sharma  A. Inflammation: its role and interplay in the development of cancer, with special focus on gynecological malignancies. Int J Gynecol Cancer. 2008; 18:591–599.","[{'entity1': 'Inflammation', 'relationship': 'role and interplay', 'entity2': 'development of cancer'}, {'entity1': 'Inflammation', 'relationship': 'focus', 'entity2': 'gynecological malignancies'}]"
290.0,"Levi  M,  van  der  Poll  T.  Two-way  interactions  between inflammation and coagulation. Trends  Cardiovascular Med. 2005; 15:254–259.","[{'entity1': 'inflammation', 'relationship': 'interactions', 'entity2': 'coagulation'}]"
291.0,"Sepsis is a life-threatening organ dysfunction caused by infection, which results from dysregulated host response.","[{'entity1': 'Sepsis', 'relationship': 'caused by', 'entity2': 'infection'}, {'entity1': 'Sepsis', 'relationship': 'results from', 'entity2': 'dysregulated host response'}]"
292.0,"A study reported in Lancet showed that sepsis remains a major cause of health loss worldwide, with 48.9 million cases each year and approximately 11 million deaths, which accounts around one-fifth of the total global deaths.","[{'entity1': 'Sepsis', 'relationship': 'remains', 'entity2': 'a major cause of health loss worldwide'}, {'entity1': 'Sepsis', 'relationship': 'around', 'entity2': 'one-fifth of the total global deaths'}]"
293.0,"According to Nature Reviews Disease Primers, more than half of sepsis patients are complicated with coagulation system imbalance.","[{'entity1': 'more than half of sepsis patients', 'relationship': 'complicated with', 'entity2': 'coagulation system imbalance'}]"
294.0,"Moreover, in patients who have sepsis with disseminated intravascular coagulation (DIC) the mortality rate is almost twice that of sepsis patients without DIC.","[{'entity1': 'patients who have sepsis with disseminated intravascular coagulation', 'relationship': 'mortality rate', 'entity2': 'almost twice that of sepsis patients without DIC'}]"
295.0,"Therefore, reducing inflammation and coagulation disorders could be the key to reducing sepsis mortality.","[{'entity1': 'reducing inflammation and coagulation disorders', 'relationship': 'could be', 'entity2': 'the key to reducing sepsis mortality'}]"
296.0,"Macrophages are involved in various pathophysiological processes in sepsis, including inflammation, coagulation, immunity and metabolism, and play a crucial role in sepsis-induced acute lung injury.","[{'entity1': 'Macrophages', 'relationship': 'involved in', 'entity2': 'various pathophysiological processes in sepsis'}, {'entity1': 'pathophysiological processes', 'relationship': 'including', 'entity2': 'inflammation'}, {'entity1': 'pathophysiological processes', 'relationship': 'including', 'entity2': 'coagulation'}, {'entity1': 'pathophysiological processes', 'relationship': 'including', 'entity2': 'immunity'}, {'entity1': 'pathophysiological processes', 'relationship': 'including', 'entity2': 'metabolism'}, {'entity1': 'Macrophages', 'relationship': 'play', 'entity2': 'a crucial role in sepsis-induced acute lung injury'}]"
297.0,"In the early stages of sepsis, macrophages engulf pathogens and activate the innate immune system.","[{'entity1': 'macrophages', 'relationship': 'engulf', 'entity2': 'pathogens'}, {'entity1': 'macrophages', 'relationship': 'activate', 'entity2': 'the innate immune system'}]"
298.0,"Macrophages express pattern recognition receptors (PRRs), which can detect pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs), initiating a series of immune cell activations and upregulating the expression of inflammation-related genes, that produce a series of inflammatory cytokines.","[{'entity1': 'Pattern recognition receptors', 'relationship': 'can detect', 'entity2': 'pathogen-associated molecular patterns'}, {'entity1': 'Pattern recognition receptors', 'relationship': 'can detect', 'entity2': 'damage-associated molecular patterns'}, {'entity1': 'Pattern recognition receptors', 'relationship': 'initiating', 'entity2': 'a series of immune cell activations'}, {'entity1': 'Pattern recognition receptors', 'relationship': 'upregulating', 'entity2': 'the expression of inflammation-related genes'}, {'entity1': 'inflammation-related genes', 'relationship': 'produce', 'entity2': 'a series of inflammatory cytokines'}]"
299.0,"However, there is also a defense strategy, called disease tolerance, which refers to limiting the negative impact of infection on the host without affecting the pathogen load.","[{'entity1': 'a defense strategy', 'relationship': 'called', 'entity2': 'disease tolerance'}, {'entity1': 'disease tolerance', 'relationship': 'refers to', 'entity2': 'limiting the negative impact of infection on the host without affecting the pathogen load'}]"
300.0,"The expression of high levels of PRRs and other receptors, including cytokines by tissue-resident macrophages contributes to the establishment of disease tolerance.","[{'entity1': 'The expression of high levels of PRRs and other receptors, including cytokines by tissue-resident macrophages', 'relationship': 'contributes to', 'entity2': 'the establishment of disease tolerance'}]"
301.0,"In addition, signal transduction pathways that are activated in response to PAMPs or DAMPs also contribute to tissue damage control and establishment of disease tolerance, both of which limit the negative effects of infection.","[{'entity1': 'signal transduction pathways', 'relationship': 'activated in response to', 'entity2': 'PAMPs or DAMPs'}, {'entity1': 'signal transduction pathways', 'relationship': 'contribute to', 'entity2': 'tissue damage control'}, {'entity1': 'signal transduction pathways', 'relationship': 'contribute to', 'entity2': 'establishment of disease tolerance'}, {'entity1': 'tissue damage control', 'relationship': 'limit', 'entity2': 'the negative effects of infection'}, {'entity1': 'establishment of disease tolerance', 'relationship': 'limit', 'entity2': 'the negative effects of infection'}]"
302.0,"Lipopolysaccharide (LPS), an important cell wall constituent of Gram-negative bacteria, is a potent inducer of inflammatory responses.","[{'entity1': 'Lipopolysaccharide', 'relationship': 'is', 'entity2': 'a potent inducer of inflammatory responses'}]"
303.0,"After exposure to LPS, macrophages produce large amounts of inflammatory cytokines, interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF).","[{'entity1': 'macrophages', 'relationship': 'produce', 'entity2': 'inflammatory cytokines'}, {'entity1': 'macrophages', 'relationship': 'produce', 'entity2': 'interleukin 1'}, {'entity1': 'macrophages', 'relationship': 'produce', 'entity2': 'interleukin 6'}, {'entity1': 'macrophages', 'relationship': 'produce', 'entity2': 'tumor necrosis factor'}]"
304.0,"Recent studies have shown that monocytes and macrophages, especially those from myeloid origin, are main cell types that express tissue factor (TF), which causes pathological coagulation in sepsis.","[{'entity1': 'monocytes and macrophages, especially those from myeloid origin', 'relationship': 'express', 'entity2': 'tissue factor'}, {'entity1': 'tissue factor', 'relationship': 'causes', 'entity2': 'pathological coagulation in sepsis'}]"
305.0,"In severe sepsis, macrophages secrete inflammatory mediators and the coagulation system is activated, which promotes fibrin production and thrombosis.","[{'entity1': 'macrophages', 'relationship': 'secrete', 'entity2': 'inflammatory mediators'}, {'entity1': 'the coagulation system', 'relationship': 'activated', 'entity2': ''}, {'entity1': 'coagulation system', 'relationship': 'promotes', 'entity2': 'fibrin production'}, {'entity1': 'coagulation system', 'relationship': 'promotes', 'entity2': 'thrombosis'}]"
306.0,"In addition, coagulation abnormalities contribute to the lethality of sepsis and septic acute lung injury (ALI).","[{'entity1': 'coagulation abnormalities', 'relationship': 'contribute to', 'entity2': 'the lethality of sepsis'}, {'entity1': 'coagulation abnormalities', 'relationship': 'contribute to', 'entity2': 'septic acute lung injury'}]"
307.0,"Many in vivo studies use cecal ligation and puncture (CLP) model in mice, which can simulate the pathological condition of abdominal infection through cecal contamination and, to some extent, mimic the response of clinical patients with sepsis.","[{'entity1': 'cecal ligation and puncture model in mice', 'relationship': 'can simulate', 'entity2': 'the pathological condition of abdominal infection'}, {'entity1': 'cecal ligation and puncture model in mice', 'relationship': 'mimic', 'entity2': 'the response of clinical patients with sepsis'}]"
308.0,"Eupatilin (Eup) is a lipophilic flavonoid isolated from Artemisia argyi, which has the effect of warming the meridian to stop bleeding, dispersing cold and relieving pain.","[{'entity1': 'Eupatilin', 'relationship': 'isolated from', 'entity2': 'Artemisia argyi'}, {'entity1': 'Eupatilin', 'relationship': 'has effect', 'entity2': 'warming the meridian to stop bleeding, dispersing cold and relieving pain'}]"
309.0,"In recent years, Eupatilin has been found to have biological activities against  inflammation,  oxidation,  and  tumors.","[{'entity1': 'Eupatilin', 'relationship': 'have activities against', 'entity2': 'inflammation'}, {'entity1': 'Eupatilin', 'relationship': 'have activities against', 'entity2': 'oxidation'}, {'entity1': 'Eupatilin', 'relationship': 'have activities against', 'entity2': 'tumors'}]"
310.0,"It has antioxidant and anti-apoptotic effects against  cisplatin-induced ototoxicity,  as  well  as  inhibiting  inflammatory  responses  and  aging  in  nucleus  pulposus  (NP)  cells.","[{'entity1': 'It', 'relationship': 'has effects against', 'entity2': 'cisplatin-induced ototoxicity'}, {'entity1': 'It', 'relationship': 'inhibiting', 'entity2': 'inflammatory responses'}, {'entity1': 'It', 'relationship': 'inhibiting', 'entity2': 'aging in nucleus pulposus cells'}]"
311.0,"In addition, a derivative of Eupatilin to treat dry eye disease is being developed and is undergoing Phase I study.","[{'entity1': 'a derivative of Eupatilin', 'relationship': 'to treat', 'entity2': 'dry eye disease'}, {'entity1': 'a derivative of Eupatilin', 'relationship': 'undergoing', 'entity2': 'Phase I study'}]"
312.0,"Eupatilin can also reduce  the  inflammatory  response  in  LPS-induced  rats,  decreasing  the  level  of  surfactant  protein  (SP)-A,  SP-D,  and inflammatory  factors.","[{'entity1': 'Eupatilin', 'relationship': 'reduce', 'entity2': 'the inflammatory response in LPS-induced rats'}, {'entity1': 'Eupatilin', 'relationship': 'decreasing', 'entity2': 'the level of surfactant protein A'}, {'entity1': 'Eupatilin', 'relationship': 'decreasing', 'entity2': 'the level of surfactant protein D'}, {'entity1': 'Eupatilin', 'relationship': 'decreasing', 'entity2': 'the level of inflammatory factors'}]"
313.0,"Moreover,  Eupatilin  can  reduce  the  number  of  inflammatory  cells  in  OVA-induced  asthmatic mice  and  inhibit  the  NF-κB  and  MAPK  pathways  in  both  mice  and  RAW264.7  cells.","[{'entity1': 'Eupatilin', 'relationship': 'reduce', 'entity2': 'the number of inflammatory cells in OVA-induced asthmatic mice'}, {'entity1': 'Eupatilin', 'relationship': 'inhibit', 'entity2': 'the NF-κB pathway in mice'}, {'entity1': 'Eupatilin', 'relationship': 'inhibit', 'entity2': 'the MAPK pathway in mice'}, {'entity1': 'Eupatilin', 'relationship': 'inhibit', 'entity2': 'the NF-κB pathway in RAW264.7 cells'}, {'entity1': 'Eupatilin', 'relationship': 'inhibit', 'entity2': 'the MAPK pathway in RAW264.7 cells'}]"
314.0,"Besides,  by inhibiting  STAT3, Eupatilin  attenuates  airway  remodeling  and  inhibits  gastric  cancer  cell  growth.","[{'entity1': 'Eupatilin', 'relationship': 'attenuates by inhibiting STAT3', 'entity2': 'airway remodeling'}, {'entity1': 'Eupatilin', 'relationship': 'inhibits by inhibiting STAT3', 'entity2': 'gastric cancer cell growth'}]"
315.0,A  recent  study  has  shown  that Eupatilin  is  associated  with  coagulation.,"[{'entity1': 'Eupatilin', 'relationship': 'associated with', 'entity2': 'coagulation'}]"
316.0,It can inhibit  arachidonic  acid  (AA)-induced  platelet  aggregation  and  throm-boxane  A2  (TXA2)  and  5-hydroxytryptophan  (5-HT)  generation.,"[{'entity1': 'It', 'relationship': 'inhibit', 'entity2': 'arachidonic acid-induced platelet aggregation'}, {'entity1': 'It', 'relationship': 'inhibit', 'entity2': 'thromboxane A2 generation'}, {'entity1': 'It', 'relationship': 'inhibit', 'entity2': '5-hydroxytryptophan generation'}]"
317.0,"Nevertheless,  the  underlying  mechanisms  and whether  it  can  be  used  to  protect  sepsis-induced  coagulation  disorders  is  unclear.","[{'entity1': 'underlying mechanisms', 'relationship': 'unclear', 'entity2': 'whether Eupatilin can protect sepsis-induced coagulation disorders'}]"
318.0,"Besides,  our  previous  study  has shown that in sepsis, phosphorylation of STAT3 at Tyr705 can affect the coagulation and inflammation systems, resulting in fatal damage.","[{'entity1': 'phosphorylation of STAT3 at Tyr705', 'relationship': 'affect', 'entity2': 'coagulation system in sepsis'}, {'entity1': 'phosphorylation of STAT3 at Tyr705', 'relationship': 'affect', 'entity2': 'inflammation system in sepsis'}, {'entity1': 'phosphorylation of STAT3 at Tyr705', 'relationship': 'result in', 'entity2': 'fatal damage in sepsis'}]"
319.0,"Thus,  we  hypothesized  that  Eupatilin  can  exert  anti-inflammatory  and  anti-coagulation  effects  in  LPS-induced  RAW264.7 macrophages and CLP mouse model by suppressing the JAK2/STAT3 signaling pathway.","[{'entity1': 'Eupatilin', 'relationship': 'exert', 'entity2': 'anti-inflammatory effects by suppressing JAK2/STAT3 signaling pathway'}, {'entity1': 'Eupatilin', 'relationship': 'exert', 'entity2': 'anti-coagulation effects by suppressing JAK2/STAT3 signaling pathway'}]"
320.0,"Insulin resistance (IR) is known to be characteristic of type 2 diabetes mellitus,  and is regarded as an important mechanism in disease pathogenesis. One of the key pathogenetic mechanisms  of  IR  progression  is  impaired  free  fatty  acid  (FFA)  metabolism.","[{'entity1': 'Insulin resistance', 'relationship': 'characteristic', 'entity2': 'Type 2 diabetes mellitus'}, {'entity1': 'Insulin resistance', 'relationship': 'mechanism', 'entity2': 'disease pathogenesis'}, {'entity1': 'Insulin resistance progression', 'relationship': 'mechanism', 'entity2': 'impaired free fatty acid metabolism'}]"
321.0,"Plasminogen-activator inhibitor 1 (PAI-1) and key inflammation markers, ie, interleukin 6 (IL-6) and C-reactive protein (CRP), also play a role.","[{'entity1': 'Plasminogen-activator inhibitor 1', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'Interleukin 6', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'C-reactive protein', 'relationship': 'role', 'entity2': 'Insulin resistance'}]"
322.0,"Among  proinflammatory  cytokines  contributing  to         IR  development,  the  role  of  interleukin  (IL)-6,  which  has         autocrine and paracrine properties and is involved in insulin         reception and free fatty acid (FFA) metabolism regulation,         has been extensively studied.","[{'entity1': 'proinflammatory cytokines', 'relationship': 'contributing', 'entity2': 'Insulin resistance development'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'insulin reception'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'free fatty acid metabolism regulation'}]"
323.0,"The  mice  were  randomly  assigned  into  three  groups  according  to  the  random  number  table  method:  sham  operation         (SHAM) group, CLP group, CLP + Eup group.","[{'entity1': 'mice', 'relationship': 'assigned', 'entity2': 'sham operation group'}, {'entity1': 'mice', 'relationship': 'assigned', 'entity2': 'CLP group'}, {'entity1': 'mice', 'relationship': 'assigned', 'entity2': 'CLP + Eup group'}]"
324.0,"Cecal Ligation and Puncture (CLP) and Animal Tests. After the mice were anesthetized, we opened the abdominal cavity and carefully exposed the cecum","[{'entity1': 'Cecal Ligation and Puncture', 'relationship': 'performed on', 'entity2': 'mice'}]"
325.0,"To assess the effect of Eupatilin on cell viability and cytotoxicity, we examined the effect of Eupatilin on RAW 264.7 macrophages  using  the  CCK8  assay.  As  shown  in  Figure  1B,  the  cell  viability  of  RAW  264.7  macrophages  was  little affected  within  24  hours  at  concentrations  less  than  10μM.","[{'entity1': 'Eupatilin', 'relationship': 'affect', 'entity2': 'cell viability'}, {'entity1': 'Eupatilin', 'relationship': 'examined on', 'entity2': 'RAW 264.7 macrophages'}]"
326.0,"LPS  induced  cell  proliferation  in  macrophages,  while  Eupatilin  could  inhibit  the  LPS-induced  cell  proliferation.","[{'entity1': 'LPS', 'relationship': 'induce', 'entity2': 'cell proliferation'}, {'entity1': 'Eupatilin', 'relationship': 'inhibit', 'entity2': 'LPS-induced cell proliferation'}]"
327.0,"After the stimulation with LPS, the mRNA expression raised sharply in TNF-α (25.15±4.10), IL-1β (3753.55±114.04) and IL-6 (36976.14±1121.44).","[{'entity1': 'LPS stimulation', 'relationship': 'raise', 'entity2': 'TNF-α mRNA expression'}, {'entity1': 'LPS stimulation', 'relationship': 'raise', 'entity2': 'IL-1β mRNA expression'}, {'entity1': 'LPS stimulation', 'relationship': 'raise', 'entity2': 'IL-6 mRNA expression'}]"
328.0,"However, pretreatment with Eupatilin apparently attenuated the LPS-induced increase in inflammatory cytokine expression.","[{'entity1': 'Eupatilin pretreatment', 'relationship': 'attenuate', 'entity2': 'LPS-induced inflammatory cytokine expression'}]"
329.0,Eupatilin apparently inhibited LPS-induced mRNA expression of TF (84.66±4.86 in LPS group vs 48.49±3.39 in LPS+Eup group).,"[{'entity1': 'Eupatilin', 'relationship': 'inhibit', 'entity2': 'LPS-induced TF mRNA expression'}]"
330.0,"In the supernatants from the LPS group, the concentrations of TNF-α, IL-1β and IL-6 were higher than the control group, whereas this increase was significantly reduced in the LPS + Eup group.","[{'entity1': 'LPS', 'relationship': 'increase', 'entity2': 'TNF-α concentration'}, {'entity1': 'LPS', 'relationship': 'increase', 'entity2': 'IL-1β concentration'}, {'entity1': 'LPS', 'relationship': 'increase', 'entity2': 'IL-6 concentration'}, {'entity1': 'Eupatilin', 'relationship': 'reduce', 'entity2': 'LPS-induced TNF-α, IL-1β and IL-6 concentration'}]"
331.0,"Moreover, the Western blot results illustrated that pretreatment with Eupatilin significantly reduced LPS-induced inflammatory cytokine expression in RAW264.7 cells.","[{'entity1': 'Eupatilin pretreatment', 'relationship': 'reduce', 'entity2': 'LPS-induced inflammatory cytokine expression'}]"
332.0,Western blot analysis also revealed a decrease in TF expression in the LPS + Eup group.,"[{'entity1': 'Eupatilin', 'relationship': 'decrease', 'entity2': 'TF expression'}]"
333.0,"Compared with the CON group, the LPS group had significantly higher expression levels of both p-JAK2 and p-STAT3.","[{'entity1': 'LPS', 'relationship': 'increase', 'entity2': 'p-JAK2 expression'}, {'entity1': 'LPS', 'relationship': 'increase', 'entity2': 'p-STAT3 expression'}]"
334.0,"However, after pretreatment with Eupatilin, the expression levels of both p-JAK2 and p-STAT3 were diminished.","[{'entity1': 'Eupatilin pretreatment', 'relationship': 'diminish', 'entity2': 'p-JAK2 expression'}, {'entity1': 'Eupatilin pretreatment', 'relationship': 'diminish', 'entity2': 'p-STAT3 expression'}]"
335.0,"AG490 is an inhibitor of JAK2, which reduced the phosphorylation of JAK2 and STAT3.","[{'entity1': 'AG490', 'relationship': 'inhibit', 'entity2': 'JAK2'}, {'entity1': 'AG490', 'relationship': 'reduce', 'entity2': 'JAK2 phosphorylation'}, {'entity1': 'AG490', 'relationship': 'reduce', 'entity2': 'STAT3 phosphorylation'}]"
336.0,"Western blot analysis revealed that AG490 inhibited the phosphorylation of both STAT3 and JAK2, while Eupatilin pretreatment strengthened this inhibition.","[{'entity1': 'AG490', 'relationship': 'inhibit', 'entity2': 'STAT3 phosphorylation'}, {'entity1': 'AG490', 'relationship': 'inhibit', 'entity2': 'JAK2 phosphorylation'}, {'entity1': 'Eupatilin pretreatment', 'relationship': 'strengthen', 'entity2': 'AG490 inhibition'}]"
337.0,"Moreover, comparing with CLP group, the use of AG490 could reduce the expression of TNF-α, IL-1β, IL-6 and TF, while the use of Eupatilin strengthened this inhibition.","[{'entity1': 'AG490', 'relationship': 'reduce', 'entity2': 'TNF-α expression'}, {'entity1': 'AG490', 'relationship': 'reduce', 'entity2': 'IL-1β expression'}, {'entity1': 'AG490', 'relationship': 'reduce', 'entity2': 'IL-6 expression'}, {'entity1': 'AG490', 'relationship': 'reduce', 'entity2': 'TF expression'}, {'entity1': 'Eupatilin', 'relationship': 'strengthen', 'entity2': 'AG490 inhibition'}]"
338.0,"In addition, cell immunofluorescence showed a reduction in the nuclear translocation of p-STAT3 after the pretreatment with Eupatilin in RAW264.7 cells.","[{'entity1': 'Eupatilin pretreatment', 'relationship': 'reduce', 'entity2': 'p-STAT3 nuclear translocation'}]"
339.0,"The results showed that compared with SHAM group, the survival rate in CLP group dropped sharply.","[{'entity1': 'CLP', 'relationship': 'drop', 'entity2': 'survival rate'}]"
340.0,"Moreover, compared to mice in CLP group, the survival rate in CLP+Eup group increased.","[{'entity1': 'Eupatilin', 'relationship': 'increase', 'entity2': 'survival rate'}]"
341.0,"As anticipated, the level of inflammatory cytokines, such as TNF-α, IL-1β and IL-6, as well as coagulation factors, such as TF, TAT, PAI-1 and D-dimer, were lower in the plasma for mice in CLP+Eup group than those in the CLP group.","[{'entity1': 'Eupatilin', 'relationship': 'lower', 'entity2': 'TNF-α level'}, {'entity1': 'Eupatilin', 'relationship': 'lower', 'entity2': 'IL-1β level'}, {'entity1': 'Eupatilin', 'relationship': 'lower', 'entity2': 'IL-6 level'}, {'entity1': 'Eupatilin', 'relationship': 'lower', 'entity2': 'TF level'}, {'entity1': 'Eupatilin', 'relationship': 'lower', 'entity2': 'TAT level'}, {'entity1': 'Eupatilin', 'relationship': 'lower', 'entity2': 'PAI-1 level'}, {'entity1': 'Eupatilin', 'relationship': 'lower', 'entity2': 'D-dimer level'}]"
342.0,"Eupatilin Alleviated Pulmonary Inflammation and Lung Injury in Septic Mice We performed H&E staining to detect lung injury. H&E staining revealed that in the CLP models, the alveolar wall was thickened, hyaline membranes were formed, and neutrophils had accumulated in the interstitial space.","[{'entity1': 'Eupatilin', 'relationship': 'Alleviated', 'entity2': 'Pulmonary Inflammation'}, {'entity1': 'Eupatilin', 'relationship': 'Alleviated', 'entity2': 'Lung Injury'}, {'entity1': 'H&E staining', 'relationship': 'revealed', 'entity2': 'the alveolar wall was thickened'}, {'entity1': 'H&E staining', 'relationship': 'revealed', 'entity2': 'hyaline membranes were formed'}, {'entity1': 'H&E staining', 'relationship': 'revealed', 'entity2': 'neutrophils had accumulated in the interstitial space'}]"
343.0,"As anticipated, the CLP+Eup group exhibited slighter lung tissue injury (Figure 5A). Moreover, the expression of inflammatory cytokines in lung tissue among the three groups was analyzed.","[{'entity1': 'CLP+Eup group', 'relationship': 'exhibited', 'entity2': 'slighter lung tissue injury'}, {'entity1': 'the expression', 'relationship': 'analyzed', 'entity2': 'inflammatory cytokines in lung tissue'}]"
344.0,"As shown in Figure 5B-E, Eupatilin reduced the expression of TNF-α, IL-1β and IL-6 in lung tissue of mice. Macrophages initiate the primary inflammatory process, and F4/80 is a biomarker for them.","[{'entity1': 'Eupatilin', 'relationship': 'reduced', 'entity2': 'the expression of TNF-α in lung tissue of mice'}, {'entity1': 'Eupatilin', 'relationship': 'reduced', 'entity2': 'the expression of IL-1β in lung tissue of mice'}, {'entity1': 'Eupatilin', 'relationship': 'reduced', 'entity2': 'the expression of IL-6 in lung tissue of mice'}, {'entity1': 'Macrophages', 'relationship': 'initiate', 'entity2': 'the primary inflammatory process'}, {'entity1': 'F4/80', 'relationship': 'biomarker for', 'entity2': 'Macrophages'}]"
345.0,"Immunofluorescence staining demonstrated that the CLP group had stronger F4/80 fluorescent signals than the sham group, while Eupatilin pretreatment decreased these signals (Figure 5F).","[{'entity1': 'the CLP group', 'relationship': 'had', 'entity2': 'stronger F4/80 fluorescent signals'}, {'entity1': 'Eupatilin pretreatment', 'relationship': 'decreased', 'entity2': 'F4/80 fluorescent signals'}]"
346.0,"We used Western blot, immunohistochemistry and immunofluorescence staining to investigate whether Eupatilin reduces coagulation in lung tissue.","[{'entity1': 'We', 'relationship': 'investigate', 'entity2': 'whether Eupatilin reduces coagulation in lung tissue'}]"
347.0,"The exposure of TF is the way to promote coagulation. The results of Western blot and immunofluorescence showed that Eupatilin could lower the exposure of TF in the lung tissue of septic mice (Figure 6A, B and E).","[{'entity1': 'The exposure of TF', 'relationship': 'promote', 'entity2': 'coagulation'}, {'entity1': 'Eupatilin', 'relationship': 'lower', 'entity2': 'the exposure of TF in the lung tissue of septic mice'}]"
348.0,"Furthermore, Western blot showed decreased expression levels of thrombin, and PAI-1 in the lung tissue of septic mice after Eupatilin pretreatment (Figure 6A, C and D).","[{'entity1': 'Western blot', 'relationship': 'showed', 'entity2': 'decreased expression levels of thrombin in the lung tissue of septic mice after Eupatilin pretreatment'}, {'entity1': 'Western blot', 'relationship': 'showed', 'entity2': 'decreased expression levels of PAI-1 in the lung tissue of septic mice after Eupatilin pretreatment'}]"
349.0,"Additionally, according to immunohistochemistry results, fibrin deposition (brown stain) was observed in the CLP group.","[{'entity1': 'fibrin deposition', 'relationship': 'observed', 'entity2': 'in the CLP group'}]"
350.0,"However, the amount of fibrin deposition was less in the lung tissue from mice pretreated with Eupatilin (Figure 6F).","[{'entity1': 'the amount of fibrin deposition', 'relationship': 'less', 'entity2': 'in the lung tissue from mice pretreated with Eupatilin'}]"
351.0,"The Western blot analysis revealed that the expression of p-JAK2 and p-STAT3 was considerably higher in the CLP group than in the SHAM group, and decreased with Eupatilin pretreatment (Figure 7A-C, 1.79±0.24 and 2.21±0.20 in CLP group vs 1.24±0.16 and 1.11±0.15 in CLP+Eup group, respectively).","[{'entity1': 'the expression of p-JAK2', 'relationship': 'higher', 'entity2': 'in the CLP group'}, {'entity1': 'the expression of p-STAT3', 'relationship': 'higher', 'entity2': 'in the CLP group'}, {'entity1': 'the expression of p-JAK2', 'relationship': 'decreased', 'entity2': 'with Eupatilin pretreatment'}, {'entity1': 'the expression of p-STAT3', 'relationship': 'decreased', 'entity2': 'with Eupatilin pretreatment'}]"
352.0,One of the pathological features of sepsis is the hyperactivation of inflammation and coagulation systems; both can promote and impact upon each other.,"[{'entity1': 'hyperactivation of inflammation', 'relationship': 'pathological features', 'entity2': 'sepsis'}, {'entity1': 'hyperactivation of coagulation systems', 'relationship': 'pathological features', 'entity2': 'sepsis'}, {'entity1': 'inflammation', 'relationship': 'promote', 'entity2': 'coagulation systems'}, {'entity1': 'coagulation systems', 'relationship': 'promote', 'entity2': 'inflammation'}, {'entity1': 'inflammation', 'relationship': 'impact upon', 'entity2': 'coagulation systems'}, {'entity1': 'coagulation systems', 'relationship': 'impact upon', 'entity2': 'inflammation'}]"
353.0,Pro-inflammatory cytokines have the ability to stimulate coagulation in vitro. TF is the main factor in the coagulation process  and  is  also  a  link  between  coagulation  and  inflammation.,"[{'entity1': 'Pro-inflammatory cytokines', 'relationship': 'stimulate', 'entity2': 'coagulation'}, {'entity1': 'TF', 'relationship': 'main factor', 'entity2': 'coagulation process'}, {'entity1': 'TF', 'relationship': 'link', 'entity2': 'coagulation and inflammation'}]"
354.0,"Under  normal  physiological  conditions,  mono-cytes,  endothelial  cells  and  epithelial  cells  have  low  TF  expression.40  However,  during  sepsis,  these  cells  express  and release TF into circulation after being stimulated by inflammatory factors and LPS.","[{'entity1': 'mono-cytes, endothelial cells and epithelial cells', 'relationship': 'express', 'entity2': 'TF'}, {'entity1': 'mono-cytes, endothelial cells and epithelial cells', 'relationship': 'release', 'entity2': 'TF'}, {'entity1': 'inflammatory factors and LPS', 'relationship': 'stimulate', 'entity2': 'mono-cytes, endothelial cells and epithelial cells'}]"
355.0,Previous  research has  also  demonstrated  that  blocking  IL-6  inhibits  endotoxin-induced coagulation  activation.,"[{'entity1': 'blocking IL-6', 'relationship': 'inhibits', 'entity2': 'endotoxin-induced coagulation activation'}]"
356.0,Numerous  investigations  have  shown  that  the  stimulation  of  human  monocytes  with  LPS increases  TF  expression.,"[{'entity1': 'stimulation of human monocytes with LPS', 'relationship': 'increases', 'entity2': 'TF expression'}]"
357.0,"Moreover,  healthy  humans  who  received  a  low-dose  endotoxemia  injection  had  a  125- fold increase in the amount of TF mRNA in their circulating monocytes.","[{'entity1': 'low-dose endotoxemia injection', 'relationship': 'increases', 'entity2': 'TF mRNA in circulating monocytes'}]"
358.0,"In a model of endotoxemia, early research showed  that  inhibiting  the  expression  of  TF  attenuated  septic  shock,  and  animals  with  low  TF  levels  had  decreased coagulation,  inflammation,  and  mortality.","[{'entity1': 'inhibiting TF expression', 'relationship': 'attenuates', 'entity2': 'septic shock'}, {'entity1': 'low TF levels', 'relationship': 'decreases', 'entity2': 'coagulation, inflammation and mortality'}]"
359.0,"In our study, we discovered that TF expression was noticeably higher in sepsis models, while the pretreatment with Eupatilin reversed these changes.","[{'entity1': 'Eupatilin pretreatment', 'relationship': 'reverses', 'entity2': 'increased TF expression'}]"
360.0,The TF–VIIa complex then activates factor X and initiates coagulation activation.,"[{'entity1': 'The TF–VIIa complex', 'relationship': 'activates', 'entity2': 'factor X'}, {'entity1': 'The TF–VIIa complex', 'relationship': 'initiates', 'entity2': 'coagulation activation'}]"
361.0,"Thrombin  then  cleaves  fibrinogen  into  fibrin,51  and  fibrin  degradation  products can  induce  IL-6  production by monocytes in vitro.","[{'entity1': 'thrombin', 'relationship': 'cleaves', 'entity2': 'fibrinogen'}, {'entity1': 'fibrin degradation products', 'relationship': 'induces', 'entity2': 'IL-6 production'}]"
362.0,Increased fibrin formation due to impaired fibrinolysis causes organ injury and mortality in sepsis.,"[{'entity1': 'Increased fibrin formation', 'relationship': 'causes', 'entity2': 'organ injury and mortality'}]"
363.0,"According to a number of studies, the STAT3 signaling pathway can regulate inflammatory responses in LPS-induced macrophages and acute lung injury.","[{'entity1': 'STAT3 signaling pathway', 'relationship': 'regulates', 'entity2': 'inflammatory responses'}, {'entity1': 'STAT3 signaling pathway', 'relationship': 'regulates', 'entity2': 'LPS-induced macrophages'}, {'entity1': 'STAT3 signaling pathway', 'relationship': 'regulates', 'entity2': 'acute lung injury'}]"
364.0,"In addition, the use of the STAT3 inhibitor BP-1-102 decreased the expression of LPS-induced inflammatory cytokines such as IL-1β, IL-6, TNF-α, and TF in RAW264.7 cells.","[{'entity1': 'STAT3 inhibitor BP-1-102', 'relationship': 'decreases', 'entity2': 'LPS-induced inflammatory cytokines and TF'}]"
365.0,"Insulin resistance (IR) is known to be characteristic of type 2 diabetes mellitus,             and is regarded as an important mechanism in disease pathogenesis.","[{'entity1': 'Insulin resistance', 'relationship': 'characteristic', 'entity2': 'Type 2 diabetes mellitus'}, {'entity1': 'Insulin resistance', 'relationship': 'mechanism', 'entity2': 'disease pathogenesis'}]"
366.0,One of the key pathogenetic             mechanisms  of  IR  progression  is  impaired  free  fatty  acid  (FFA)  metabolism.,"[{'entity1': 'pathogenesis', 'relationship': 'progression', 'entity2': 'impaired free fatty acid metabolism'}]"
367.0,"Plasminogen-            activator inhibitor 1 (PAI-1) and key inflammation markers, ie, interleukin 6 (IL-6) and C-reactive             protein (CRP), also play a role.","[{'entity1': 'Plasminogen-activator inhibitor 1', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'Interleukin 6', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'C-reactive protein', 'relationship': 'role', 'entity2': 'Insulin resistance'}]"
368.0,"Among  proinflammatory  cytokines  contributing  to         IR  development,  the  role  of  interleukin  (IL)-6,  which  has         autocrine and paracrine properties and is involved in insulin         reception and free fatty acid (FFA) metabolism regulation,         has been extensively studied.","[{'entity1': 'Interleukin 6', 'relationship': 'contributing', 'entity2': 'Insulin resistance development'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'insulin reception'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'free fatty acid metabolism regulation'}]"
369.0,Coagulation in sepsis.,"[{'entity1': 'Coagulation', 'relationship': 'in', 'entity2': 'sepsis'}]"
370.0,Thrombin: coagulation’s master regulator of innate immunity.,"[{'entity1': 'Thrombin', 'relationship': 'master regulator', 'entity2': 'coagulation'}, {'entity1': 'Thrombin', 'relationship': 'regulator', 'entity2': 'innate immunity'}]"
371.0,The roles of fibrinogen and fibrin in hemostasis and thrombosis.,"[{'entity1': 'fibrinogen', 'relationship': 'roles', 'entity2': 'hemostasis and thrombosis'}, {'entity1': 'fibrin', 'relationship': 'roles', 'entity2': 'hemostasis and thrombosis'}]"
372.0,Blood coagulation and the risk of atherothrombosis: a complex relationship.,"[{'entity1': 'Blood coagulation', 'relationship': 'risk', 'entity2': 'atherothrombosis'}]"
373.0,Disseminated intravascular coagulation in sepsis.,"[{'entity1': 'Disseminated intravascular coagulation', 'relationship': 'in', 'entity2': 'sepsis'}]"
374.0,Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation.,"[{'entity1': 'Activity and antigen levels', 'relationship': 'of', 'entity2': 'thrombin-activatable fibrinolysis inhibitor'}, {'entity1': 'thrombin-activatable fibrinolysis inhibitor', 'relationship': 'in', 'entity2': 'plasma'}, {'entity1': 'plasma', 'relationship': 'of', 'entity2': 'patients'}, {'entity1': 'patients', 'relationship': 'with', 'entity2': 'disseminated intravascular coagulation'}]"
375.0,Hepatic acute phase proteins–regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling.,"[{'entity1': 'Hepatic acute phase proteins', 'relationship': 'regulation by', 'entity2': 'IL-6- and IL-1-type cytokines'}, {'entity1': 'regulation', 'relationship': 'involving', 'entity2': 'STAT3 and its crosstalk with NF-κB-dependent signaling'}]"
376.0,The roles of SOCS3 and STAT3 in bacterial infection and inflammatory diseases.,"[{'entity1': 'SOCS3', 'relationship': 'roles', 'entity2': 'bacterial infection and inflammatory diseases'}, {'entity1': 'STAT3', 'relationship': 'roles', 'entity2': 'bacterial infection and inflammatory diseases'}]"
377.0,STAT3 in the systemic inflammation of cancer cachexia.,"[{'entity1': 'STAT3', 'relationship': 'in', 'entity2': 'the systemic inflammation of cancer cachexia'}]"
378.0,"The inflammatory response is an adaptive mechanism that evolved to fight against infections and tissue damage. This complex mechanism is vital for the proper function of the organism, and because of that, is under tight regulation involving a complex network of factors, cells, and systems.","[{'entity1': 'inflammatory response', 'relationship': 'evolved', 'entity2': 'fight against infections and tissue damage'}, {'entity1': 'inflammatory response', 'relationship': 'vital', 'entity2': 'proper function of the organism'}, {'entity1': 'inflammatory response', 'relationship': 'under', 'entity2': 'tight regulation'}]"
379.0,"Physiological inflammation is perfectly orchestrated to allow the mobilization of leukocytes from the circulation to the injured tissues for the removal of pathogens, tissue repair, and return to homeostasis.","[{'entity1': 'Physiological inflammation', 'relationship': 'orchestrated', 'entity2': 'mobilization of leukocytes'}, {'entity1': 'mobilization of leukocytes', 'relationship': 'allow', 'entity2': 'removal of pathogens'}, {'entity1': 'mobilization of leukocytes', 'relationship': 'allow', 'entity2': 'tissue repair'}, {'entity1': 'mobilization of leukocytes', 'relationship': 'allow', 'entity2': 'return to homeostasis'}]"
380.0,"However, when the self-limited nature of the inflammatory response and the mechanisms of resolution fail, inflammation might become chronic, leading to the development of many disabling serious diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), or psoriasis.","[{'entity1': 'self-limited nature of inflammatory response', 'relationship': 'fail', 'entity2': 'mechanisms of resolution'}, {'entity1': 'inflammation', 'relationship': 'become', 'entity2': 'chronic'}, {'entity1': 'chronic inflammation', 'relationship': 'leading', 'entity2': 'development of disabling serious diseases'}]"
381.0,"This resulted in enormous improvements in the treatments for immune-mediated inflammatory diseases, but also revealed the complexity of the cytokine networks and immune cell subtypes involved in non-resolving inflammatory responses.","[{'entity1': 'enormous improvements', 'relationship': 'in', 'entity2': 'treatments for immune-mediated inflammatory diseases'}, {'entity1': 'also revealed', 'relationship': '', 'entity2': 'complexity of cytokine networks and immune cell subtypes'}, {'entity1': 'cytokine networks and immune cell subtypes', 'relationship': 'involved', 'entity2': 'non-resolving inflammatory responses'}]"
382.0,The 34 original and review articles included in this Special Issue contributed to the aim of describing and understanding new mechanisms that trigger inflammation and highlighted new putative treatments for different inflammatory conditions.,"[{'entity1': 'articles', 'relationship': 'contributed', 'entity2': 'aim of describing and understanding new mechanisms that trigger inflammation'}, {'entity1': 'articles', 'relationship': 'highlighted', 'entity2': 'new putative treatments for different inflammatory conditions'}]"
383.0,"Neuroinflammation is a perfect example of the two faces of inflammation. While an acute inflammatory response is protective, chronic neuroinflammation leads to inflammatory conditions such as multiple sclerosis, and it also contributes to other neurological [1] and psychiatric disorders such as Alzheimer’s or Parkinson’s disease [2].","[{'entity1': 'acute inflammatory response', 'relationship': 'protective', 'entity2': ''}, {'entity1': 'chronic neuroinflammation', 'relationship': 'leads to', 'entity2': 'inflammatory conditions such as multiple sclerosis'}, {'entity1': 'chronic neuroinflammation', 'relationship': 'contributes to', 'entity2': 'neurological and psychiatric disorders'}]"
384.0,"Microglia is pivotal for regulating central nervous system inflammation. Therefore, it would be interesting to develop therapeutic strategies conducted to mitigate their hyperactivation.","[{'entity1': 'Microglia', 'relationship': 'pivotal', 'entity2': 'regulating central nervous system inflammation'}, {'entity1': 'therapeutic strategies', 'relationship': 'conducted', 'entity2': 'mitigate their hyperactivation'}]"
385.0,"Microsporidia are obligatory intracellular eukaryotic parasites belonging to the phy-lum  Microsporidia  within  the  kingdom  Opisthokonta  infecting  a  broad  range  of animals  including  protists,  invertebrates,  and  vertebrates.","[{'entity1': 'Microsporidia', 'relationship': 'infecting', 'entity2': 'broad range of animals'}]"
386.0,"In mammals, infections typically establish a balanced host–parasite relationship  that produce minimal  clinically overt disease  in  immunocompetent nat-ural  hosts.","[{'entity1': 'infections', 'relationship': 'establish', 'entity2': 'balanced host-parasite relationship'}, {'entity1': 'infections', 'relationship': 'produce', 'entity2': 'minimal clinically overt disease'}, {'entity1': 'infections', 'relationship': 'in', 'entity2': 'immunocompetent natural hosts'}]"
387.0,"A  shift  in  the  balance  toward  immune  deficiency  or  hyperimmune responses,  however,  produces  overt  clinical  signs  of  disease.","[{'entity1': 'shift in balance', 'relationship': 'produces', 'entity2': 'overt clinical signs of disease'}]"
388.0,"Of the ~1500  described  microsporidia  species,  17  species  are  known  to  infect  humans,  of which  Encephalitozoon  spp.  and  Enterocytozoon  bieneusi are reported from most of the symptomatic patients.","[{'entity1': '~1500 microsporidia species', 'relationship': '', 'entity2': ''}, {'entity1': '17 species', 'relationship': 'infect', 'entity2': 'humans'}, {'entity1': 'Encephalitozoon spp.', 'relationship': 'reported from', 'entity2': 'most symptomatic patients'}, {'entity1': 'Enterocytozoon bieneusi', 'relationship': 'reported from', 'entity2': 'most symptomatic patients'}]"
389.0,"Encephalitozoon species infect sev-eral cell types in mammalian hosts, including epithelial and endothelial cells, fibroblasts, macrophages, and astrocytes.","[{'entity1': 'Encephalitozoon species', 'relationship': 'infect', 'entity2': 'several cell types'}, {'entity1': 'several cell types', 'relationship': 'including', 'entity2': 'epithelial cells'}, {'entity1': 'several cell types', 'relationship': 'including', 'entity2': 'endothelial cells'}, {'entity1': 'several cell types', 'relationship': 'including', 'entity2': 'fibroblasts'}, {'entity1': 'several cell types', 'relationship': 'including', 'entity2': 'macrophages'}, {'entity1': 'several cell types', 'relationship': 'including', 'entity2': 'astrocytes'}]"
390.0,"Eight-week-old severe combined immunodeficient (SCID) and immunocompetent (BALB/c) mice originally obtained from Charles River (Sulzfeld, Germany) were bred under sterile condition and supplied with a sterilized diet and sterilized water ad libitum.","[{'entity1': 'Eight-week-old severe combined immunodeficient (SCID) mice', 'relationship': 'obtained from', 'entity2': 'Charles River'}, {'entity1': 'Eight-week-old immunocompetent (BALB/c) mice', 'relationship': 'obtained from', 'entity2': 'Charles River'}, {'entity1': 'Eight-week-old severe combined immunodeficient (SCID) mice', 'relationship': 'bred under', 'entity2': 'sterile condition'}, {'entity1': 'Eight-week-old immunocompetent (BALB/c) mice', 'relationship': 'bred under', 'entity2': 'sterile condition'}]"
391.0,The spores of E. cuniculi genotype II originally isolated from a dexamethasone-treated laboratory mouse31 were cultivated in vitro for the purpose of the experiment according to Kotková et al.32,"[{'entity1': 'The spores of E. cuniculi genotype II', 'relationship': 'originally isolated from', 'entity2': 'a dexamethasone-treated laboratory mouse'}, {'entity1': 'The spores of E. cuniculi genotype II', 'relationship': 'cultivated', 'entity2': 'in vitro'}, {'entity1': 'The spores of E. cuniculi genotype II', 'relationship': 'cultivated', 'entity2': 'for the purpose of the experiment'}, {'entity1': 'The spores of E. cuniculi genotype II', 'relationship': 'cultivated according to', 'entity2': 'Kotková et al.'}]"
392.0,All mice were per orally infected with the dose of 107  E. cuniculi genotype II spores in 0.2 mL of deionized water using intragastric gavage.,"[{'entity1': 'All mice', 'relationship': 'infected with', 'entity2': 'the dose of 107 E. cuniculi genotype II spores'}, {'entity1': 'the dose of 107  E. cuniculi genotype II spores', 'relationship': 'in', 'entity2': '0.2 mL of deionized water'}, {'entity1': 'All mice', 'relationship': 'infected', 'entity2': 'using intragastric gavage'}]"
393.0,"The inflammation in experimen-tal SCID and BALB/c was induced by the usage of 50 μL of Freund’s Incomplete Adjuvant (Sigma-Aldrich, St.","[{'entity1': 'The inflammation', 'relationship': 'induced by', 'entity2': 'the usage of 50 μL of Freund’s Incomplete Adjuvant'}, {'entity1': 'The inflammation', 'relationship': 'in', 'entity2': 'experimen-tal SCID and BALB/c'}]"
394.0,Three mice from each group were euthanized by cervical dislocation every seventh DPI and sterile samples for molecular detection and histology were prepared from limb muscles and liver by the usage of a different pair of sterile dissection tools,"[{'entity1': 'Three mice from each group', 'relationship': 'euthanized by', 'entity2': 'cervical dislocation'}, {'entity1': 'sterile samples', 'relationship': 'prepared from ', 'entity2': 'limb muscles and liver'}, {'entity1': 'sterile samples', 'relationship': 'prepared', 'entity2': ' for molecular detection and histology'}, {'entity1': 'sterile samples', 'relationship': 'prepared by', 'entity2': 'the usage of a different pair of sterile dissection tools'}]"
395.0,Total DNA from samples was extracted as described by Sak et al33 following bead homogenization.,"[{'entity1': 'Total DNA from samples', 'relationship': 'extracted', 'entity2': 'as described by Sak et al'}, {'entity1': 'Total DNA from samples', 'relationship': 'extracted', 'entity2': 'following bead homogenization'}]"
396.0,"Positive results were determined based on mathematical algorithms included with the LightCycler system (Roche, Praha, the Czech Republic).","[{'entity1': 'Positive results', 'relationship': 'determined based on', 'entity2': 'mathematical algorithms'}, {'entity1': 'mathematical algorithms', 'relationship': 'included with', 'entity2': 'the LightCycler system'}]"
397.0,Tissues samples were processed by the usual paraffin method following fixation in 10% buffered formalin.,"[{'entity1': 'Tissues samples', 'relationship': 'processed by', 'entity2': 'the usual paraffin method'}, {'entity1': 'Tissues samples', 'relationship': 'processed', 'entity2': 'following fixation in 10% buffered formalin'}]"
398.0,"In the control immunocompetent BALB/c mice inoculated with PBS in the chronic phase of infection, microsporidia were not detected in selected organs and tissues throughout the whole experimental period.","[{'entity1': 'microsporidia', 'relationship': 'not detected', 'entity2': 'selected organs and tissues'}]"
399.0,"However, after the inflammation induction in the chronic phase of infection of 56 DPI in BALB/c mice, the infection was reactivated in all experimental mice and microsporidia were detected in both legs regardless of the site of inflammation induction.","[{'entity1': 'inflammation induction', 'relationship': 'caused', 'entity2': 'infection reactivation'}, {'entity1': 'microsporidia', 'relationship': 'detected', 'entity2': 'both legs'}]"
400.0,"In addition, E. cuniculi genotype II reappeared also in the liver, even though the maximum spore burden was 10-times lower than in the case of induction of inflammation in the acute phase of infection.","[{'entity1': 'E. cuniculi genotype II', 'relationship': 'reappeared', 'entity2': 'the liver'}, {'entity1': 'maximum spore burden', 'relationship': 'lower', 'entity2': 'induction of inflammation in the acute phase of infection'}]"
401.0,"A similar effect was observed after secondary induction of inflammation in the chronic phase of infection of 77 DPI with no specific migration of E. cuniculi genotype II to the inflammatory focus, but activation of latent infection in experimental BALB/c mice, showing a significant increase in the spore burden in the induced group compared to control mice.","[{'entity1': 'secondary induction of inflammation', 'relationship': 'caused', 'entity2': 'activation of latent infection'}, {'entity1': 'spore burden', 'relationship': 'increased', 'entity2': 'induced group'}]"
402.0,"After induction of inflammation of 7 DPI, in the experimental group a significant increase in the number of spores in the induced right hind leg of 21 DPI reaching 7.8×105 spores per gram of tissue was observed compared to the left leg containing 3.5×105 spores per gram of tissue.","[{'entity1': 'induction of inflammation', 'relationship': 'caused', 'entity2': 'increase in the number of spores'}, {'entity1': 'number of spores', 'relationship': 'compared', 'entity2': 'left leg'}]"
403.0,"In contrast to BALB/c mice, clinical signs of microsporidiosis, including bristly hair, hunched back, and cachexia, were observed in SCID mice, especially at the end of the study period.","[{'entity1': 'clinical signs of microsporidiosis', 'relationship': 'observed', 'entity2': 'SCID mice'}]"
404.0,"Systemic  E.  cuniculi  infections  acquired  by  ingesting  spores are also initiated in the gut epithelial cells followed by     the  invasion  of  other  tissues. The  rapid  spreading  of     Encephalitozoon has been reported in murine models, where system is reported within several days.","[{'entity1': 'Systemic E. cuniculi infections', 'relationship': 'acquired by', 'entity2': 'ingesting spores'}, {'entity1': 'Systemic E. cuniculi infections', 'relationship': 'initiated in', 'entity2': 'gut epithelial cells'}, {'entity1': 'Systemic E. cuniculi infections', 'relationship': 'followed by', 'entity2': 'invasion of other tissues'}, {'entity1': 'spreading of Encephalitozoon', 'relationship': 'reported in', 'entity2': 'murine models'}, {'entity1': 'systemic infection', 'relationship': 'reported within', 'entity2': 'several days'}]"
405.0,"Encephalitozoon  cuniculi  was  recognized  as  a  neglected etiological agent for more common, sometimes life-threatening diseases,         such as encephalitis and meningitis, in otherwise healthy individuals         or  contribute  to  aseptic  periprosthetic osteolysis         after  primary  hip  arthroplasty,  leading  to  implant loosening.","[{'entity1': 'Encephalitozoon cuniculi', 'relationship': 'recognized as', 'entity2': 'neglected etiological agent'}, {'entity1': 'Encephalitozoon cuniculi', 'relationship': 'cause', 'entity2': 'life-threatening diseases like encephalitis and meningitis'}, {'entity1': 'Encephalitozoon cuniculi', 'relationship': 'contribute to', 'entity2': 'aseptic periprosthetic osteolysis'}, {'entity1': 'aseptic periprosthetic osteolysis', 'relationship': 'leading to', 'entity2': 'implant loosening'}]"
406.0,"Compared to the control group injected with sterile PBS, the occurrence of microsporidia in the limbs was random, suggesting that microsporidia             may have been eliminated by the host immune system.","[{'entity1': 'occurrence of microsporidia', 'relationship': 'compared', 'entity2': 'control group with sterile PBS injection'}, {'entity1': 'occurrence of microsporidia in limbs', 'relationship': 'was', 'entity2': 'random'}, {'entity1': 'microsporidia', 'relationship': 'eliminated by', 'entity2': 'host immune system'}]"
407.0,induction of inflammation in the experimental group of SCID mice led to a significant increase of spore burden at the site of inflammation.,"[{'entity1': 'induction of inflammation', 'relationship': 'led to', 'entity2': 'increase of spore burden'}, {'entity1': 'increase of spore burden', 'relationship': 'at', 'entity2': 'site of inflammation'}]"
408.0,"Unexpectedly, whereas the presence of E. cuniculi geno-type II in the feces of control groups of immunocompetent BALB/c mice in both acute and chronic phase of infection was detected intermittently thorough the whole experimental period, in experimental groups the excretion of E. cuniculi in feces was  reduced  for several  days  or disappeared, respec-tively,  after  inflammation  induction.","[{'entity1': 'E. cuniculi genotype II', 'relationship': 'presence', 'entity2': 'feces of control groups of immunocompetent BALB/c mice'}, {'entity1': 'E. cuniculi genotype II', 'relationship': 'detected', 'entity2': 'intermittently thorough the whole experimental period'}, {'entity1': 'excretion of E. cuniculi', 'relationship': 'reduced', 'entity2': 'experimental groups'}, {'entity1': 'excretion of E. cuniculi', 'relationship': 'disappeared', 'entity2': 'experimental groups'}, {'entity1': 'excretion of E. cuniculi', 'relationship': 'after', 'entity2': 'inflammation induction'}]"
409.0,It  can  be  assumed  that  E.  cuniculi genotype  II  could  be  secondarily  transported  to  the  site of  inflammation  with  the  contribution  of  immune  cells participating  in  its  formation.,"[{'entity1': 'E. cuniculi genotype II', 'relationship': 'transported', 'entity2': 'site of inflammation'}, {'entity1': 'immune cells', 'relationship': 'contributing', 'entity2': 'transport of E. cuniculi genotype II'}, {'entity1': 'immune cells', 'relationship': 'participating', 'entity2': 'inflammation formation'}]"
410.0,"However,  the  mechanisms  of  such  migration  as  well  as the  vehicle  cells  and  mechanism  of  infection  reactivation remain speculative and need to be specified in detail.","[{'entity1': 'mechanisms', 'relationship': 'remain', 'entity2': 'speculative'}, {'entity1': 'vehicle cells', 'relationship': 'remain', 'entity2': 'speculative'}, {'entity1': 'mechanism of infection reactivation', 'relationship': 'remain', 'entity2': 'speculative'}]"
411.0,"18. Del Aguila C, Rueda C, de la Camara C, Fenoy S. Seroprevalence of anti-Encephalitozoon  antibodies  in  Spanish  immunocompetent  sub-ject.","[{'entity1': 'Encephalitozoon', 'relationship': 'Seroprevalence', 'entity2': 'Spanish immunocompetent subjects'}]"
412.0,"19. Enriquez FJ, Taren D, Cruz-Lopez A, Muramoto M, Palting JD, Cruz P.  Prevalence  of  intestinal  encephalitozoonnosis  in  Mexico.","[{'entity1': 'intestinal encephalitozoonnosis', 'relationship': 'Prevalence', 'entity2': 'Mexico'}]"
413.0,"20. Lopez-Velez  R, Turrientes MC, Garron C,  et al. Microsporidiosis  in travelers  with  diarrhea  from  the  tropics.","[{'entity1': 'Microsporidiosis', 'relationship': 'in', 'entity2': 'travelers with diarrhea from the tropics'}]"
414.0,"21. Lores B, Lopez-Miragaya I,  Arias C,  Fenoy S, Torres J, Del Aguila C.  Intestinal  microsporidiosis  due  to  Enterocytozoon  bieneusi  in elderly  human  immunodeficiency  virus–negative  patients  from Vigo, Spain.","[{'entity1': 'Intestinal microsporidiosis', 'relationship': 'due to', 'entity2': 'Enterocytozoon bieneusi'}, {'entity1': 'Intestinal microsporidiosis', 'relationship': 'in', 'entity2': 'elderly human immunodeficiency virus-negative patients'}]"
415.0,"22. Müller  A,  Bialek  R,  Kamper  A,  Fatkenheuer  G,  Salzberger  B, Franzen  C.  Detection  of  microsporidia  in  travelers  with  diarrhea.","[{'entity1': 'microsporidia', 'relationship': 'Detection', 'entity2': 'travelers with diarrhea'}]"
416.0,"23. van  Gool  T,  Vetter  JCM,  Weinmayr  B,  van  Dam  A,  Derouin  F, Dankert J. High seroprevalence of Encephalitozoon species in immu-nocompetent  subjects.","[{'entity1': 'Encephalitozoon species', 'relationship': 'High seroprevalence', 'entity2': 'immunocompetent subjects'}]"
417.0,"24. Morio  F,  Poirier  P,  Le  Govic  Y,  et  al.  Assessment  of  the  first commercial  multiplex  PCR  kit  (ParaGENIE  crypto-micro  real-time PCR)  for  the  detection  of  Cryptosporidium  spp.,  Enterocytozoon bieneusi,  and  Encephalitozoon  intestinalis  from  fecal  samples.","[{'entity1': 'first commercial multiplex PCR kit', 'relationship': 'Assessment', 'entity2': 'detection of Cryptosporidium spp., Enterocytozoon bieneusi and Encephalitozoon intestinalis from fecal samples'}]"
418.0,Experimental Encephalitozoon cuniculi infection acquired from fermented meat products.,"[{'entity1': 'Encephalitozoon cuniculi infection', 'relationship': 'acquired from', 'entity2': 'fermented meat products'}]"
419.0,Acute disseminated encephalomyelitis and reactivation of cerebral toxoplasmosis in a child: case report.,"[{'entity1': 'Acute disseminated encephalomyelitis', 'relationship': 'and', 'entity2': 'reactivation of cerebral toxoplasmosis'}]"
420.0,The course of infection caused by Encephalitozoon cuniculi genotype III in immunocompetent and immunodeficient mice.,"[{'entity1': 'infection', 'relationship': 'caused by', 'entity2': 'Encephalitozoon cuniculi genotype III'}, {'entity1': 'infection', 'relationship': 'in', 'entity2': 'immunocompetent and immunodeficient mice'}]"
421.0,Microsporidiosis: not just in AIDS patients.,"[{'entity1': 'Microsporidiosis', 'relationship': 'in', 'entity2': 'AIDS patients'}]"
422.0,"In  recent  years,  growing  evidence  has  indicated  that  the  inflammatory  response,  immunity  and  nutrition  status  of individuals  have  a  close  relationship  with  the  occurrence,  progression,  and  metastasis  of  tumours.","[{'entity1': 'inflammatory response', 'relationship': 'relationship', 'entity2': 'occurrence, progression and metastasis of tumours'}, {'entity1': 'immunity status', 'relationship': 'relationship', 'entity2': 'occurrence, progression and metastasis of tumours'}, {'entity1': 'nutrition status', 'relationship': 'relationship', 'entity2': 'occurrence, progression and metastasis of tumours'}]"
423.0,"Many  studies  have  reported  that  the  ratios  of  different  peripheral  blood  mononuclear  subtypes,  such  as  the  neutrophil  to  lymphocyte  ratio  (NLR), lymphocyte to monocyte ratio (LMR), platelet-lymphocyte ratio (PLR), and monocyte to leukocyte ratio (MWR), play an important role in predicting the prognosis of patients with various cancers.","[{'entity1': 'neutrophil to lymphocyte ratio', 'relationship': 'role', 'entity2': 'predicting prognosis of patients with various cancers'}, {'entity1': 'lymphocyte to monocyte ratio', 'relationship': 'role', 'entity2': 'predicting prognosis of patients with various cancers'}, {'entity1': 'platelet-lymphocyte ratio', 'relationship': 'role', 'entity2': 'predicting prognosis of patients with various cancers'}, {'entity1': 'monocyte to leukocyte ratio', 'relationship': 'role', 'entity2': 'predicting prognosis of patients with various cancers'}]"
424.0,High-sensitivity C-reactive protein (hs-CRP) is a critical inflammatory-related protein synthesized by the liver and has been shown to affect patient survival in hepatocellular carcinoma and nasopharyngeal carcinoma.,"[{'entity1': 'High-sensitivity C-reactive protein', 'relationship': 'affect', 'entity2': 'patient survival in hepatocellular carcinoma'}, {'entity1': 'High-sensitivity C-reactive protein', 'relationship': 'affect', 'entity2': 'patient survival in nasopharyngeal carcinoma'}]"
425.0,The levels of serum albumin (ALB) intuitively reflect the nutritional status of individuals and have been confirmed to be an effective tool for predicting the outcomes of patients with gastric cancer and haematological malignancy.,"[{'entity1': 'levels of serum albumin', 'relationship': 'reflect', 'entity2': 'nutritional status of individuals'}, {'entity1': 'levels of serum albumin', 'relationship': 'tool for predicting', 'entity2': 'outcomes of patients with gastric cancer'}, {'entity1': 'levels of serum albumin', 'relationship': 'tool for predicting', 'entity2': 'outcomes of patients with haematological malignancy'}]"
426.0,"The inflammation-immunity-nutrition score (IINS), which reflects hs-CRP, lymphocytes (LYM), and ALB, is considered a superior prognostic evaluation system indicator.","[{'entity1': 'inflammation-immunity-nutrition score', 'relationship': 'reflects', 'entity2': 'hs-CRP'}, {'entity1': 'inflammation-immunity-nutrition score', 'relationship': 'reflects', 'entity2': 'lymphocytes'}, {'entity1': 'inflammation-immunity-nutrition score', 'relationship': 'reflects', 'entity2': 'serum albumin'}, {'entity1': 'inflammation-immunity-nutrition score', 'relationship': 'indicator', 'entity2': 'superior prognostic evaluation system'}]"
427.0,"We obtained the baseline clinicopathological parameters of patients, such as age, sex, Ann Arbor stage, and haematological parameters,  including  hs-CRP,  ALB,  and  LYM.  According  to  receiver  operating  characteristic  (ROC)  curve  analysis,  we determined the  optimal cutoff value for  each  indicator associated with OS and  grouped each  parameter as  follows:  hs-CRP score =0 (≤10.1 mg/L) and score=1 (>10.1 mg/L), ALB score=0 (>41.1 g/L) and score=1 (≤41.1 g/L), LYM score= 0 (>1.12×109/ L), score =1 (≤1.12×109/L).","[{'entity1': 'baseline clinicopathological parameters', 'relationship': 'include', 'entity2': 'age'}, {'entity1': 'baseline clinicopathological parameters', 'relationship': 'include', 'entity2': 'sex'}, {'entity1': 'baseline clinicopathological parameters', 'relationship': 'include', 'entity2': 'Ann Arbor stage'}, {'entity1': 'baseline clinicopathological parameters', 'relationship': 'include', 'entity2': 'haematological parameters'}, {'entity1': 'haematological parameters', 'relationship': 'include', 'entity2': 'hs-CRP'}, {'entity1': 'haematological parameters', 'relationship': 'include', 'entity2': 'ALB'}, {'entity1': 'haematological parameters', 'relationship': 'include', 'entity2': 'LYM'}, {'entity1': 'receiver operating characteristic curve analysis', 'relationship': 'determine', 'entity2': 'optimal cutoff value'}, {'entity1': 'optimal cutoff value', 'relationship': 'associate', 'entity2': 'overall survival'}, {'entity1': 'hs-CRP', 'relationship': 'grouped as', 'entity2': 'score 0 and score 1'}, {'entity1': 'ALB', 'relationship': 'grouped as', 'entity2': 'score 0 and score 1'}, {'entity1': 'LYM', 'relationship': 'grouped as', 'entity2': 'score 0 and score 1'}]"
428.0,"The IINS scores were defined as the sum of the hs-CRP, LYM, and ALB scores.12 The patients were then  allocated  to  three  groups  according  to  IINS  scores:  Low  IINS  (IINS=0),  medium  IINS  (IINS=1),  and  high  IINS (IINS=2 or 3).","[{'entity1': 'IINS scores', 'relationship': 'defined as', 'entity2': 'sum of hs-CRP, LYM and ALB scores'}, {'entity1': 'patients', 'relationship': 'allocated to', 'entity2': 'three groups'}, {'entity1': 'three groups', 'relationship': 'according to', 'entity2': 'IINS scores'}, {'entity1': 'three groups', 'relationship': 'include', 'entity2': 'Low IINS'}, {'entity1': 'three groups', 'relationship': 'include', 'entity2': 'medium IINS'}, {'entity1': 'three groups', 'relationship': 'include', 'entity2': 'high IINS'}]"
429.0,"Univariate analysis revealed that high IINS scores (IINS=2 or 3) had a significant influence on OS, with high hazard ratios (HR=2.093, 95% CI: 1.634–2.682, p<0.001).","[{'entity1': 'high IINS scores', 'relationship': 'influence', 'entity2': 'overall survival'}, {'entity1': 'high IINS scores', 'relationship': 'have', 'entity2': 'high hazard ratios'}]"
430.0,"In addition, age (HR=1.648, 95% CI: 1.062–2.558, p=0.026), ECOG PS (HR=5.252, 95% CI: 3.105–8.885,  p<0.001),  B  symptoms  (HR=1.941,  95%  CI:  1.316–2.862,  p<0.001),  primary  sites  (HR=1.952,  95%  CI: ","[{'entity1': 'age', 'relationship': 'influence', 'entity2': 'overall survival'}, {'entity1': 'ECOG PS', 'relationship': 'influence', 'entity2': 'overall survival'}, {'entity1': 'B symptoms', 'relationship': 'influence', 'entity2': 'overall survival'}, {'entity1': 'primary sites', 'relationship': 'influence', 'entity2': 'overall survival'}]"
431.0,"Insulin resistance (IR) is known to be characteristic of type 2 diabetes mellitus, and is regarded as an important mechanism in disease pathogenesis. One of the key pathogenetic mechanisms  of  IR  progression  is  impaired  free  fatty  acid  (FFA)  metabolism.  Plasminogen-activator inhibitor 1 (PAI-1) and key inflammation markers, ie, interleukin 6 (IL-6) and C-reactive protein (CRP), also play a role.","[{'entity1': 'Insulin resistance', 'relationship': 'characteristic', 'entity2': 'Type 2 diabetes mellitus'}, {'entity1': 'Insulin resistance', 'relationship': 'mechanism', 'entity2': 'disease pathogenesis'}, {'entity1': 'pathogenesis', 'relationship': 'progression', 'entity2': 'impaired free fatty acid metabolism'}, {'entity1': 'Plasminogen-activator inhibitor 1', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'Interleukin 6', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'C-reactive protein', 'relationship': 'role', 'entity2': 'Insulin resistance'}]"
432.0,"Among  proinflammatory  cytokines  contributing  to         IR  development,  the  role  of  interleukin  (IL)-6,  which  has         autocrine and paracrine properties and is involved in insulin         reception and free fatty acid (FFA) metabolism regulation,         has been extensively studied.","[{'entity1': 'Interleukin 6', 'relationship': 'contributing', 'entity2': 'Insulin resistance development'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'insulin reception'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'free fatty acid metabolism regulation'}]"
433.0,"Larger  points  suggested  a  higher  probability  of  death.  By  adding  the  scores  for  all  risk  factors,  we  could  calculate  the  survival  probability  of  patients  at  different  time  points.","[{'entity1': 'Larger points', 'relationship': 'suggested', 'entity2': 'higher probability of death'}]"
434.0,"We observed that IINS had a greater impact on OS than  ECOG  PS,  bone  marrow  involvement,  and  Ann  Arbor  stage.","[{'entity1': 'IINS', 'relationship': 'greater impact', 'entity2': 'Overall survival'}, {'entity1': 'IINS', 'relationship': 'greater impact', 'entity2': 'ECOG Performance Status'}, {'entity1': 'IINS', 'relationship': 'greater impact', 'entity2': 'bone marrow involvement'}, {'entity1': 'IINS', 'relationship': 'greater impact', 'entity2': 'Ann Arbor stage'}]"
435.0,"The C-index of the nomogram was 0.733 (95% CI: 0.684–0.781), which indicated better performance than that of the PINK, IPI, and KPI systems.","[{'entity1': 'nomogram', 'relationship': 'better performance', 'entity2': 'PINK system'}, {'entity1': 'nomogram', 'relationship': 'better performance', 'entity2': 'IPI system'}, {'entity1': 'nomogram', 'relationship': 'better performance', 'entity2': 'KPI system'}]"
436.0,"ENKTL,  as  a  haematological  malignancy  originating  from  mature  NK  cells  or  cytotoxic  T cells  (CTLs),  exhibits obvious  heterogeneity  in  clinical  manifestations  and  prognosis.","[{'entity1': 'ENKTL', 'relationship': 'originating from', 'entity2': 'mature NK cells'}, {'entity1': 'ENKTL', 'relationship': 'originating from', 'entity2': 'cytotoxic T cells'}, {'entity1': 'ENKTL', 'relationship': 'exhibits', 'entity2': 'heterogeneity in clinical manifestations and prognosis'}]"
437.0,"Although  patients  with  early-stage  ENKTL  exhibit a  good  prognosis  after  treatment  with  standard  radiotherapy  or  combination  chemotherapy,  patients  with  advanced disease  often  present  dismal  outcomes,  with  a  5-year  survival  rate  of  approximately  70%.","[{'entity1': 'patients with early-stage ENKTL', 'relationship': 'exhibit', 'entity2': 'a good prognosis after treatment with standard radiotherapy or combination chemotherapy'}, {'entity1': 'patients with advanced disease', 'relationship': 'present', 'entity2': 'dismal outcomes'}, {'entity1': 'patients with advanced disease', 'relationship': 'have', 'entity2': 'a 5-year survival rate of approximately 70%'}]"
438.0,"To  identify  patients’ prognostic  risks  more  accurately,  researchers  have  gradually explored  the  prognostic  value  of  the  PINK,  IPI  and  KPI prognostic  systems  in  ENKTL  patients.","[{'entity1': 'researchers', 'relationship': 'explored', 'entity2': 'the prognostic value of the PINK, IPI and KPI prognostic systems'}, {'entity1': 'PINK, IPI and KPI prognostic systems', 'relationship': 'in', 'entity2': 'ENKTL patients'}]"
439.0,"Previous studies have  demonstrated that systemic  inflammation  affects  the  occurrence  and  development  of  tumours  by  inducing  gene  mutations,  inhibiting  cell apoptosis, inducing angiogenesis, and activating abnormal inflammatory signalling pathways.","[{'entity1': 'systemic  inflammation', 'relationship': 'affects', 'entity2': 'the occurrence and development of tumours'}, {'entity1': 'systemic inflammation', 'relationship': 'by inducing', 'entity2': 'gene mutations'}, {'entity1': 'systemic inflammation', 'relationship': 'by inhibiting', 'entity2': 'cell apoptosis'}, {'entity1': 'systemic inflammation', 'relationship': 'by inducing', 'entity2': 'angiogenesis'}, {'entity1': 'systemic inflammation', 'relationship': 'by activating', 'entity2': 'abnormal inflammatory signalling pathways'}]"
440.0,"A growing number of studies  have  illustrated  the  diagnostic  and  prognostic  values  of  inflammatory  markers,  such  as  LMR,  NLR,  systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI), in various cancers.","[{'entity1': 'studies', 'relationship': 'illustrated', 'entity2': 'the diagnostic and prognostic values of inflammatory markers'}, {'entity1': 'inflammatory markers', 'relationship': 'such as', 'entity2': 'LMR, NLR, systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI)'}, {'entity1': 'inflammatory markers', 'relationship': 'in', 'entity2': 'various cancers'}]"
441.0,"Recently, a study found that the Glasgow Prognostic Score (GPS), an inflammation-based prognostic evaluation system comprising measures of C-reactive  protein  and  albumin,  showed  significant  prognostic  value  in  ENKTL.","[{'entity1': 'a study', 'relationship': 'found', 'entity2': 'the Glasgow Prognostic Score (GPS) showed significant prognostic value in ENKTL'}, {'entity1': 'Glasgow Prognostic Score (GPS)', 'relationship': 'comprising', 'entity2': 'measures of C-reactive protein and albumin'}, {'entity1': 'Glasgow Prognostic Score (GPS)', 'relationship': 'is', 'entity2': 'an inflammation-based prognostic evaluation system'}]"
442.0,ENKTL  is  a  distinct  subtype  of  non-Hodgkin’s  lymphoma  (NHL)  frequently characterized by prominent necrosis and inflammation.,"[{'entity1': 'ENKTL', 'relationship': 'is', 'entity2': 'a distinct subtype of non-Hodgkin’s lymphoma'}, {'entity1': 'ENKTL', 'relationship': 'characterized by', 'entity2': 'prominent necrosis and inflammation'}]"
443.0,"Particularly, due to its unique pathological features, ENKTL has  a  relatively  high  probability  of  haemophagocytic  lymphohistiocytosis  (HLH),  a  potentially  fatal  systemic inflammatory response syndrome caused by uncontrolled overactivation of lymphocytes and macrophages.","[{'entity1': 'ENKTL', 'relationship': 'due to', 'entity2': 'its unique pathological features'}, {'entity1': 'ENKTL', 'relationship': 'has', 'entity2': 'a relatively high probability of haemophagocytic lymphohistiocytosis (HLH)'}, {'entity1': 'haemophagocytic lymphohistiocytosis (HLH))', 'relationship': 'is', 'entity2': 'a potentially fatal systemic inflammatory response syndrome'}, {'entity1': 'haemophagocytic lymphohistiocytosis (HLH)', 'relationship': 'caused by', 'entity2': 'uncontrolled overactivation of lymphocytes and macrophages'}]"
444.0,"Therefore,  we  needed  to  explore  a  more  comprehensive  prognostic  system  that  could  reflect  the  inflammatory,  immune,  and nutritional status of patients to predict the survival of patients more accurately.","[{'entity1': 'we', 'relationship': 'needed to explore', 'entity2': 'a more comprehensive prognostic system'}, {'entity1': 'a more comprehensive prognostic system', 'relationship': 'could reflect', 'entity2': 'the inflammatory, immune, and nutritional status of patients'}, {'entity1': 'a more comprehensive prognostic system', 'relationship': 'to predict', 'entity2': 'the survival of patients more accurately'}]"
445.0,"Recently, the IINS score, which is derived from hs-CRP, ALB, and lymphocyte LYM, has been reported as a strong clinical prognostic indicator in hepatocellular carcinoma patients.","[{'entity1': 'IINS score', 'relationship': 'derived from', 'entity2': 'hs-CRP, ALB, and lymphocyte LYM'}, {'entity1': 'IINS score', 'relationship': 'reported as', 'entity2': 'a strong clinical prognostic indicator in hepatocellular carcinoma patients '}]"
446.0,"In  summary,  we  first  established  and  validated  a  new  nomogram  based  on  the  IINS  score  and  traditional  prognostic indicators and evaluated the prognostic value of the nomogram in ENKTL patients.","[{'entity1': 'IINS score', 'relationship': 'based', 'entity2': 'nomogram'}, {'entity1': 'nomogram', 'relationship': 'evaluated', 'entity2': 'prognostic value'}]"
447.0,Our findings suggest that IINS may act as a strong prognostic predictor in patients with ENKTL.,"[{'entity1': 'IINS', 'relationship': 'act as', 'entity2': 'prognostic predictor'}, {'entity1': 'IINS', 'relationship': 'predictor in', 'entity2': 'ENKTL patients'}]"
448.0,"Specifically, IINS combined with traditional prognostic factors presents better  prognostic  performance  than  PINK,  IPI,  and  KPI,  possibly  providing  an  easy  way  to  identify  patients  with  a  poor prognosis and an opportunity to guide treatment and follow-up strategies to improve the outcomes of ENKTL patients.","[{'entity1': 'IINS', 'relationship': 'combined with', 'entity2': 'traditional prognostic factors'}, {'entity1': 'IINS combined with traditional prognostic factors', 'relationship': 'presents', 'entity2': 'better prognostic performance'}, {'entity1': 'IINS', 'relationship': 'providing', 'entity2': 'way to identify patients with poor prognosis'}, {'entity1': 'IINS', 'relationship': 'opportunity', 'entity2': 'guide treatment and follow-up strategies'}]"
449.0,This  study  was  supported  by  the  Ethics  Committee  of  Sun  Yat-sen  University  Cancer  Center  (Ethics  approval  number: B202353601) and complied with the Declaration of Helsinki.,"[{'entity1': 'This study', 'relationship': 'supported by', 'entity2': 'Ethics Committee of Sun Yat-sen University Cancer Center'}, {'entity1': 'This study', 'relationship': 'complied with', 'entity2': 'Declaration of Helsinki'}]"
450.0,We thank all patients and clinical staff who participated in the study.,"[{'entity1': 'patients', 'relationship': 'participated in', 'entity2': 'the study'}, {'entity1': 'clinical staff', 'relationship': 'participated in', 'entity2': 'the study'}]"
451.0,"Qi S-N, Xu LM, Yuan ZY, et al. Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK/T-cell lymphoma in the modern  chemotherapy  era:  a  multicenter  study  from  the  China  Lymphoma  Collaborative  Group  (CLCG).  Leukemia  Lymphoma.  2019;60 (11):2669–2678. doi:10.1080/10428194.2019.1602265",[]
452.0,"Yamaguchi M, Suzuki R, Oguchi M, et al. Treatments and outcomes of patients with extranodal natural killer/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan. J Clin Oncol. 2017;35(1):32–39. doi:10.1200/jco.2016.68.1619",[]
453.0,"Wan  L,  Wu  C,  Luo  S,  et  al.  Prognostic  value  of  Lymphocyte-to-Monocyte  Ratio  (LMR)  in  cancer  patients  undergoing  immune  checkpoint inhibitors. Dis Markers. 2022;2022:3610038. doi:10.1155/2022/3610038","[{'entity1': 'Lymphocyte-to-Monocyte Ratio', 'relationship': 'Prognostic value', 'entity2': 'cancer patients undergoing immune checkpoint inhibitors'}]"
454.0,"Gawinski C, Holdakowska A, Wyrwicz L. Correlation between Lymphocyte-to-Monocyte Ratio (LMR), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR) and Extramural Vascular Invasion (EMVI) in locally advanced rectal cancer. Curr Oncol. 2022;30(1):545–558. doi:10.3390/curroncol30010043","[{'entity1': 'Lymphocyte-to-Monocyte Ratio', 'relationship': 'Correlation', 'entity2': 'Extramural Vascular Invasion in locally advanced rectal cancer'}, {'entity1': 'Neutrophil-to-Lymphocyte Ratio', 'relationship': 'Correlation', 'entity2': 'Extramural Vascular Invasion in locally advanced rectal cancer'}, {'entity1': 'Platelet-to-Lymphocyte Ratio', 'relationship': 'Correlation', 'entity2': 'Extramural Vascular Invasion in locally advanced rectal cancer'}]"
455.0,"Ding P, Guo H, Sun C, et al. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response  and  prognosis  in  locally  advanced  gastric  cancer  patients  receiving  neoadjuvant  chemotherapy  with  PD-1  antibody  sintilimab  and XELOX: a prospective study. BMC Gastroenterol. 2022;22(1):121. doi:10.1186/s12876-022-02199-9","[{'entity1': 'systemic immune-inflammatory index', 'relationship': 'predicts', 'entity2': 'chemotherapy response and prognosis in locally advanced gastric cancer patients'}, {'entity1': 'prognostic nutritional index', 'relationship': 'predicts', 'entity2': 'chemotherapy response and prognosis in locally advanced gastric cancer patients'}]"
456.0,"Wang  HK,  Wei  Q,  Yang  YL,  et  al.  Clinical  usefulness  of  the  lymphocyte-to-monocyte  ratio  and  aggregate  index  of  systemic  inflammation  in patients with esophageal cancer: a retrospective cohort study. Cancer Cell Int. 2023;23(1):13. doi:10.1186/s12935-023-02856-3","[{'entity1': 'lymphocyte-to-monocyte ratio', 'relationship': 'Clinical usefulness', 'entity2': 'patients with esophageal cancer'}, {'entity1': 'aggregate index of systemic inflammation', 'relationship': 'Clinical usefulness', 'entity2': 'patients with esophageal cancer'}]"
457.0,"Li  Y-J,  Jiang  WQ,  Huang  JJ,  et  al.  The  Glasgow  Prognostic  Score  (GPS)  as  a  novel  and  significant  predictor  of  extranodal  natural  killer/T-cell lymphoma, nasal type. Am J Hematol. 2013;88(5):394–399. doi:10.1002/ajh.23422","[{'entity1': 'The Glasgow Prognostic Score', 'relationship': 'significant predictor', 'entity2': 'extranodal natural killer/T-cell lymphoma, nasal type'}]"
458.0,"Tse E, Fox CP, Glover A, et al. Extranodal natural killer/T-cell lymphoma: an overview on pathology and clinical management. Semin Hematol. 2022;59(4):198–209. doi:10.1053/j.seminhematol.2022.10.002",[]
459.0,"He Y, Gao Y, Ping L, et al. The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis. J Cancer Res Clin Oncol. 2022. doi:10.1007/s00432-022-04147-2","[{'entity1': 'anti-PD-1 antibody-based regimens', 'relationship': 'emerging role', 'entity2': 'treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis'}]"
460.0,"Currently, Cholecystitis cannot be definitively diagnosed through a single examination. Diagnosis relies primarily on a thorough medical history, symptoms, physical examination, and imaging findings.","[{'entity1': 'Cholecystitis', 'relationship': 'diagnosed', 'entity2': 'medical history, symptoms, physical examination and imaging findings'}]"
461.0,The gold standard for differentiating between acute and chronic cholecystitis is the use of pathologic findings from cholecystectomy.,"[{'entity1': 'pathologic findings from cholecystectomy', 'relationship': 'differentiating', 'entity2': 'acute and chronic cholecystitis'}]"
462.0,"While ultrasonography  is  commonly  used,  it  may  not  provide  conclusive  results  in  some  patients.","[{'entity1': 'ultrasonography', 'relationship': 'not provide conclusive results', 'entity2': 'some patients'}]"
463.0,"Computed tomography (CT)  has  its  limitations,  including  the  risk  of  false-positive  and  false-negative  diagnoses,  radiation exposure, and potential  nephrotoxic  effects  from  contrast  media.","[{'entity1': 'Computed tomography', 'relationship': 'limitations', 'entity2': 'false-positive diagnoses'}, {'entity1': 'Computed tomography', 'relationship': 'limitations', 'entity2': 'false-negative diagnoses'}, {'entity1': 'Computed tomography', 'relationship': 'risk', 'entity2': 'radiation exposure'}, {'entity1': 'contrast media', 'relationship': 'effects', 'entity2': 'potential nephrotoxic effects'}]"
464.0,"Magnetic resonance imaging (MRI)  is  accurate  in  differentiating ACC from CCC due to its superior soft-tissue contrast resolution,","[{'entity1': 'Magnetic resonance imaging', 'relationship': 'differentiating', 'entity2': 'acute calculus cholecystitis and chronic calculus cholecystitis'}]"
465.0,Tokyo Guidelines 2018 (TG18) is a  widely  accepted  standard  for  assessing  the  severity  of  ACC  using  scoring  systems.,"[{'entity1': 'Tokyo Guidelines 2018', 'relationship': 'assessing severity', 'entity2': 'acute calculus cholecystitis'}]"
466.0,white  blood  cell  (WBC)  count  and  leukocyte  subtype  cells  are  valuable indicators  for  predicting  the  inflammatory  process  in  acute  cholecystitis.,"[{'entity1': 'white blood cell count', 'relationship': 'indicators', 'entity2': 'predicting inflammatory process in acute cholecystitis'}, {'entity1': 'leukocyte subtype cells', 'relationship': 'indicators', 'entity2': 'predicting inflammatory process in acute cholecystitis'}]"
467.0,WBC  count  has  been  established  as  the primary biomarker for assessing the severity of cholecystitis.,"[{'entity1': 'WBC count', 'relationship': 'biomarker', 'entity2': 'assessing severity of cholecystitis'}]"
468.0,"Several  inflammatory  parameters  based  on  WBC  and  platelet  counts,  such  as  the  neutrophil-to-lymphocyte ratio  (NLR),  platelet-to-lymphocyte  ratio  (PLR),  systemic  immune-inflammation  index  (SII),  and  neutrophil-to- lymphocyte  platelet  ratio  (NLPR),  as  potential  valuable  indicators  in  assessing  the  inflammatory  process.","[{'entity1': 'neutrophil-to-lymphocyte ratio', 'relationship': 'indicators', 'entity2': 'assessing inflammatory process'}, {'entity1': 'platelet-to-lymphocyte ratio', 'relationship': 'indicators', 'entity2': 'assessing inflammatory process'}, {'entity1': 'systemic immune-inflammation index', 'relationship': 'indicators', 'entity2': 'assessing inflammatory process'}, {'entity1': 'neutrophil-to-lymphocyte platelet ratio', 'relationship': 'indicators', 'entity2': 'assessing inflammatory process'}]"
469.0,"This prospective, observational, and single-center study was conducted at the hepatobiliary surgery of Wenzhou Central Hospital. The research was carried out from June 2022 to September 2023, involving 250 patients who had undergone cholecystectomy  due  to  ACC  or  CCC.","[{'entity1': 'study', 'relationship': 'conducted at', 'entity2': 'hepatobiliary surgery of Wenzhou Central Hospital'}, {'entity1': 'study', 'relationship': 'involving', 'entity2': '250 patients'}, {'entity1': '250 patients', 'relationship': 'undergone', 'entity2': 'cholecystectomy'}, {'entity1': 'cholecystectomy', 'relationship': 'due to', 'entity2': 'ACC or CCC'}]"
470.0,Histopathological  examination  was  performed  on  the  resected  gallbladders.,"[{'entity1': 'Histopathological examination', 'relationship': 'performed on', 'entity2': 'resected gallbladders'}]"
471.0,"Diagnosis of CCC and ACC before surgery primarily relied on a combination of detailed medical history, comprehensive clinical examination, laboratory tests, and imaging investigations.","[{'entity1': 'Diagnosis', 'relationship': 'relied on', 'entity2': 'medical history'}, {'entity1': 'Diagnosis', 'relationship': 'relied on', 'entity2': 'clinical examination'}, {'entity1': 'Diagnosis', 'relationship': 'relied on', 'entity2': 'laboratory tests'}, {'entity1': 'Diagnosis', 'relationship': 'relied on', 'entity2': 'imaging investigations'}]"
472.0,The final confirmation of the diagnosis of both ACC and CCC was based on the pathological examination of  postoperative gallbladder tissue specimens.,"[{'entity1': 'final confirmation', 'relationship': 'based on', 'entity2': 'pathological examination'}, {'entity1': 'pathological examination', 'relationship': 'of', 'entity2': 'postoperative gallbladder tissue specimens'}]"
473.0,The ACC patients underwent  further  classification  by  the  TG18  into  three  severity  grades:4  Moderate  ACC  is  related  to  any  one  of the  following  conditions:,"[{'entity1': 'ACC patients', 'relationship': 'underwent', 'entity2': 'classification'}, {'entity1': 'classification', 'relationship': 'by', 'entity2': 'TG18'}, {'entity1': 'classification', 'relationship': 'into', 'entity2': 'three severity grades'}, {'entity1': 'Moderate ACC', 'relationship': 'related to', 'entity2': 'conditions'}]"
474.0,Patients  with  Moderate-  and  severe-degree inflammations  were  grouped  as  the  high-degree  inflammation  group  and  compared  with  the  mild-degree  inflammation group.,"[{'entity1': 'Patients', 'relationship': 'grouped as', 'entity2': 'high-degree inflammation group'}, {'entity1': 'high-degree inflammation group', 'relationship': 'compared with', 'entity2': 'mild-degree inflammation group'}]"
475.0,"Among the patients with ACC, there were 36 cases of mild-degree inflammation (M-ACC) and 52 cases of moderate- and  severe-degree  inflammation  (MS-ACC).","[{'entity1': 'patients', 'relationship': 'have', 'entity2': 'mild-degree inflammation'}, {'entity1': 'patients', 'relationship': 'have', 'entity2': 'moderate and severe degree inflammation'}]"
476.0,"Severe ACC was present in only three patients, with one case involving hepatic dysfunction, another with respiratory complications, and the third demonstrating cardiological dysfunction.","[{'entity1': 'Severe ACC', 'relationship': 'present', 'entity2': 'patients'}, {'entity1': 'case', 'relationship': 'involving', 'entity2': 'hepatic dysfunction'}, {'entity1': 'case', 'relationship': 'involving', 'entity2': 'respiratory complications'}, {'entity1': 'case', 'relationship': 'demonstrating', 'entity2': 'cardiological dysfunction'}]"
477.0,"The average age of patients with M-ACC was 50.4 years, while for the MS-ACC group, it was 59.5 years.","[{'entity1': 'average age', 'relationship': 'was', 'entity2': '50.4 years'}, {'entity1': 'patients', 'relationship': 'have', 'entity2': 'M-ACC'}, {'entity1': 'average age', 'relationship': 'was', 'entity2': '59.5 years'}, {'entity1': 'patients', 'relationship': 'have', 'entity2': 'MS-ACC'}]"
478.0,Apo AI levels were notably lower in MS-ACC patients compared to those with M-ACC.,"[{'entity1': 'Apo AI levels', 'relationship': 'lower', 'entity2': 'MS-ACC patients'}, {'entity1': 'Apo AI levels', 'relationship': 'compared', 'entity2': 'M-ACC patients'}]"
479.0,"Analysis of blood parameters revealed a significant increase in WBC and neutrophil counts in MS-ACC patients compared to M-ACC patients, whereas the lymphocyte count was significantly lower in the MS-ACC group than in the M-ACC group.","[{'entity1': 'WBC count', 'relationship': 'increase', 'entity2': 'MS-ACC patients'}, {'entity1': 'neutrophil count', 'relationship': 'increase', 'entity2': 'MS-ACC patients'}, {'entity1': 'WBC count', 'relationship': 'compared', 'entity2': 'M-ACC patients'}, {'entity1': 'neutrophil count', 'relationship': 'compared', 'entity2': 'M-ACC patients'}, {'entity1': 'lymphocyte count', 'relationship': 'lower', 'entity2': 'MS-ACC group'}, {'entity1': 'lymphocyte count', 'relationship': 'compared', 'entity2': 'M-ACC group'}]"
480.0,"Furthermore, in MS-ACC patients, the NLR, SII, and NPLR values were significantly higher compared to M-ACC patients","[{'entity1': 'NLR values', 'relationship': 'higher', 'entity2': 'MS-ACC patients'}, {'entity1': 'SII values', 'relationship': 'higher', 'entity2': 'MS-ACC patients'}, {'entity1': 'NPLR values', 'relationship': 'higher', 'entity2': 'MS-ACC patients'}, {'entity1': 'NLR values', 'relationship': 'compared', 'entity2': 'M-ACC patients'}, {'entity1': 'SII values', 'relationship': 'compared', 'entity2': 'M-ACC patients'}, {'entity1': 'NPLR values', 'relationship': 'compared', 'entity2': 'M-ACC patients'}]"
481.0,"In addition, ROC Curve Analysis demonstrated that NLR, SII, and NLPR might be acceptable in the differentiation of M-ACC and MS-ACC patients. The areas under the curve (AUC) for NLR, SII, and NLPR were 0.760, 0.723, and 0.778, respectively.","[{'entity1': 'NLR', 'relationship': 'acceptable', 'entity2': 'differentiation of M-ACC and MS-ACC patients'}, {'entity1': 'SII', 'relationship': 'acceptable', 'entity2': 'differentiation of M-ACC and MS-ACC patients'}, {'entity1': 'NLPR', 'relationship': 'acceptable', 'entity2': 'differentiation of M-ACC and MS-ACC patients'}]"
482.0,"The optimal cut-off values were identified as 6.399, 1261, and 0.044 for NLR, SII, and NLPR. Sensitivities for NLR, SII, and NLPR were found to be 71.15%, 72.22%, and 61.54%, while specificities were 80.56%, 73.08%, and 91.67%.","[{'entity1': 'NLR', 'relationship': 'cut-off value', 'entity2': '6.399'}, {'entity1': 'SII', 'relationship': 'cut-off value', 'entity2': '1261'}, {'entity1': 'NLPR', 'relationship': 'cut-off value', 'entity2': '0.044'}]"
483.0,Univariate  and  multivariable  binary  logistic  analyses  were  conducted  to  evaluate  the  clinical  significance  of Inflammation  Indices  as  biomarkers  in  distinguishing  between  ACC  and  CCC  patients.,"[{'entity1': 'Inflammation Indices', 'relationship': 'biomarkers', 'entity2': 'distinguishing between ACC and CCC patients'}]"
484.0,"It was shown that when the NLR was more than the cutoff value, there was an increased risk of (10.308 times higher) moderate to severe degree inflammation compared to the lower NLR","[{'entity1': 'NLR', 'relationship': 'associated', 'entity2': 'increased risk of moderate to severe degree inflammation'}]"
485.0,"Considering the four inflammatory parameters associated with CC, NLR has been extensively studied and is considered a reliable marker for prognosticating diseases involving inflammatory and infective processes.20,21  Previous literature has shown that NLR is significantly higher in acute cholecystitis compared to healthy controls, ranging from 5.29–12.16 compared to 1.73–2.98.14,22–25","[{'entity1': 'NLR', 'relationship': 'marker', 'entity2': 'diseases involving inflammatory and infective processes'}, {'entity1': 'NLR', 'relationship': 'higher', 'entity2': 'acute cholecystitis'}, {'entity1': 'NLR in acute cholecystitis', 'relationship': 'compared to', 'entity2': 'NLR in healthy controls'}]"
486.0,"Our study supports previous findings that NLR levels were significantly higher in acute cholecystitis compared to chronic cholecystitis.23 We found that an NLR value above 3.89 was significant in the ACC group compared to the CCC group, and above 6.399 was significant in the MS-ACC patients.","[{'entity1': 'NLR levels', 'relationship': 'higher', 'entity2': 'acute cholecystitis'}, {'entity1': 'NLR levels', 'relationship': 'compared to', 'entity2': 'chronic cholecystitis'}, {'entity1': 'NLR value above 3.89', 'relationship': 'significant', 'entity2': 'ACC group'}, {'entity1': 'NLR value above 3.89', 'relationship': 'compared to', 'entity2': 'CCC group'}, {'entity1': 'NLR value above 6.399', 'relationship': 'significant', 'entity2': 'MS-ACC patients'}]"
487.0,The binary logistic regression analysis revealed that an  NLR  exceeding  the  cutoff  value  independently  predicts  ACC  and  its  severity.,"[{'entity1': 'NLR exceeding the cutoff value', 'relationship': 'predicts', 'entity2': 'ACC'}, {'entity1': 'NLR exceeding the cutoff value', 'relationship': 'predicts', 'entity2': 'ACC severity'}]"
488.0,"Consistent with our findings, a study by Sang Kuon Lee et al observed a significant association between NLR and gangrenous cholecystitis (GC), where each standard deviation increase in NLR corresponded to a 48% heightened probability of GC.24","[{'entity1': 'NLR', 'relationship': 'association', 'entity2': 'gangrenous cholecystitis'}, {'entity1': 'standard deviation increase in NLR', 'relationship': 'corresponded to', 'entity2': 'heightened probability of GC'}]"
489.0,"PLR, another inflammatory marker based on complete blood count values, has shown potential as a prognostic marker in inflammatory diseases and malignancies.","[{'entity1': 'PLR', 'relationship': 'marker', 'entity2': 'inflammatory diseases'}, {'entity1': 'PLR', 'relationship': 'marker', 'entity2': 'malignancies'}]"
490.0,"In our research, we observed that a PLR of 144.7 effectively distinguished between  ACC  and  CCC,  with  a  sensitivity  of  68.18%,  specificity  of  61.9%,  and  ROC  AUC  of  66.20%.","[{'entity1': 'PLR of 144.7', 'relationship': 'distinguished', 'entity2': 'ACC'}, {'entity1': 'PLR of 144.7', 'relationship': 'distinguished', 'entity2': 'CCC'}]"
491.0,"Insulin resistance (IR) is known to be characteristic of type 2 diabetes mellitus, and is regarded as an important mechanism in disease pathogenesis.","[{'entity1': 'Insulin resistance', 'relationship': 'characteristic', 'entity2': 'Type 2 diabetes mellitus'}, {'entity1': 'Insulin resistance', 'relationship': 'mechanism', 'entity2': 'disease pathogenesis'}]"
492.0,One of the key pathogenetic mechanisms of IR progression is impaired free fatty acid (FFA) metabolism.,"[{'entity1': 'pathogenesis', 'relationship': 'progression', 'entity2': 'impaired free fatty acid metabolism'}]"
493.0,"Plasminogen-activator inhibitor 1 (PAI-1) and key inflammation markers, ie, interleukin 6 (IL-6) and C-reactive protein (CRP), also play a role.","[{'entity1': 'Plasminogen-activator inhibitor 1', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'Interleukin 6', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'C-reactive protein', 'relationship': 'role', 'entity2': 'Insulin resistance'}]"
494.0,"Among proinflammatory cytokines contributing to IR development, the role of interleukin (IL)-6, which has autocrine and paracrine properties and is involved in insulin reception and free fatty acid (FFA) metabolism regulation, has been extensively studied.","[{'entity1': 'Interleukin 6', 'relationship': 'contributing', 'entity2': 'Insulin resistance development'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'insulin reception'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'free fatty acid metabolism regulation'}]"
495.0,The role of the hematological inflammatory index and systemic immuno-inflammation index in acute cholecystitis,"[{'entity1': 'hematological inflammatory index', 'relationship': 'role', 'entity2': 'acute cholecystitis'}, {'entity1': 'systemic immuno-inflammation index', 'relationship': 'role', 'entity2': 'acute cholecystitis'}]"
496.0,Predicting immunoglobulin resistance in Kawasaki disease: an assessment of neutrophil to lymphocyte platelet ratio,"[{'entity1': 'neutrophil to lymphocyte platelet ratio', 'relationship': 'assessment', 'entity2': 'Predicting immunoglobulin resistance in Kawasaki disease'}]"
497.0,haematological ratios as risk factor for acute kidney injury in patients suspected of an infection at the emergency department,"[{'entity1': 'haematological ratios', 'relationship': 'risk factor', 'entity2': 'acute kidney injury'}]"
498.0,"Role of leukocytes and systemic inflammation indexes (NLR, PLR, MLP, dNLR, NLPR, AISI, SIR-I, and SII) on admission predicts in-hospital mortality in non-elderly and elderly COVID-19 patients","[{'entity1': 'leukocytes and systemic inflammation indexes', 'relationship': 'predicts', 'entity2': 'in-hospital mortality in non-elderly and elderly COVID-19 patients'}]"
499.0,"Inflammatory  mechanisms  are  part  of  the  normal  body’s  defense  against  aggressions,  however,  when  they  last  for prolonged periods of time (months to years), they can induce a chronic inflammatory state that can be detrimental to the organism.","[{'entity1': 'Inflammatory mechanisms', 'relationship': 'part of', 'entity2': 'normal body’s defense'}, {'entity1': 'Inflammatory mechanisms', 'relationship': 'induce', 'entity2': 'chronic inflammatory state'}, {'entity1': 'chronic inflammatory state', 'relationship': 'detrimental to', 'entity2': 'organism'}]"
500.0,"Besides the context  of  auto-immune  disorders,  some  of  the  reasons  that  can  perpetuate  a  low-grade  inflammation  could  be:  (i)  the organism’s inability to eliminate infectious agents such as bacteria, viruses or parasites, (ii) its prolonged exposure to low levels of chemicals, biochemicals or irritants,","[{'entity1': 'auto-immune disorders', 'relationship': 'perpetuate', 'entity2': 'low-grade inflammation'}, {'entity1': 'infectious agents', 'relationship': 'eliminate', 'entity2': 'organism'}, {'entity1': 'chemicals, biochemicals or irritants', 'relationship': 'exposure to', 'entity2': 'organism'}]"
501.0,"If  those  triggers  are  maintained  over  a  long  period  of  time,  they  can  lead  to  chronic  inflammatory-related diseases  that  can  involve  many  other  organs  and  tissue  of  the  body  like  the  gut,  driving  inflammatory  bowel  diseases (IBD);","[{'entity1': 'triggers', 'relationship': 'lead to', 'entity2': 'chronic inflammatory-related diseases'}, {'entity1': 'chronic inflammatory-related diseases', 'relationship': 'involve', 'entity2': 'organs and tissue'}, {'entity1': 'inflammatory-related diseases', 'relationship': 'driving', 'entity2': 'inflammatory bowel diseases'}]"
502.0,"the  cardio-vascular  system  (stroke,  atherosclerosis);  the  brain  (depression,  neurodegenerative  diseases);  the immune system (auto-immune diseases and cancer); the endocrine-metabolic system (diabetes and obesity)","[{'entity1': 'chronic inflammation', 'relationship': 'related to', 'entity2': 'cardiovascular system disorders'}, {'entity1': 'chronic inflammation', 'relationship': 'related to', 'entity2': 'brain disorders'}, {'entity1': 'chronic inflammation', 'relationship': 'related to', 'entity2': 'immune system disorders'}, {'entity1': 'chronic inflammation', 'relationship': 'related to', 'entity2': 'endocrine-metabolic system disorders'}]"
503.0,"In this regard, Micro-immunotherapy (MI) might be a promising therapeutic strategy. MI employs low doses (LD) and ultra-low doses (ULD) of immune regulators in their formulations.","[{'entity1': 'Micro-immunotherapy', 'relationship': 'promising strategy for', 'entity2': 'therapy'}, {'entity1': 'Micro-immunotherapy', 'relationship': 'employs', 'entity2': 'low doses of immune regulators'}, {'entity1': 'Micro-immunotherapy', 'relationship': 'employs', 'entity2': 'ultra-low doses of immune regulators'}]"
504.0,"Numerous treatment strategies have been employed in order to reduce inflammation and immunotherapies are one of them.  For  instance,  the  use  of  cytokine-based  therapies  has  been  reported  in  the  management  of  sepsis,  diabetes,  or cardiovascular  diseases  with  quite  promising  results.","[{'entity1': 'treatment strategies', 'relationship': 'employed', 'entity2': 'reduce inflammation'}, {'entity1': 'immunotherapies', 'relationship': 'reduce', 'entity2': 'inflammation'}, {'entity1': 'cytokine-based therapies', 'relationship': 'reported', 'entity2': 'management of sepsis, diabetes, cardiovascular diseases'}]"
505.0,"However,  unwanted  side  effects  still  remain,  probably  due  to  the cytokines or immune factors dosages employed.","[{'entity1': 'unwanted side effects', 'relationship': 'remain', 'entity2': 'cytokines or immune factors dosages'}]"
506.0,A therapeutic approach that includes micro-immunotherapy (MI) could thus be of great interest in order to face such concerns.,"[{'entity1': 'A therapeutic approach', 'relationship': 'includes', 'entity2': 'micro-immunotherapy'}, {'entity1': 'micro-immunotherapy', 'relationship': 'interest', 'entity2': 'face such concerns'}]"
507.0,"Indeed, MI medicines (MIM) are immune-factor-based medicines, which formulations either encompass a sole active substance (unitary preparations; referred to as u-MIM) or a distinctive combination of several ingredients (complex MIM; referred to as c-MIM).","[{'entity1': 'MI medicines', 'relationship': 'are', 'entity2': 'immune-factor-based medicines'}, {'entity1': 'formulations', 'relationship': 'encompass', 'entity2': 'a sole active substance'}, {'entity1': 'formulations', 'relationship': 'encompass', 'entity2': 'a distinctive combination of several ingredients'}]"
508.0,"These medicines are manufactured in the form of sucrose-lactose pillules impregnated with the corresponding active ingredients, for oromucosal administration, and are intended  to  be  taken  in  a  fasted  state.","[{'entity1': 'These medicines', 'relationship': 'manufactured', 'entity2': 'sucrose-lactose pillules'}, {'entity1': 'sucrose-lactose pillules', 'relationship': 'impregnated', 'entity2': 'active ingredients'}, {'entity1': 'These medicines', 'relationship': 'intended', 'entity2': 'oromucosal administration'}]"
509.0,"In  this  manner,  the  active  substances  can  reach  the  oral-pharyngeal  mucosal immune system,2 as well as the mucosal immune system of the gastrointestinal (GI) tract, with their associated lymphoid tissues and cell populations of the innate and adaptative immune responses.","[{'entity1': 'the active substances', 'relationship': 'reach', 'entity2': 'oral-pharyngeal mucosal immune system'}, {'entity1': 'the active substances', 'relationship': 'reach', 'entity2': 'mucosal immune system'}]"
510.0,"This route of administration will, in turn, elicit systemic and local effects, as we could observe in previous published preclinical in vivo studies.","[{'entity1': 'This route of administration', 'relationship': 'elicit', 'entity2': 'systemic and local effects'}]"
511.0,"Through their exclusive preparation, MIM aim at gently modulating the expression and the related signaling pathways of cytokines and immune factors by providing to the organism these molecules at low doses (LD) and ultra-low doses (ULD) (Figure 1).","[{'entity1': 'MIM', 'relationship': 'aim', 'entity2': 'gently modulating the expression and the related signaling pathways'}, {'entity1': 'MIM', 'relationship': 'providing', 'entity2': 'the organism these molecules at low doses and ultra-low doses'}]"
512.0,"LD of bioactive  molecules  (ranging  from  3  to  5  CH)  are  used  in  MI  formulations  to  mimic  the  low  doses  occurring  in  the organism,7,8 and are employed to induce their own biological effects, stimulating their functions (Figure 1, green part).","[{'entity1': 'LD of bioactive molecules', 'relationship': 'used', 'entity2': 'MI formulations'}, {'entity1': 'LD of bioactive molecules ', 'relationship': 'employed', 'entity2': 'induce their own biological effects'}, {'entity1': 'LD of bioactive molecules', 'relationship': 'employed', 'entity2': 'stimulating their functions'}]"
513.0,"Recent literature delineated the importance of IL-8 and IL-10 in the molecular mechanisms driving GI inflammatory diseases.14,15 The fact that c-MIM-1 includes ULD of IL-8 and LD of IL-10 in its formulation thus motivated the choice of assessing the cellular effects of this medicine in an in vitro model of intestinal inflammation (Figure 2B, red box).","[{'entity1': 'IL-8', 'relationship': 'importance', 'entity2': 'molecular mechanisms driving GI inflammatory diseases'}, {'entity1': 'IL-10', 'relationship': 'importance', 'entity2': 'molecular mechanisms driving GI inflammatory diseases'}, {'entity1': 'c-MIM-1', 'relationship': 'includes', 'entity2': 'ULD of IL-8'}, {'entity1': 'c-MIM-1', 'relationship': 'includes', 'entity2': 'LD of IL-10'}, {'entity1': 'c-MIM-1', 'relationship': 'motivated', 'entity2': 'assessing cellular effects in intestinal inflammation model'}]"
514.0,"In a more general approach, c-MIM-2 and c-MIM-3 have been investigated in vitro, on the immune axis in different cell types and inflamed experimental contexts (Figure 2B, blue box).","[{'entity1': 'c-MIM-2', 'relationship': 'investigated', 'entity2': 'in vitro'}, {'entity1': 'c-MIM-3', 'relationship': 'investigated', 'entity2': 'in vitro'}, {'entity1': 'c-MIM-2', 'relationship': 'investigated', 'entity2': 'immune axis'}, {'entity1': 'c-MIM-3', 'relationship': 'investigated', 'entity2': 'immune axis'}]"
515.0,"These two formulations employ ULD of IL-1β and TNF-α in association with ULD of PGE2, or ULD of IL-6, IL-13, and OSM, and LD of IL-10, or LD of TGF-β and IL- 1Ra.","[{'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'ULD of IL-1β'}, {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'ULD of TNF-α'}, {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'ULD of PGE2'}, {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'ULD of IL-6'}, {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'ULD of IL-13'}, {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'ULD of OSM'}, {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'LD of IL-10'}, {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'LD of TGF-β'}, {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'LD of IL-1Ra'}]"
516.0,"Numerous publications, nicely put together in the review from Tsuge et al indeed reported the major role played by PGE2 in the mediation of inflammation and immune diseases, notably through its implication in mechanisms related to Th1 differentiation, and Th1/Th17/Th22 signaling.16","[{'entity1': 'PGE2', 'relationship': 'role', 'entity2': 'mediation of inflammation and immune diseases'}, {'entity1': 'PGE2', 'relationship': 'implication', 'entity2': 'mechanisms related to Th1 differentiation'}, {'entity1': 'PGE2', 'relationship': 'implication', 'entity2': 'Th1/Th17/Th22 signaling'}]"
517.0,"In the context of immunity, IL-10 is produced by a broad type of myeloid  and  lymphoid  cells  during  infections,  and  suppresses  macrophages  and  dendritic  cells  functions,  thereby impeding Th1 and  Th2  effector responses.17","[{'entity1': 'IL-10', 'relationship': 'produced by', 'entity2': 'myeloid and lymphoid cells'}, {'entity1': 'IL-10', 'relationship': 'suppresses', 'entity2': 'macrophages and dendritic cells functions'}, {'entity1': 'IL-10', 'relationship': 'impeding', 'entity2': 'Th1 and Th2 effector responses'}]"
518.0,"In immune effector cell types, and  in a wide  range of  established models of chronic inflammation, IL-10 is reported to play a central role in the regulation of homeostasis.18","[{'entity1': 'IL-10', 'relationship': 'role', 'entity2': 'regulation of homeostasis'}]"
519.0,"On another side, TGF- β is  important  in  maintaining the  T cell  tolerance to  self  or  innocuous  environmental  antigens.19","[{'entity1': 'TGF-β', 'relationship': 'important', 'entity2': 'maintaining T cell tolerance'}]"
520.0,IL-1 is  known  for  its crucial  involvement  in  the  onset  and/or  the  etiopathogenesis  of  several  inflammatory-mediated  diseases.,"[{'entity1': 'IL-1', 'relationship': 'involvement', 'entity2': 'onset of inflammatory diseases'}, {'entity1': 'IL-1', 'relationship': 'involvement', 'entity2': 'etiopathogenesis of inflammatory diseases'}]"
521.0,"Given its importance,  several  therapeutic  approaches  consisting  of  the  use  of  IL-Ra  have  been  used  in  clinical  practice  to  block the activity of IL-1.20","[{'entity1': 'IL-Ra', 'relationship': 'used', 'entity2': 'block IL-1 activity'}]"
522.0,"OSM is a pleiotropic cytokine playing important roles  in a wide range of homeostatic functions (such as hematopoiesis, bone/fat turnover, liver regeneration) and, under chronic inflammatory diseases, it may play pro- inflammatory  roles,  depending  on  the  microenvironment  and  the  interested  tissue,  without  being  overexpressed  at systemic  levels.21","[{'entity1': 'OSM', 'relationship': 'roles', 'entity2': 'homeostatic functions'}, {'entity1': 'OSM', 'relationship': 'roles', 'entity2': 'inflammatory diseases'}]"
523.0,"IL-6  is  also  a  pleiotropic  cytokine  playing  important  roles  in  hematopoiesis,  bone  metabolism embryonic  development,  immunity,  and  host  responses.","[{'entity1': 'IL-6', 'relationship': 'roles', 'entity2': 'hematopoiesis'}, {'entity1': 'IL-6', 'relationship': 'roles', 'entity2': 'bone metabolism'}, {'entity1': 'IL-6', 'relationship': 'roles', 'entity2': 'embryonic development'}, {'entity1': 'IL-6', 'relationship': 'roles', 'entity2': 'immunity'}, {'entity1': 'IL-6', 'relationship': 'roles', 'entity2': 'host responses'}]"
524.0,"Its  expression  is  finely  regulated  at  multiple  levels,  and  when a dysregulated and persistent IL-6 expression occurs, it may lead to the development of various inflammatory-mediated diseases.22,23","[{'entity1': 'dysregulated IL-6 expression', 'relationship': 'lead to', 'entity2': 'inflammatory diseases'}]"
525.0," Similarly,  IL-13  is  known  to  exert  pleiotropic  effects  and  to  be  involved  in  inflammatory-mediated diseases.24","[{'entity1': 'IL-13', 'relationship': 'involved in', 'entity2': 'inflammatory diseases'}]"
526.0,"Finally, in the case of c-MIM-4, which employs ULD of both IL-6 and IL-12 in its formulation, as well as IL-4 at LD, one  of  the  goals  of  this  study  was  to  assess  its  effects  using  an  in  vitro  preclinical  model  of  neuronal  inflammation.","[{'entity1': 'c-MIM-4', 'relationship': 'employs', 'entity2': 'ULD of IL-6'}, {'entity1': 'c-MIM-4', 'relationship': 'employs', 'entity2': 'ULD of IL-12'}, {'entity1': 'c-MIM-4', 'relationship': 'employs', 'entity2': 'LD of IL-4'}, {'entity1': 'c-MIM-4', 'relationship': 'assess effects', 'entity2': 'neuronal inflammation model'}]"
527.0,"The rationale behind the choice of the neuronal-inflammation context was supported by a rich bibliography,  illustrated  by  the  following  examples.","[{'entity1': 'neuronal-inflammation context', 'relationship': 'supported by', 'entity2': 'bibliography'}]"
528.0,"For instance,  according  to  the  results  of  a  recent  meta-analysis, patients suffering from depressive symptoms express higher levels of IL-6.25","[{'entity1': 'depressive symptoms', 'relationship': 'associated with', 'entity2': 'higher IL-6 levels'}]"
529.0,"Another study also reported that the IL-12 serum  levels  of  patients  with  major  depression  were  significantly  higher  than  healthy  controls,  and  that  an  8-weeks treatment led to a reduction of these levels.26","[{'entity1': 'major depression', 'relationship': 'associated with', 'entity2': 'higher IL-12 levels'}]"
530.0,"On the other hand, it was suggested that IL-4 could modulate IL-1β-induced depressive behavior in rats, by inhibiting IL-1β-induced central glial activation and neurotransmitter alterations.27","[{'entity1': 'IL-4', 'relationship': 'modulate', 'entity2': 'IL-1β-induced depressive behavior'}, {'entity1': 'IL-4', 'relationship': 'inhibiting', 'entity2': 'IL-1β-induced glial activation'}, {'entity1': 'IL-4', 'relationship': 'inhibiting', 'entity2': 'IL-1β-induced neurotransmitter alterations'}]"
531.0,"Human peripheral blood mononuclear cells (PBMC) from healthy adult volunteer donors were isolated by centrifugation of venous blood on Ficoll-Hypaque density gradients (Amersham Pharmacia Biotech, Piscataway, NJ, USA).","[{'entity1': 'Human peripheral blood mononuclear cells', 'relationship': 'isolated from', 'entity2': 'venous blood'}, {'entity1': 'venous blood', 'relationship': 'centrifugation on', 'entity2': 'Ficoll-Hypaque density gradients'}]"
532.0,Cells (105/mL) were cultured in 24-well round-bottom plates in 2 mL of complete medium and stimulated with phytohemagglutinin (PHA) (5 μg/mL) for 48 hours.,"[{'entity1': 'Cells', 'relationship': 'cultured in', 'entity2': '24-well round-bottom plates'}, {'entity1': 'Cells', 'relationship': 'stimulated with', 'entity2': 'phytohemagglutinin'}]"
533.0,The SN were collected and stored at −80°C until use.,"[{'entity1': 'The SN', 'relationship': 'collected and stored at', 'entity2': '-80°C'}]"
534.0,"Human Colonic Epithelial Cells (HCoEpiC) were purchased from Innoprot, Bizkaia, Spain.","[{'entity1': 'Human Colonic Epithelial Cells', 'relationship': 'purchased from', 'entity2': 'Innoprot, Bizkaia, Spain'}]"
535.0,The cells were seeded at the density of 5×105 cells in 24-well plate inserts whose diameter is 6.5 mm and the membrane area 0.3 cm2 and grown until tight confluence.,"[{'entity1': 'The cells', 'relationship': 'seeded at', 'entity2': 'density of 5×105 cells'}, {'entity1': 'The cells', 'relationship': 'grown until', 'entity2': 'tight confluence'}]"
536.0,"The trans-epithelial resistance (TEER) measurements were obtained as Ω/cm2 and performed with a Millicell® ERS-2 device at different incubation times (24 hours and 72 hours), in the presence/absence of the PBMC SN, with/without c-MIM-4 or Veh. added 30 minutes before reading.","[{'entity1': 'The trans-epithelial resistance measurements', 'relationship': 'obtained as', 'entity2': 'Ω/cm2'}, {'entity1': 'The trans-epithelial resistance measurements', 'relationship': 'performed with', 'entity2': 'Millicell® ERS-2 device'}, {'entity1': 'The trans-epithelial resistance measurements', 'relationship': 'performed at', 'entity2': 'different incubation times'}, {'entity1': 'c-MIM-4', 'relationship': 'added', 'entity2': 'The trans-epithelial resistance measurements'}, {'entity1': 'Veh.', 'relationship': 'added', 'entity2': 'The trans-epithelial resistance measurements'}]"
537.0,"10 mM of sodium caprate (C10) (Sigma-Aldrich, ref # C4151) was used as a positive control.","[{'entity1': 'sodium caprate', 'relationship': 'used as', 'entity2': 'a positive control'}]"
538.0,HCoEpiC cells were treated with or without Veh. or c-MIM-1 for 24 h.,"[{'entity1': 'HCoEpiC cells', 'relationship': 'treated with', 'entity2': 'Veh.'}, {'entity1': 'HCoEpiC cells', 'relationship': 'treated with', 'entity2': 'c-MIM-1'}]"
539.0,"After that, 400 μL of human PBMC SN previously activated with PHA during 48 h was added to each well for 30 minutes.","[{'entity1': 'human PBMC SN', 'relationship': 'activated with', 'entity2': 'PHA'}, {'entity1': 'human PBMC SN', 'relationship': 'added to', 'entity2': 'each well'}]"
540.0,"For quantitative reverse transcriptase-PCR assays, total RNA (1 μg) was retrotranscribed using the iScript cDNA Synthesis Kit (Ref #1708891, Bio-Rad, Hercules, CA, USA) and the cDNA was analyzed by real-time PCR using the iQTM SYBR Green Supermix (Ref #1708880, Bio-Rad) and a CFX96 Real-time PCR Detection System (Bio-Rad).","[{'entity1': 'total RNA', 'relationship': 'retrotranscribed using', 'entity2': 'iScript cDNA Synthesis Kit'}, {'entity1': 'the cDNA', 'relationship': 'analyzed by', 'entity2': 'real-time PCR'}, {'entity1': 'real-time PCR', 'relationship': 'using', 'entity2': 'iQTM SYBR Green Supermix'}, {'entity1': 'real-time PCR', 'relationship': 'using', 'entity2': 'CFX96 Real-time PCR Detection System'}]"
541.0,Claudin-1: F: 5’-AGG TCT GGC GAC ATT AGT GG-3’; R: 5’-CGT GGT GTT GGG TAA GAG GT-3’; GAPDH: F: 3’-TGG CAA AGT GGA GAT TGT TGC C-3’; R: 5’-AAG ATG GTG ATG GGC TTC CCG-3’.,"[{'entity1': 'Claudin-1', 'relationship': 'F', 'entity2': '5’-AGG TCT GGC GAC ATT AGT GG-3’'}, {'entity1': 'Claudin-1', 'relationship': 'R', 'entity2': '5’-CGT GGT GTT GGG TAA GAG GT-3’'}, {'entity1': 'GAPDH', 'relationship': 'F', 'entity2': '3’-TGG CAA AGT GGA GAT TGT TGC C-3’'}, {'entity1': 'GAPDH', 'relationship': 'R', 'entity2': '5’-AAG ATG GTG ATG GGC TTC CCG-3’'}]"
542.0,"The cells were washed with phosphate-buffered saline (PBS) and proteins were extracted in 50 μL of lysis buffer (50 mM Tris–HCl pH 7.5, 150 mM NaCl, 10% glycerol, and 1% NP-40) supplemented with 10 mM NaF, 1 mM Na3VO4, 10 μg/mL leupeptin, 1 μg/mL pepstatin and aprotinin, and 1 μL/mL phenylmethyl sulfonyl fluoride (PMSF) saturated.","[{'entity1': 'The cells', 'relationship': 'washed with', 'entity2': 'phosphate-buffered saline'}, {'entity1': 'proteins', 'relationship': 'extracted in', 'entity2': 'lysis buffer'}]"
543.0,Human primary monocytes were prepared from buffy coats of three healthy human blood donors.,"[{'entity1': 'Human primary monocytes', 'relationship': 'prepared from', 'entity2': 'buffy coats of healthy human blood donors'}]"
544.0,"Monocytes were incubated with LPS (10 ng/mL, Salmonella typhimurium SL1181) for 30 min before treatment with either the Veh., or c-MIM-2 for an additional 24 hours.","[{'entity1': 'Monocytes', 'relationship': 'incubated with', 'entity2': 'LPS'}, {'entity1': 'Monocytes', 'relationship': 'treatment with', 'entity2': 'Veh.'}, {'entity1': 'Monocytes', 'relationship': 'treatment with', 'entity2': 'c-MIM-2'}]"
545.0,Human CD14+ monocytes were isolated from the blood of a healthy donor (67 years old man).,"[{'entity1': 'Human CD14+ monocytes', 'relationship': 'isolated from', 'entity2': 'the blood of a healthy donor'}]"
546.0,"Monocytes were then cultivated for 6 days in 24-well plates, with α-MEM medium supplemented with 10% fetal bovine serum (FBS) and 100 ng/mL macrophage colony-stimulating factor (M-CSF) (R&D Systems, Inc., Minneapolis, MN, USA, Ref: #216-MC).","[{'entity1': 'Monocytes', 'relationship': 'cultivated in', 'entity2': '24-well plates'}, {'entity1': 'α-MEM medium', 'relationship': 'supplemented with', 'entity2': 'fetal bovine serum'}, {'entity1': 'α-MEM medium', 'relationship': 'supplemented with', 'entity2': 'macrophage colony-stimulating factor'}]"
547.0,"Human primary granulocytes were freshly isolated from the blood of a healthy donor obtained from the EFS, and seeded in 48-well plates in optimized RPMI 1640 supplemented with 10% inactivated FBS.","[{'entity1': 'Human primary granulocytes', 'relationship': 'isolated from', 'entity2': 'the blood of a healthy donor'}, {'entity1': 'Human primary granulocytes', 'relationship': 'seeded in', 'entity2': '48-well plates'}, {'entity1': 'optimized RPMI 1640', 'relationship': 'supplemented with', 'entity2': 'inactivated FBS'}]"
